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 ABSTRACT 
Genetic Susceptibility to Arsenic Exposure and Arsenical Skin Lesion Prevalence  
in Bangladesh  
Maria Argos 
Elevated concentrations of arsenic in groundwater pose a public health threat to 
millions of people worldwide. While arsenic is an established human carcinogen, a mode 
of action has yet to be determined for arsenic carcinogenesis. However, the oxidative 
stress and DNA repair pathways have been implicated in arsenic toxicity and have been 
hypothesized to underlie arsenic carcinogenesis. To date, few epidemiologic studies have 
evaluated genetic susceptibility to arsenical skin lesions based on single nucleotide 
polymorphisms (SNPs) in antioxidant enzyme or DNA repair genes. Utilizing cross-
sectional data from the 2000-2002 survey of the Health Effects of Arsenic Longitudinal 
Study (HEALS) for 610 prevalent arsenical skin lesion cases and 1,079 randomly 
selected controls, I evaluated the associations of SNPs in genes encoding antioxidant 
enzymes and DNA repair enzymes on skin lesion prevalence. I also evaluated potential 
interactions between the SNPS as well as SNP-environment interactions in determining 
skin lesion prevalence.       
In the first study of this dissertation (Chapter 2), I assessed the relationship 
between SNPs in antioxidant enzyme genes and skin lesion prevalence, as well as 
possible interactions of these associations on the additive scale by various environmental 
factors. There were no statistically significant associations between these SNPs (SOD2, 
rs4880; CAT, rs1001179; GPX1, rs1050450; and MPO, rs2333227) and skin lesion 
prevalence. Additionally, there was no evidence of additive interaction by arsenic 
 exposure levels, body mass index, smoking status, or fruit and vegetable intake with the 
SNPs in relation to skin lesion prevalence. However, there was marginal evidence that 
skin lesion prevalence was increased among individuals who carried 4 or more risk 
alleles compared to individuals carrying 0-3 risk alleles in these SNPs. Additionally, I 
observed a significant departure from additivity for the risk allele score and primary 
methylation index on skin lesion prevalence.  
In the second study of this dissertation (Chapter 3), I assessed the relationship 
between SNPs in DNA repair genes (OGG1, rs1052133; XRCC1, rs25487 and 
rs1799782; XRCC3, rs861539; ERCC2, rs1052559; ERCC5, rs17655; and LIG4, 
rs1805388) and skin lesion prevalence, as well as possible interactions of these 
associations on the additive scale by various environmental factors. In logistic regression 
models controlling for sex, age, and well water arsenic concentration, no associations 
were observed between measured SNPs and skin lesion prevalence. The results did not 
vary by arsenic exposure levels, body mass index, or smoking status. However, I did 
observe a significant inverse association of total fruit and vegetable consumption with 
skin lesion prevalence, and its additive interaction with the polymorphism in ERCC5.         
 In the third study of this dissertation (Chapter 4), I utilized a multi-analytic 
approach to explore gene-gene, gene-environment, and higher-order interactions among 
10 SNPs related to the oxidative stress and DNA repair pathways by MDR, CART, and 
logistic regression models. As shown in Chapters 2 and 3, none of these SNPs were 
associated with skin lesion prevalence, however, were evaluated for potential SNP-SNP 
interactions. MDR and CART modeling approaches were utilized for the selection of 
potential gene-gene and gene-environment interactions. Considerable overlap of the 
 interactions detected by both these methods was observed, which were further evaluated 
by logistic regression. Results from logistic regression modeling, provided some evidence 
of these statistical interactions; however, their biological interpretation was limited.     
In summary, there was marginal evidence that skin lesion prevalence was 
increased among individuals who carried 4 or more risk alleles in genotyped SNPs 
related to the oxidative stress pathway compared to individuals carrying 0-3 risk alleles in 
these SNPs and, a significant departure from additivity was observed for the risk allele 
score and primary methylation index on skin lesion prevalence. Additionally, a 
significant inverse association of total fruit and vegetable consumption with skin lesion 
prevalence was observed and, a significant interaction between the polymorphism in 
ERCC5 and total fruit and vegetable intake was observed in relation to skin lesion 
prevalence on the additive scale. However, these finding require replication in other 
studies.    
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ARSENIC IN DRINKING WATER IN BANGLADESH 
 Arsenic is a naturally occurring metalloid, ubiquitously present in the 
environment. Through reduction-oxidation reactions, arsenic can be released from soil 
and rock into the surrounding aquifers. Elevated concentrations of arsenic in groundwater 
were first realized in Bangladesh in the 1990s with the appearance of skin lesion 
epidemics in Bangladeshi villages, which accessed drinking water by tubewells that tap 
into the arsenic-enriched aquifers (1). The tubewells were installed through Bangladesh 
governmental initiatives supported by UNICEF beginning in the 1970s to provide safe 
drinking water to the population through the consumption of groundwater. This was an 
effort to reduce mortality and morbidity from cholera and other waterborne diseases that 
had plagued the population, and proved to be effective towards this end with the 
subsequent reduction of infant mortality.  
The permissible level of arsenic in drinking water regulated by the Government of 
Bangladesh is 50 μg/L. In the Health Effects of Arsenic Longitudinal Study (HEALS)—a 
prospective cohort study to examine the health effects of arsenic exposure in a 
Bangladeshi adult population established in 2000 through funding from the National 
Institute of Environmental Health Sciences (NIEHS)-sponsored Columbia University 
Superfund Research Program (Project PI: Habibul Ahsan)—we have the ability to 
characterize exposure distributions and health outcomes within a representative rural 
population in Bangladesh. Within the HEALS study sample alone, 55.3% of the cohort 
has been exposed to arsenic concentrations greater than the Bangladeshi national drinking 
water standard. In 1993, the World Health Organization revised its guideline from 50 
μg/L to 10 μg/L. By this new standard, 76.6% of the study cohort is considered at risk for 
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arsenic toxicity. Estimates from a 1998 British Geological Survey of tubewells in 
Bangladesh indicate that 46% of samples had water arsenic concentrations greater than 
10 μg/L and 27% of samples had water arsenic concentrations greater than 50 μg/L; 
based on population estimates from 1999, it is believed that approximately 28-35 million 
in Bangladesh were exposed to arsenic concentrations greater than 50 μg/L in their 
drinking water and 46-57 million exposed to arsenic concentrations greater than 10 μg/L. 
There has not been reliable data to quantify the global burden of arsenic in drinking water 
worldwide; however, arsenic in drinking water has been detected at concentrations 
greater than 10 μg/L or the prevailing national standard in several countries including 
Argentina, Australia, Bangladesh, Chile, China, Hungary, India, Mexico, Peru, Thailand, 
and the United States of America (2). 
Chronic exposure to arsenic in drinking water, particularly at concentrations >100 
µg/L, has been associated with a multitude of health effects including cancers of the skin, 
lung, liver, bladder and kidney, cardiovascular disease, peripheral neuropathy, obstetric 
outcomes and respiratory diseases (3-16). Additionally, the International Agency for 
Research on Cancer has classified arsenic as a class I human carcinogen (17). Health 
effects at the lower dose range (≤100 µg/L) remain in question due to limited power of 
studies to observe dose-dependent associations in this range.              
 
ARSENIC AND SKIN LESIONS 
 Skin is the major target organ of arsenic, with skin lesions a hallmark 
characteristic of chronic arsenic exposure and an early manifestation of arsenic toxicity 
(18). These lesions are chiefly subclassified as (listed in order of increasing severity): 
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melanosis, leucomelanosis, and keratosis. Melanosis, increased melanin deposition in the 
skin present as diffuse or spotted hyperpigmentation over the trunk and extremities, 
usually is the first effect observed with chronic arsenic ingestion. Melanosis often 
coincides with or progresses to leucomelanosis, which is characterized by diffuse 
hypopigmentation of the skin over the trunk and extremities. The most severe type of 
arsenical skin lesion is keratosis. Arsenical keratoses are thought to be precancerous 
lesions with the potential to become squamous cell or basal cell carcinomas. Classically, 
they are located on the palms and soles but may be found elsewhere on the body, with the 
most characteristic form as punctate papules, yellow in color, with numerous small, 
horny, corn-like elevations, usually 2 to 10 mm in diameter (19, 20). Arsenical keratoses 
may also present as plaques with slightly elevated, erythematous, scaly or pigmented 
features (20). It is estimated that the latency for the appearance of arsenical keratoses is 
extremely variable, but averages around 9 to 19 years (21, 22). The appearance of 
melanosis and leucomenalosis may appear with a shorter latency period following 
chronic arsenic exposure; however, this has not been well documented. Depending on the 
amount of exposure to arsenic, hyperpigmentation can be observed within 6 months.    
 The association between arsenic exposure and arsenical skin lesion prevalence has 
been well-established in various ethnic populations and a dose-response trend has been 
clearly demonstrated. Yoshida et al. (23) published a recent review of the major 
epidemiologic studies examining the association between arsenic and skin lesions. A 
striking aspect of this systematic summary is that a dose-response relationship with 
arsenic exposure was nearly consistently seen across various ethnic populations, despite 
varying definitions of arsenic exposure and skin lesions. This suggests that even with 
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variability in the measurement constructs for exposure and disease classification, the 
effects are probably an underestimate of the true dose-response and the effects are 
plausible. The association between arsenic exposure (as measured by various exposure 
constructs) and prevalent skin lesions (defined as presence of at least 1 type of skin 
lesion) has been previously evaluated in the HEALS cohort and a dose-response trend 
was demonstrated based on quintiles of increasing water arsenic exposure (prevalence 
odds ratios=1.0, 1.91, 3.03, 3.71, and 5.39) (24). In recent prospective analyses from the 
HEALS cohort, we found multivariate adjusted HRs for incident skin lesions comparing 
10.1–50.0, 50.1–100.0, 100.1–200.0, and ≥200.1 µg/L to ≤10 µg/L of well water arsenic 
exposure to be 1.17 (95% CI: 0.92, 1.49), 1.69 (95% CI: 1.33, 2.14), 1.97 (95% CI: 1.58, 
2.46), and 2.98 (95% CI: 2.40, 3.71), respectively (P for trend=0.0001) (25).  
Evidence has suggested that arsenic exposure itself fails to fully explain the 
presence of arsenical skin lesions in an exposed population and that genetic susceptibility 
may play an important role in determining sub-populations at higher risk of developing 
the disease at similarly exposed levels (26). Epidemiologic studies have shown 
interaction with sex, age, body mass index (24), smoking (27), socioeconomic status (28), 
nutritional status (29), and genetic polymorphisms (as reviewed in (30, 31)).   
 
ARSENIC METABOLITES AND SKIN LESIONS 
 Arsenic is primarily present in the inorganic form (arsenate and arsenite) in 
drinking water (32). Once internalized, it goes through a series of reduction and oxidative 
methylation steps (33). While methylation of an exogenous compound is typically 
considered to be a detoxification process, there is mounting evidence that the methylation 
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of arsenic increases it’s toxicity in vivo particularly with the trivalent methylated arsenic 
species that are more toxic than the inorganic and pentavalent methylated arsenic species 
(34-37). The proposed pathway for arsenic methylation (38), with S-adenosyl methionine 
(SAM) serving as the methyl donor (CH3+) is:  
Arsenate + 2 e– → Arsenite + CH3+ → Methylarsonic acid + 2 e– → 
Methylarsonous acid + CH3+ → Dimethylarsinic acid + 2 e– → Dimethylarsinous acid. 
 The chemical structures of these arsenic compounds are shown in Figure 1. 
Typically, ingested inorganic arsenic is excreted as 10–20% inorganic arsenic, 10–15% 
monomethylated arsenic (MMA), and 60–75% dimethylated arsenic (DMA) (39). 
However, there is known inter-individual variability in the methylation capacity of 
arsenic (as reviewed in (40)), which has been hypothesized to partly explain the 
variability in susceptibility to arsenic toxicity. Recent in vitro evidence by Kojima et al. 
showed that arsenic methylation enhanced arsenic-induced oxidative DNA damage (41).   
In a cross-sectional study in the Lagunera region of Mexico, Del Razo et al. 
showed that arsenic-exposed individual with cutaneous symptoms of arsenic toxicity 
compared to exposed individuals without skin lesions had significantly elevated levels of 
%MMA in urine (14.3% versus 9.5%, respectively), higher primary methylation index—
ratio of MMA to inorganic arsenic—(0.5 versus 0.3, respectively), and a lower secondary 
methylation index—ratio of DMA to MMA—(3.5 versus 6.0, respectively) (42). In a 
population-based study conducted by Valenzuela et al. among residents of Zimapan, 
Mexico—an area known to have high arsenic exposure in groundwater caused by mining 
activity in the region—showed that arsenic-exposed individuals with manifest skin 
lesions had a significantly larger mean percentage of MMAIII in their urine as compared 
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to arsenic-exposed individuals with no visible skin lesions (7.7% versus 5.9%, 
respectively), while there was no difference in the percent of MMAV (43). In a Taiwanese 
population, Yu et al. showed in a case-control study that individuals with skin lesions 
(selected with non-melanoma skin cancers, Bowen’s disease, melanosis and 
hyperkeratosis) had significantly larger mean percentage of MMA in urine, lower mean 
percentage of DMA, and higher ratio of MMA to DMA than control subjects (44). They 
showed that individuals with high %MMA (>15.5%) had 5.5 (95% CI=1.2-24.8) times 
the risk of skin lesions compared to individuals with low MMA and, individuals with low 
%DMA (<72.2%) had 3.2 (95% CI=1.1-10.0) times the risk of skin lesions compared to 
individuals with high DMA (44). Finally, in a cross-sectional study in a Bangladeshi 
population, Ahsan et al. previously reported increased prevalence of skin lesions with 
increasing urinary %MMA and decreasing secondary methylation index (45). In 
summary, based on these cross-sectional studies of prevalent skin lesion cases, there is 
good epidemiologic evidence to suggest an association between higher %MMA and 
lower %DMA in urine and increased skin lesion prevalence.    
 
LIFESTYLE FACTORS AND SKIN LESIONS 
There have been several lifestyle factors that have been associated with skin 
lesion prevalence. The associations between body mass index (24), cigarette smoking 
(27), and dietary factors (29, 46) with skin lesions have been previously demonstrated in 
the HEALS cohort. These lifestyle factors all share in common their implication in the 
oxidative stress pathway. There is substantial evidence to suggest that body mass index 
(47, 48), cigarette smoking (49), and fruit/vegetable consumption (49-51) are related to 
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oxidative stress in humans. Additionally, there has been some evidence to suggest that 
these lifestyle factors also play a role in DNA repair capacity (52, 53).   
 
Body Mass Index 
 In a hospital-based cross-sectional study in Bangladesh, it was observed that body 
mass index was inversely associated with skin lesion prevalence and duration (54). In a 
cross-sectional analysis from HEALS, Ahsan et al. showed a dose-response trend for skin 
lesion prevalence based on quintiles of increasing body mass index (prevalence odds 
ratios=1.0, 0.94, 1.01, 0.82, and 0.76), adjusted for potential confounders including well 
water arsenic concentration (24).  
  
Cigarette Smoking 
 In a previous cross-sectional study from HEALS, Ahsan et al. showed marginal 
increased risk of skin lesion prevalence with tobacco smoking, adjusted for potential 
confounders including well water arsenic concentration (24). Additionally, significant 
additive interaction was observed between arsenic exposure and tobacco use in males on 
skin lesion prevalence (27). In recent prospective analyses from HEALS, we observed 
that former smokers (HR=5.10, 95% CI=4.19, 6.21) and current smokers (HR=3.39, 95% 
CI=2.93, 3.92) were at increased risk of incident skin lesions compared to never smokers 
(25). Additionally, we also observed significant additive interaction between arsenic 






 Several analyses from the HEALS cohort have evaluated the association of 
dietary factors with skin lesion prevalence and incidence. Zablotska et al. observed 
riboflavin, pyridoxine, folic acid, vitamin A, vitamin C, and vitamin E were all inversely 
associated with skin lesion prevalence (29). In a recent analysis, Pierce et al. observed 
that dietary patterns that were related to increased gourd, root vegetable, and vegetable 
intake were inversely associated with skin lesion incidence (56). In a nested case-control 
study from HEALS, folate deficiency was found to be associated with increased skin 
lesion incidence (57). Additionally, in a prospective analysis, Chen et al. found blood 
selenium to be inversely associated with skin lesion incidence (46).     
 
MECHANISMS OF ARSENIC TOXICITY 
 Arsenic is a well-established human carcinogen (17) and dose-response 
associations with skin lesion prevalence (24) and incidence (25) have been observed—
precursor conditions to non-melanoma skin cancers. However, the mechanisms by which 
arsenic acts remain in question, which has primarily been attributed to the absence of a 
suitable animal model to study arsenic toxicity (58, 59). Yet, several mechanisms of 
arsenic toxicity have been proposed, including genotoxicity (60), increased cell 
proliferation through the activation of signal transduction pathways (61), induction of 
oxidative stress (62-64), altered DNA methylation and gene expression (65), impairment 





ARSENIC EXPOSURE AND OXIDATIVE STRESS  
One of the proposed pathways that may be implicated in the association between 
arsenic and skin lesion risk is oxidative stress (62, 63). Arsenic has been shown to induce 
reactive oxygen species (ROS) (70). Oxidative stress is hypothesized to play a role in 
initiation, promotion, and progression within the framework of a multistage 
carcinogenesis model (71). Matsui et al. conducted a study of 8-hydroxy-2'-
deoxyguanosine (8-OHdG), a well established marker of oxidative stress, in skin tissue 
and found 8-OHdG to be significantly higher in arsenic-related Bowen’s disease 
(squamous cell carcinoma in situ) as compared to arsenic-unrelated Bowen’s disease 
(72). Similar findings were seen by An et al., who additionally showed that 8-OHdG was 
elevated in the normal and keratotic skin tissue of arsenic-exposed individuals (73).  
 
GENES ENCODING OXIDATIVE STRESS RELATED ENZYMES 
 There are several well-established antioxidant enzyme genes that are related to the 
oxidative stress pathway: superoxide dismutase 2, mitochondrial (SOD2); catalase (CAT); 
glutathione peroxidase 1 (GPX1); and myeloperoxidase (MPO).   
 
SOD2 
 SOD2 protein plays a major role in maintaining oxidative balance by converting 
superoxide (O2-)—a precursor molecule for all other ROS—into hydrogen peroxide and 
oxygen (74). Additionally, prior in vitro experiments have shown SOD2 to play a role in 
mitigating arsenic-induced DNA damage from oxidative stress (75, 76). This gene is 
located in chromosome region 6q25.3. A nonsynonymous SNP (C>T, Ala16Val, rs4880) 
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in SOD2 has been extensively studied (77). The C allele retains the alpha helical structure 
of the protein for normal activity of the enzyme (78). This particular SNP in SOD2 has 
been previously shown to be associated with other diseases caused by oxidative stress, 
including lung cancer (79), prostate cancer (80), diabetic neuropathy (81), Alzheimer's 
disease (82), radiation injury in patients treated with radiation therapy for prostate 
adenocarcinoma (83), alcoholic cirrhosis (84), urolithiasis (85), and acoustic neuroma 
(86). While contrary to the biological direction that would be hypothesized based on the 
current literature, Hsueh et al. in a study of arsenic-exposed individuals in Taiwan found 
the C allele of this SNP to be associated with increased risk (OR=2.0; 95% CI=1.0-3.9) 
of hypertension, adjusted for arsenic exposure; there was no evidence of statistical 
interaction between arsenic and SOD2 (87).        
 
CAT 
 CAT protein plays a major role at times of severe oxidative stress by converting 
hydrogen peroxide (H2O2) into water and oxygen (88). Additionally, prior in vitro 
experiments have shown CAT to play a role in mitigating arsenic-induced DNA damage 
from oxidative stress (70, 75, 89). This gene is located in chromosome region 11p13. A 
synonymous SNP (T>C, rs1001179) in CAT has been investigated with regard to arsenic 
toxicity in the epidemiologic literature. The T allele has been associated with higher 
erythrocyte CAT levels (90). Hsueh et al. examined the association of this SNP with 
hypertension and saw no significant independent risk of the SNP among arsenic-exposed 
individuals in Taiwan (87). In pilot work, Ahsan et al. examined this SNP in relation to 
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arsenical keratosis and found a nonsignificant increased risk (OR=1.9; 95% CI=0.8-4.7) 
associated with the T allele, adjusted for arsenic exposure (91).     
 
GPX1 
 GPX1 is the main antioxidant enzyme in normal conditions that functions in the 
detoxification of hydrogen peroxide by using it to oxidize glutathione (92). Additionally, 
prior in vitro experiments have shown GPx to play a role in mitigating arsenic-induced 
DNA damage from oxidative stress (93, 94). This gene is located in chromosome region 
3p21.3. A nonsynonymous SNP (C>T, Pro200Leu, rs1050450) in GPX1 has been 
associated with oxidative stress-related diseases. There is some evidence to suggest that 
the T allele is associated with decreased enzyme activity levels (95, 96), particularly 
among men (97). This particular SNP in GPX1 has been previously shown to be 
associated with other diseases caused by oxidative stress, including lung cancer (98, 99), 
atherosclerosis in diabetics (100), aging and longevity (101), and interaction with SOD2 
for breast cancer risk (102).       
 
MPO 
 MPO has been implicated in oxidative stress because of its utilization of hydrogen 
peroxide to produce the oxidant hypochlorite, which may lead to oxidative damage of 
biological tissues (103). Additionally, prior in vitro experiments have shown MPO to 
play a role in mitigating arsenic-induced DNA damage from oxidative stress (76). This 
gene is located in chromosome region 17q23.1. A synonymous SNP (G>A, rs2333227) in 
MPO has been previously examined with respect to arsenic toxicity. The A allele has 
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been shown to have lower enzyme activity (104) and lower transcriptional activity (105). 
The A allele has been associated with lower risk of aerodigestive tract cancer (106) and 
lung cancer (107) and increased risk of prostate cancer among a subset of men with 
aggressive disease (108). In pilot work, Ahsan et al. examined this SNP in relation to 
arsenical keratosis and found a nonsignificant increased risk (OR=2.1; 95% CI=0.7-6.2) 
associated with the GG genotype, adjusted for arsenic exposure (91). Additionally, 
Huang et al. examined this SNP in relation to urinary arsenic concentrations and found 
marginally increased urinary total arsenic concentrations among smokers with the GG 
genotype compared to the GA/AA genotype (109).    
 
ARSENIC AND DNA REPAIR  
 DNA repair has been an additionally proposed pathway that may be implicated in 
the association between arsenic and skin lesion risk (110). In a cross-sectional study, 
arsenic concentrations in drinking water and toenail clippings were positively associated 
with ERCC1 mRNA expression levels suggesting arsenic exposure may induce a DNA 
repair response (111); although, an inverse association was found in another study (112). 
In vitro experiments have shown that arsenic induces DNA strand breaks in a 
concentration dependent manner (113). Arsenic has been shown to inhibit nucleotide 
excision repair (114, 115). DNA repair deficiency has been associated with increased 
micronuclei frequency (116). Reduced DNA repair capacity has been associated with 





GENES ENCODING DNA REPAIR PROTEINS 
There are several genes that are known to encode DNA repair proteins including: 
8-oxoguanine DNA glycosylase (OGG1); X-ray repair complementing defective repair in 
Chinese hamster cells 1 (XRCC1); X-ray repair complementing defective repair in 
Chinese hamster cells 3 (XRCC3); excision repair cross-complementing rodent repair 
deficiency, complementation group 2 (ERCC2); excision repair cross-complementing 




 OGG1 is a DNA glycosylase involved in base excision repair (BER) of 8-OHdG, 
an adduct formed from oxidative stress (118). During BER, OGG1 removes damaged 
bases by cleaving N-glycosylic bonds (118). Prior in vitro (119) and animal (120, 121) 
studies have shown OGG1 to play a role in mitigating arsenic-induced oxidative damage. 
This gene is located in chromosome region 3p26.2. A nonsynonymous SNP (C>G, 
Ser326Cys, rs1052133) in OGG1 has been previously associated with cancer (122). 
Proteins encoded with the G allele exhibit reduced 8-OHdG repair activity (123). This 
specific polymorphism in OGG1 has been shown to be associated with multiple cancers 
(124-129). Mo et al. showed OGG1 expression to be significantly correlated with water 
arsenic concentration among a Mongolian adult population and associated with 







 XRCC1 is a DNA repair enzyme that interacts with polynucleotide kinase (PNK), 
DNA polymerase-beta (POLB) and DNA ligase III (LIG3) as part of a complex to repair 
single-strand breaks and functions in BER to repair damage caused by agents such as 
ROS (131). This gene is located in chromosome region 19q13.2.  
There is a well characterized nonsynonymous SNP (G>A, Arg399Gln, rs25487) 
in this gene. Phenotype studies suggest that the A allele is associated with reduced DNA 
repair (132-135) and ionizing radiation sensitivity (136, 137). The A allele has been 
associated with several cancers, including increased risk of colorectal (138), lung (139), 
and breast cancers (140, 141). Although, carriers of the A allele had a reduced risk of 
non-melanoma skin cancers (142), squamous cell carcinoma of the head and neck (143), 
bladder cancer (144), and lung cancer (145). 
Another known nonsynonymous SNP (C>T, Arg194Trp, rs1799782) in this gene 
has been previously studied in relation to arsenic. The T allele has been associated with 
deficient DNA repair (146). A case-control study of lung cancer found homozygous 
variants (TT genotype) to have a 3-fold increased risk (147); while other case-control 
studies have shown a reduced risk for lung cancer among carriers of the T allele (145, 
148). The T allele has been associated with borderline increased risk of colorectal cancer 
(138)  and squamous cell carcinoma of the head and neck (143), but lower risk of bladder 
cancer (144). Additionally, increased risk of esophageal squamous cell carcinoma was 
observed among homozygous variants (149). The presence of both variants in rs1799782 
(T allele) and rs25487 (A allele) showed an increased risk of gastric cancer (150). Breton 
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et al. demonstrated that the rs1799782 SNP modified the association between arsenic and 
skin lesions, with a three-fold larger odds ratio for skin lesions among individuals in the 
highest tertile of arsenic exposure with the CC genotype compared to TT in the same 
exposure category (151).  
 
XRCC3 
 XRCC3 encodes a protein that forms a complex with RAD51 and RAD51C to 
repair double-strand DNA breaks through the homologous recombination pathway (152-
155). Moreover, studies from our research group have demonstrated arsenic’s ability to 
induce breaks in DNA strands of mammalian cells (156, 157); therefore, reduced ability 
to repair double-strand breaks due to polymorphisms in the XRCC3 gene may be relevant 
for arsenic carcinogenesis. This gene is located in chromosome region 14q32.3. A 
nonsynonymous SNP (C>T, Thr241Met, rs861539) in XRCC3 has been characterized. A 
recent study suggests that the T allele is associated with decreased repair capacity (158). 
The T allele has been associated with increased risk of melanocytic skin cancer (159), 
breast cancer (160), and bladder cancer (161). However, the T allele has also been 
associated with decreased basal cell carcinoma risk (162). Moreover, in a recent case-
control study in West Bengal, India, Kundu et al. observed a significant decreased risk of 
arsenical skin lesions associated with T allele of this polymorphism (163).    
 
ERCC2 
ERCC2 is a DNA helicase involved in transcription and nucleotide excision repair 
(NER) (164). This gene is located in chromosome region 19q13.2–13.3. A 
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nonsynonymous SNP (A>C, Lys751Gln, rs1052559) in ERCC2 has been previously 
established as a risk factor for various cancers and diseases. ERCC2 deficiency is 
associated with the disease xeroderma pigmentosum—characterized by a deficiency in 
NER and a greatly increased predisposition to skin cancer (165)—trichothiodystrophy 
and Cockayne syndrome (166). A phenotype study showed that carriers of the C allele 
have sub-optimal DNA repair (167). The C allele has been associated with increased risk 
of lung cancer (147), basal cell carcinoma (168), chronic lymphocytic leukemia (169), 
squamous cell carcinomas of the head and neck (170), acute myeloid leukemia (171), and 
breast cancer (170). In pilot work, Ahsan et al. showed a synergistic effect of the AA 
genotype of this SNP and arsenic exposure on increased risk of arsenical keratosis (172). 
However, in a US arsenic-exposed population no effects of this SNP were seen with 
squamous or basal cell carcinoma (173).  
 
ERCC5 
 ERCC5 is a DNA repair protein involved in the NER pathway of UV-induced 
damage (174). While there was no current literature on the association of this gene with 
arsenic, there is evidence of a potential interaction between arsenic and UV (69, 175). 
This gene is located in chromosome region 13q33. A nonsynonymous SNP (G>C, 
Asp1104His, rs17655) in ERCC5 has been examined by prior studies. Case-control 
studies have found the G allele to be associated with a decreased risk of lung cancer and 
squamous cell carcinomas of the oropharynx, larynx and esophagus (176) and of lung 
cancer risk in African Americans (177). Additionally, multifactor dimensionality 
reduction analysis found this SNP to be predictive of lung cancer risk among Hispanics 
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(177). Additionally, the C allele was associated with marginally increased breast cancer 
risk (178).    
 
LIG4 
LIG4 is a DNA double-strand break repair enzyme whose two main roles are the 
ligation step of the non-homologous end-joining pathway and V(D)J recombination 
(179). Prior in vitro studies have shown DNA ligases to play a role in mitigating arsenic-
induced oxidative damage (180, 181). This gene is located in chromosome region 13q33-
q34. A nonsynonymous SNP (C>T, Thr9Ile, rs1805388) in LIG4 has been previously 
examined. This polymorphism is not believed to significantly alter the structural 
conformation of the protein (182). The T allele of this polymorphism has been shown to 
be associated with a reduced risk of multiple myeloma (183)  as well as glioma (184) and 
non-Hodgkin lymphoma (185).   
 
GENETIC SUSCEPTIBILITY TO ARSENIC-RELATED SKIN LESIONS 
 Genetic susceptibility to arsenic-related skin lesions has been evaluated by several 
candidate gene studies in the last decade. To our knowledge, 18 genes have been 
evaluated in studies examining polymorphisms in relation to prevalent skin lesions, 
which are summarized in Table 1. For most of the candidate genes, only a single SNP in 
each gene has been evaluated and few SNPs or genes have been replicated in a second 
study. The vast majority of these studies suffer from small sample sizes and, significant 
main effects of the SNPs in most instances were not observed. Although some promising 
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results have been detected for various SNPs, the few replication studies that have been 
conducted have found divergent results (i.e., GSTT1, GSTM1, ERCC2).       
 There are only a few pathways that have been examined to date in relation to 
arsenical skin lesions. Several genes related to arsenic or xenobiotic metabolism (e.g., 
PNP, AS3MT, GSTO1, GSTO2, GSTP1, GSTTI, GSTM1, MTHFR) have been examined 
with mixed results. Additionally, several candidate SNPs have been evaluated in DNA 
repair genes (e.g., ERCC2, APEX1, XRCC1, XRCC3, OGG1) as well as oxidative stress-
related genes (e.g., MPO, CAT), inflammation (e.g., TNF, IL10), and tumor suppression 
(e.g., TP53). 
 The limited scope of work that has been done to evaluate genetic susceptibility to 
arsenical skin lesions clearly warrants further investigation. There has been inconsistency 
in case definitions (i.e., severity of skin lesions), differences in arsenic exposure 
distributions across populations as well as other covariates, and under-powered studies to 
be able to synthesize genetic risk factors from the current literature.         
 
DISSERTATION AIMS 
 This dissertation utilized cross-sectional data from the 2000-2002 survey of the 
Health Effects of Arsenic Longitudinal Study (HEALS), with 610 prevalent arsenical 
skin lesion cases and 1,079 controls selected for the present project, which has been 
adequately powered to evaluate SNP and SNP-environment associations (Appendix A). 
Data was utilized on SNPs that were genotyped in the following genes encoding 
antioxidant enzymes: SOD2, GPX1, CAT, and MPO; as well as the following genes 
encoding DNA repair enzymes: OGG1, XRCC1, XRCC3, ERCC2, ERCC5, and LIG4. 
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Data on arsenic exposure levels as well as clinical, sociodemographic and food frequency 
questionnaire data were also utilized. 
Specifically, this dissertation aims: 
 
Chapter 2: Arsenic Exposure, Antioxidant Enzymes, and Skin Lesion Prevalence in 
an Adult Bangladeshi Population. 
Aim: To evaluate whether SNPs in genes encoding antioxidant enzymes (SOD2, GPX1, 
CAT, MPO) are associated with prevalent arsenical skin lesion status in 610 cases and 
1,079 controls from the HEALS cohort. 
Hypotheses: Specifically, I tested the following hypotheses: 
a. SNPs in these candidate genes are associated with arsenical skin lesions.  
b. SNPs in these candidate genes modify the association between arsenic exposure (as 
measured by well water arsenic and urinary total arsenic concentrations) and 
arsenical skin lesions.   
c. SNPs in these candidate genes modify the association between arsenic methylation 
capacity (as measured by urinary arsenic species) and arsenical skin lesions.  
d. SNPs in these candidate genes modify the association between lifestyle factors 
(body mass index, cigarette smoking status, and fruit/vegetable consumption) and 





Chapter 3: Arsenic Exposure, DNA Repair Genes, and Skin Lesion Prevalence in an 
Adult Bangladeshi Population. 
Aim: To evaluate whether SNPs in genes encoding DNA repair proteins (OGG1, XRCC1, 
XRCC3, ERCC2, ERCC5, and LIG4) are associated with prevalent arsenical skin lesion 
status in 610 cases and 1,079 controls from the HEALS cohort.  
Hypotheses: Specifically, I tested the following hypotheses: 
a. SNPs in these candidate genes are associated with arsenical skin lesions.  
b. SNPs in these candidate genes modify the association between arsenic exposure (as 
measured by well water arsenic and urinary total arsenic concentrations) and 
arsenical skin lesions.   
c. SNPs in these candidate genes modify the association between arsenic methylation 
capacity (as measured by urinary arsenic species) and arsenical skin lesions.  
d. SNPs in these candidate genes modify the association between lifestyle factors 
(body mass index, cigarette smoking status, and fruit/vegetable consumption) and 
arsenical skin lesions.  
 
Chapter 4: Gene-Gene, Gene-Environment, and Higher Order Interactions in 
Relation to Arsenic-related Skin Lesions in an Adult Bangladeshi Population. 
Aim: To explore SNP-SNP and higher order associations to predict arsenical skin lesion 
prevalence.  
Hypotheses: Specifically, I tested the following hypotheses: 
a. Explore interactions among SNPs using multifactor dimensionality reduction 
(MDR) and classification and regression trees (CART).  
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b. Explore interactions among SNPs and arsenic exposure (as measured by well water 
arsenic, creatinine-adjusted urinary total arsenic, primary methylation index, and 
secondary methylation index) using MDR and CART. 
c. Model interaction predictions consistent between MDR and CART using logistic 
regression models to estimate interactions on the multiplicative scale.   
d. Evaluate the findings of these modeling scenarios together to propose interactions 
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more than 1 
characteristic 
skin lesion 
rs1049562 T=0.13 229 199 OR=1.69 (CT+TT vs CC) 1.08, 2.66 
rs1049564 A=0.12 OR=1.66 (GA+AA vs GG) 1.04, 2.64 
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rs7085104 G=0.38 71 51 OR=1.60 (AA+AG vs GG) 0.6, 4.3 
rs11191439 C=0.066 OR=4.28 (TC+CC vs TT) 1.0, 18.5 










rs4925 A=0.18 594 1041 OR=0.98 (CA vs CC) 
OR=1.73 (AA vs CC) 
0.74, 1.29 
0.91, 3.30 
rs11509438 T=0.10 OR=0.85 (AT vs AA) 
OR=0.45 (TT vs AA) 
0.60, 1.19 
0.14, 1.44 
rs11509437 A=0.10 OR=0.88 (GA vs GG) 
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rs1695 G=0.14 86 110 OR=0.91 (AG vs AA)  
OR=1.26 (GG vs AA) 
0.46, 1.80 
0.25, 6.40 
rs1138272       T=0.04 OR=2.09 (CT vs CC) 
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rs1801133 T=0.12 594 1041 OR=1.14 (CT vs CC)  
OR=1.56 (TT vs CC) 
0.84, 1.54 
0.57, 4.30 
rs1801131 C=0.37 OR=1.11 (CA vs CC) 









































Keratosis rs178783622 16bp 
dup=0.13 





rs1042522 G=0.43 OR=2.09 (CC vs GG+GC) 1.32, 3.30 
















Hyperkeratosis rs13181 A=0.4 165 153 OR=4.77 (AA vs AC/CC) 2.75, 8.23 
                                                            
1 N.E., Not estimateable from reported data.  













rs13181 A=0.4 555 560 OR=0.92 (AC vs AA) 
OR=0.98 (CC vs AA) 
0.69, 1.23  
0.66, 1.45 
rs1799793 A=0.3 OR=0.87 (AG vs GG) 
OR=0.76 (AA vs GG) 














G=0.26 792 792 OR=0.96 (TG vs TT) 













rs1799782 T=0.11 792 792 OR=1.01 (TC vs CC) 
OR=0.52 (TT vs CC) 
0.76, 1.35 
0.17, 1.66 
rs25487 A=0.37 OR=1.17 (GA vs GG) 




























792 792 OR=1.04 (GC vs CC) 
















Bangladesh Hyperkeratosis rs1001179 T=0.19 30 104 OR=1.9 (CT+TT vs CC) 0.8, 4.7 
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Arsenic Exposure, Antioxidant Enzymes, and Skin Lesion Prevalence in an Adult 





One of the proposed pathways that may be related to arsenic toxicity is oxidative stress 
and therefore, may play a role in the association between arsenic and skin lesion risk. The 
objective of this analysis was to assess the relationship between SNPs in antioxidant 
enzyme genes and skin lesion prevalence among 610 population-based prevalent skin 
lesion cases and 1,079 controls enrolled in the HEALS cohort. There were no statistically 
significant associations between these SNPs (SOD2, rs4880; CAT, rs1001179; GPX1, 
rs1050450; and MPO, rs2333227) and skin lesion prevalence. The results did not vary by 
arsenic exposure levels (as measured by well water arsenic concentration, urinary total 
arsenic concentration, primary methylation index, and secondary methylation index), 
body mass index, smoking status, or fruit and vegetable intake. However, there was 
marginal evidence that skin lesion prevalence was increased among individuals who 
carried 4 or more risk alleles compared to individuals carrying 0-3 risk alleles in these 
SNPs. Additionally, we observed a significant departure from additivity for the risk allele 
score and primary methylation index on skin lesion prevalence. There was no evidence 
that these SNPs were associated with skin lesion severity, such as pigmentation changes 
and keratosis. In summary, there is some evidence of a cumulative effect of these 
antioxidant SNPs that should be explored further, particularly in conjunction with arsenic 





While arsenic is a well-established human carcinogen (1) and has additionally 
been associated with an array of chronic diseases (2-15), the underlying mechanism of 
arsenic toxicity has not yet been determined. Dose-response associations between arsenic 
exposure with both prevalent and incident skin lesions have been observed (16, 17). One 
of the proposed pathways that may modify the association between arsenic and skin 
lesion risk is oxidative stress (18, 19). Arsenic has been shown to induce reactive oxygen 
species (ROS) (20). Oxidative stress is hypothesized to play a role in initiation, 
promotion, and progression within the framework of a multistage carcinogenesis model 
(21). Matsui et al. conducted a study of 8-hydroxy-2'-deoxyguanosine (8-OHdG), a well 
established marker of oxidative stress, in skin tissue and found 8-OHdG to be 
significantly higher in arsenic-related Bowen’s disease (squamous cell carcinoma in situ) 
as compared to arsenic-unrelated Bowen’s disease (22). Similar findings were seen by An 
et al., who additionally showed that 8-OHdG was elevated in the normal and keratotic 
skin tissue of arsenic-exposed individuals (23). The antioxidant defense system is 
comprised of a cell’s enzymatic and non-enzymatic antioxidants (18). The construct 
measured for the purposes of this analysis is the enzymatic antioxidant potential of the 
individual based on SNPs in genes selected from the oxidative stress pathway.   
 DNA was genotyped for four SNPs in the following antioxidant enzyme genes: 
superoxide dismutase 2, mitochondrial (SOD2; rs4880); catalase (CAT; rs1001179); 
glutathione peroxidase 1 (GPX1; rs1050450); and myeloperoxidase (MPO; rs2333227). 




superoxide (O2-)—a precursor molecule for all other ROS—into hydrogen peroxide and 
oxygen (24). CAT protein plays a major role at times of severe oxidative stress by 
converting hydrogen peroxide into water and oxygen (25). GPX1 is the main antioxidant 
enzyme in normal conditions that functions in the detoxification of hydrogen peroxide by 
using it to oxidize glutathione (26). MPO has been implicated in oxidative stress because 
of its utilization of hydrogen peroxide to produce the oxidant hypochlorite, which may 
lead to oxidative damage of biological tissues (27). Additionally, prior in vitro 
experiments have shown SOD2 (28, 29), CAT (20, 28, 30), GPx (31, 32), and MPO  (29) 
to play roles in mitigating arsenic-induced DNA damage from oxidative stress. 
 In this study, we evaluate whether SNPs in genes encoding antioxidant enzymes 
(SOD2, GPX1, CAT, MPO) are associated with prevalent arsenical skin lesion status in 
610 cases and 1,079 controls from the Health Effects of Arsenic Longitudinal Study 
(HEALS) cohort. 
 
MATERIALS AND METHODS 
Study population 
HEALS is an ongoing, population-based cohort study examining both the short- 
and long-term health effects of arsenic exposure. The study was launched in Araihazar, 
Bangladesh, in 2000. The selection of cohort participants, study design and methods have 
been described in detail elsewhere (33).  
The HEALS cohort served as the study population for the prevalent cases and 




individuals were sampled—an eligibility criteria to minimize loss to follow-up—who 
were aged 18–75 years and residents of the study area for at least 5 years. From the 
12,050 residents who met the eligibility criteria from an enumerated total 65,876  persons 
in the study area, 11,746 (97.5% response rate) men and women (4,801 married couples 
and 2,144 married individuals whose spouses did not participate) were enrolled into the 
HEALS cohort. Among the 11,746 enrolled baseline cohort participants, 11,224 
participants (95.6%) provided urine samples. At baseline, 610 cases of skin lesions were 
identified among the 11,224 cohort members who provided urine samples and were 
included as prevalent cases in this study. Of the remaining participants with an available 
urine sample and known to be free of skin lesions at baseline (n=10,614), a ~10% random 
sample (n=1,079) was selected and included as controls in this study.  
Structured baseline questionnaires were administered to participants in Bengali by 
trained interviewers, who were blind to the water arsenic concentration of the 
participants’ wells. The questionnaires assessed sociodemographic characteristics, current 
and past tubewell use, typical water consumption patterns, food frequency of thirty-nine 
items common to the population (34), occupational exposures, and smoking habits. The 
study physicians also conducted a clinical examination, which included a skin evaluation 
for the detection of arsenical skin lesions based on a structured protocol (16, 33). Venous 
blood and spot urine samples were also collected from each participant on the day of the 




The study protocol was approved by the Institutional Review Boards of Columbia 
University, The University of Chicago, and the Bangladesh Medical Research Council. 
Informed consent was obtained from all participants prior to baseline interview.  
 
Arsenic exposure assessment 
Three primary measures of arsenic exposure were estimated for each case-control 
participant: well water arsenic concentration, creatinine-adjusted urinary total arsenic 
concentration, and urinary arsenic metabolites.   
At the baseline survey, participants were asked to identify the well they primarily 
used as their source of drinking water, from which we were able to assign the appropriate 
well water arsenic concentration exposure. Well water arsenic concentrations of all 5,966 
tubewells in the study area were measured by graphite furnace atomic absorption 
spectrometry, with a detection limit of 5 μg/L. Samples below the limit of detection were 
subsequently reanalyzed by inductively coupled plasma-mass spectrometry (ICP-MS), 
with a detection limit of 0.1 μg/L (35).  
Urinary total arsenic concentration was measured in a spot urine sample collected 
at baseline by graphite furnace atomic absorption spectrometry, with a detection limit of 
2 μg/L (36). Urinary creatinine was measured by a colorimetric Sigma Diagnostics Kit 
(Sigma, St. Louis, MO), and urinary total arsenic was subsequently divided by creatinine 





Urinary arsenic metabolites were measured based on the method by Reuter et al. 
(38) using high-performance liquid chromatography separation of arsenobetaine, 
arsenocholine, arsenate (AsV), arsenite (AsIII), total monomethyl arsenic (MMAIII + 
MMAV), and total dimethyl arsenic (DMAIII + DMAV) followed by detection by ICP-
MS-dynamic reaction cell. Total inorganic arsenic (AsIII + AsV) is utilized in these 
analyses since AsIII can oxidize to AsV during sample transport, storage, and preparation.  
For purposes of analysis, well water arsenic was categorized into quartiles based 
on the distribution in the controls; however, since the first and second quartiles roughly 
corresponded to the World Health Organization’s guideline for arsenic in drinking water 
(10 μg/L) and the national standard for arsenic in drinking water in Bangladesh (50 
μg/L), respectively, we adjusted the cutoff points slightly to correspond to these 
regulatory levels. Urinary total arsenic concentration and arsenic metabolite metrics were 
quartiled based on the distribution in the controls. The percentages of MMA, DMA and 
inorganic arsenic were calculated after exclusion of arsenobetaine and arsenocholine 
from the total. In addition, two methylation indices were constructed: primary 
methylation index (PMI)—the ratio of MMA to inorganic arsenic—and secondary 
methylation index (SMI)—the ratio of DMA to MMA.  
Individuals who were missing data on a particular arsenic exposure measure were 
excluded from the analysis of that specific exposure. Well water arsenic and urinary total 
arsenic concentrations were available for all cases and controls. Arsenic metabolite data 





Single nucleotide polymorphism assessment 
High-throughput DNA extraction was completed in 96-well format using the 
QIAmp DNA 96 DNA Blood kit (Qiagen, Valencia, CA). Replica plates were made with 
12.5 ng DNA in 2.5 µL per well. In the first step, the genomic DNA was amplified by 
PCR using appropriate primers. After PCR amplification, the primers and 
deoxynucleotide triphosphates in 10 µL PCR product were digested with the 10 µL 
shrimp alkaline phosphatase cocktail containing 1.0 µL (1 unit/µL) of shrimp alkaline 
phosphatase, 0.1 µL of Escherichia coli exonuclease I (10 units/µL; U.S. Biochemical, 
Cleveland, OH), 1.0 µL of 10x shrimp alkaline phosphatase buffer, and 7.9 µL of DNase 
and RNase-free water for 45 min at 37°C followed by heating at 95°C for 15 min for 
enzyme deactivation. Then, single nucleotide extension was carried out in the presence of 
the appropriate allele-specific dideoxynucleotide triphosphates fluorescence labeled with 
either R110 or TAMRA (PerkinElmer, Waltham, MA). For single nucleotide extension 
reactions, both the forward and reverse probes were initially tested to select the better 
probe based on clear signal clustering. Reaction mixture (13 µL/well) containing 0.025 
µL AcycloPrime enzyme, 0.5 µL terminator dye, 1 µL reaction buffer, 0.25 µL extension 
probe (10 pmol/µL), and 11.225 µL water was added to 7 µL of digested PCR product to 
make 20 µL reaction volume. Thermocycling was done at 95°C for 3 min followed by 
optimum number of cycles of 95°C for 15 s and 55°C for 30 s. Finally, the fluorescence 
was measured with Wallac 1420 Multilabel Counter Victor 3 (PerkinElmer, Waltham, 
MA). In addition to our assay-specific quality control samples, 10% of the samples were 




Concordance based on the duplicates was >0.92. Call rates for the SNPs of interest 
ranged from 95.2% to 97.9%, as shown in Table 1. 
 
Skin lesion assessment 
 Arsenical skin lesion assessment was conducted through skin examination at the 
baseline interview following a structured protocol by a trained study physician (16, 33). 
Arsenical skin lesions were categorized as the presence of melanosis on the body surface, 
leucomelanosis on the body surface, and keratosis on the hands or feet. For the purposes 
of this study, cases were selected as having the presence of any type of arsenical skin 
lesion. 
The distribution of skin lesion severity among the 610 cases was as follows: 359 
cases had melanosis only, 20 had leucomelanosis only, 10 had melanosis and 
leucomelanosis, 170 had melanosis and keratosis, 40 had leucomelanosis and keratosis, 
and 11 had melanosis, leucomelanosis, and keratosis.  
Individuals without keratotic arsenical lesions are generally thought to have a 
milder form of skin lesions, manifest as changes in the dermal pigmentation of the skin. 
This suggests that there is some heterogeneity of the skin lesion definition; therefore, 
subset analyses were conducted to evaluate the association of SNPs with skin lesion 
severity. Skin lesion severity was stratified into absence of keratotic skin lesions (n=389) 







 All covariate data was derived from the baseline interview. Demographic factors 
included sex and reported age at baseline. Self-reported smoking history was ascertained 
and categorized as ever versus never smoker for the purposes of these analyses. At the 
time of the baseline interview, height and weight of each participant was measured by the 
study physician; body mass index was constructed as weight in kilograms divided by 
height in meters squared and categorized by the World Health Organization cutoff points 
for underweight, normal weight, and overweight/obese.  
Fruit and vegetable consumption as well as total caloric intake was constructed 
based on the reported intake from the food frequency questionnaire (FFQ) (34). 
Participants were exclude from this analysis if they did not complete or reported an 
unlikely total caloric intake value on the FFQ (<500 or >4000 kcal/ day; n=47 missing 
and n=29 extreme values (total n=76 excluded)). A single variable for total fruit and 
vegetable intake was constructed by summing the average daily amount of fruit and 
vegetables consumed that was reported for 26 food items (Table B.1). The total fruit and 
vegetable intake was then tertiled based on the distribution in controls for the purposes of 
these analyses.    
 
Statistical analysis 
Hardy Weinberg Equilibrium (HWE) was calculated for the controls based on 




from expected HWE frequencies based on the exact test. α is used to denote the 
magnitude of departure from HWE. 
 
where Pgg, PGg, and PGG are the genotype proportions (39).  
 The association between each SNP and arsenical skin lesion status was estimated 
by prevalence odds ratios (PORs) and their 95% confidence intervals (CIs) from logistic 
regression models employed by the LOGISTIC procedure in SAS. The PORs were 
adjusted for sex, age, and well water arsenic concentration, primarily because of the 
strong association of these covariates with the outcome. The genotype-specific PORs 
were estimated for each SNP using the homozygous major genotype as the reference 
category. Additionally, the per allele POR was estimated assuming a log-additive model. 
In these models, a single ordinal variable was included indicating the number of minor 
alleles (0, 1, 2) and the associated Wald statistic was interpreted as the P for trend.  
A summary risk allele count was created for the measured biallelic SNPs by 
summing the number of risk alleles carried by an individual, based on a priori knowledge 
of the SNP alleles on protein structure and function (SOD2=T allele, GPX1=T allele, 
CAT=C allele, MPO=A allele). For purposes of analysis, the risk allele count was 
dichotomized.    
 We also evaluated interactions of genetic factors with arsenic exposure (as 
measured by well water arsenic and urinary total arsenic concentrations) as well as 




using both genotype status and risk allele count in separate analyses. Multivariate 
adjusted estimates were used to estimate the relative excess risk for interaction (RERI), 
calculated as   
  RERI = exp(β1+β2+β3) – exp(β1) − exp(β2) +1.  
Here β1 is the coefficient of the ordinal arsenic exposure measure, β2 is the coefficient of 
the dichotomous SNP effect modifier measure, and β3 is the coefficient of the cross-
product of the ordinal arsenic exposure and dichotomous SNP measure (40, 41). Bias 
corrected and accelerated (BCa) 95% CIs of the RERI were estimated via 1000 bootstrap 
samples. CIs of the RERI were also calculated using the delta method described by 
Hosmer and Lemeshow with similar results (not shown) (42). We also evaluated effect 
modification of the associations between lifestyle factors (BMI, smoking status, and fruit 
and vegetable intake) and skin lesions by each SNP and risk allele count in separate 
analyses on the additive scale, adjusting for well water arsenic exposure and other 
covariates. In these analyses, β1 is the coefficient of the ordinal lifestyle measure, β2 is 
the coefficient of the dichotomous SNP effect modifier measure, and β3 is the coefficient 
of the cross-product of the ordinal lifestyle measure and dichotomous SNP effect 
modifier—with the exception of smoking status that was modeled as a dichotomous 
lifestyle measure.   
In exploratory subset analyses, skin lesion severity was evaluated by stratifying 
arsenical skin lesion status into absence of keratotic skin lesions and presence of keratotic 
skin lesions. Prevalent skin lesion cases with melanosis and/or leucomelanosis but not 




keratosis (n=221) were classified as keratotic skin lesions. Ordered polytomous 
regression models were employed by the LOGISTIC procedure in SAS, comparing non-
keratotic skin lesions (coded=1) and keratotic skin lesions (coded=2) to the controls 




Information on the genotyped antioxidant enzyme SNPs is shown in Table 1. 
Based on the α statistic, no SNPs were observed to deviate from Hardy-Weinberg 
equilibrium indicating no major evidence of genotyping errors for each SNP. The 
distribution of selected characteristics in the total HEALS cohort and by the 610 
prevalent skin lesion cases and 1,079 controls are shown in Table 2. Since a random 
sample of the baseline cohort without skin lesions was selected as control participants for 
genotyping, the distribution of characteristics in the controls is not appreciably different 
from the total baseline cohort except for the distribution of age, where we see that control 
subjects were underrepresented in the 31–40 age range and overrepresented in the 41–50 
age range relative to the total cohort. Similar to the previous HEALS cohort analysis for 
skin lesion prevalence (16), we observed based on the selected cases and controls for this 
analysis that males, older age, low BMI (<18.5 kg/m2), current or past cigarette smoking, 
and no formal education were associated with increased skin lesion prevalence. 




measured by well water arsenic and urinary total arsenic concentrations (Table 2), as 
well as with the distribution of urinary arsenic metabolites (Table 3).      
 
Evaluation of associations with single and cumulative SNP effects 
No significant associations were observed between each of the antioxidant 
enzyme SNPs and skin lesion prevalence, based on the genotype and per allele POR 
estimates (Table 4). A risk allele score for the genotyped SNPs was constructed based on 
a priori evidence of the risk allele for each SNP and showed evidence of marginal 
increased risk when 4 or more risk alleles were present (adjusted POR=1.2, 95% CI=0.9, 
1.6; Table 5). These results did not vary by skin lesion severity, classified as non-
keratotic and keratotic skin lesions (Table B.2). Additionally, in exploratory analyses we 
evaluated these associations in male participants only since their baseline skin lesion 
prevalence was appreciably higher than females and, we did not observe notable 
differences in the distribution of SNPs or the associations of the SNPs with skin lesion 
prevalence in males as compared to the total study sample, precluding evidence of 
interaction by sex (Table B.3).   
 
Additive interaction evaluation 
We evaluated whether the associations between antioxidant enzyme SNPs and 
skin lesion prevalence were modified by various arsenic exposure measures and lifestyle 
factors on the additive scale. Departure from additivity was evaluated by well water 




(Table 7), primary methylation index (Table 8), secondary methylation index (Table 9), 
BMI (Table 10), cigarette smoking status (Table 11), and total fruit and vegetable intake 
(Table 12). A significant departure from additivity was observed for the risk allele score 
and primary methylation index on skin lesion prevalence (RERI=0.22, 95% CI=0.03, 
0.36; Table 8). On the additive scale, we observed that skin lesion prevalence was greater 
in individuals carrying 4 or more risk alleles with each 1 quartile increase in primary 
methylation index than would be expected based on the additive independent effects of 
risk allele score and primary methylation index alone. We did not observed any other 
evidence of interaction on the additive scale by measures of arsenic exposure, arsenic 
metabolism, or lifestyle factors as characterized by RERI estimates that were not 
appreciably different from zero.  
 
DISCUSSION 
In this population-based case-control study of arsenical skin lesion prevalence in a 
Bangladeshi population, we systematically evaluated four candidate SNPs in antioxidant 
enzymes. There were no statistically significant associations between these SNPs (SOD2, 
rs4880; CAT, rs1001179; GPX1, rs1050450; and MPO, rs2333227) and skin lesion 
prevalence. However, there was marginal evidence that skin lesion prevalence was 
increased among individuals who carried 4 or more risk alleles compared to individuals 
carrying 0-3 risk alleles in these SNPs. Additionally, we observed a significant departure 





Our observation of significant modification of the association between primary 
methylation index and skin lesion prevalence by the risk allele score on the additive scale 
is consistent with evidence from the current literature. Individuals with a higher 
proportion of MMA to inorganic arsenic in their urine (represented by a larger primary 
methylation index score) were observed to have increased prevalence of arsenical skin 
lesions compared to those with a lower relative proportion, which is consistent with other 
studies examining the association between skin lesion prevalence and urinary arsenic 
metabolites (16, 43-47) as well as blood arsenic metabolites (48). Notably, a cross-
sectional study among arsenic-exposed individuals showed that lower primary 
methylation index was associated with lower plasma antioxidant capacity (49). Moreover, 
in vitro studies have shown that MMA induces reactive oxygen species, particularly the 
trivalent form of this organic arsenic species (50, 51). In the recent study by Bailey et al 
(51), in vitro experiments using normal human epidermal keratinocytes showed that 
MMAIII exhibited the greatest potential for skin carcinogenesis through the induction of 
oxidative stress, increased transcript levels of keratinocyte growth factors, and 
modulation of MAPK and NF-κB pathways, compared to the trivalent forms of inorganic 
arsenic and DMA. In a comparative functional genomics analysis in yeast, Jo et al (52) 
showed that glutathione (related to cellular antioxidant status) was more important in 
MMAIII toxicity than trivalent inorganic arsenic toxicity. Therefore, the fact that an 
interaction was observed only with the primary methylation index and not other measures 
of arsenic exposure that do not reflect the distribution of arsenic metabolites but rather 




oxidative stress may be a mechanism that is associated only with MMA—a construct that 
is best captured by the primary methylation index. Thus, individuals who do not fully 
methylate arsenic efficiently and are carriers of several risk allele variants in antioxidant 
enzyme genes could potentially be at increased risk due to this gene-environment 
interaction.              
In pilot work conducted by Ahsan et al (53) in the same cohort population as this 
analysis but using a non-overlapping set of prevalent skin lesion cases with keratosis and 
control subjects, non-significant increased risks were shown for the GG genotype of 
MPO (rs2333227) and the CT/TT genotype of CAT (rs1001179). Based on the 
polytomous regression analysis conducted in this current study, stratifying cases by 
presence of keratosis did not reveal any significant difference in estimates between 
keratotic versus non-keratotic cases for the SNPs. However, examination of the PORs 
from this analysis showed a trend toward an increased risk for the T allele of CAT (per 
allele POR=1.3, 95% CI=1.0,1.7) among keratotic skin lesion cases compared to controls, 
which was not observed among non-keratotic skin lesion cases compared to controls 
(POR=0.8, 95% CI=0.8, 1.1). Examination of the PORs for MPO showed less 
appreciable differences in the risk estimates for the A allele (non-keratotic skin lesions 
POR=0.9, 95% CI=0.7, 1.2; keratotic skin lesions POR=1.2, 95% CI=0.9, 1.7), with a 
more notable difference in estimates among individuals with the AA genotype (non-
keratotic skin lesions POR=1.1, 95% CI=0.4, 3.0; keratotic skin lesions POR=1.7, 95% 
CI=0.5, 5.1). However, only 5 keratotic cases had the AA genotype which urges caution 




would potentially be suggested for the A allele in this study, which is the opposite of 
what was observed previously for the G allele by Ahsan et al. Since both the pilot work 
and the stratified analysis in this study were based on a small number of cases (n=30 and 
n=221, respectively), further investigation of these potential findings is warranted in a 
larger sample of well-defined keratotic skin lesion cases to draw more definitive 
conclusions.          
 The major strengths of this study were the measurement of genetic variants, large 
size of the study sample, the wide range of arsenic exposure, and the multiple constructs 
of arsenic exposure. The advantage of measuring genetic variants is because they can be 
measured with little measurement error and bias. Additionally, SNPs are time-
independent measures (54), which strengthens causal inference of the associations 
evaluated in this analysis between the measured SNPs and prevalent skin lesions. 
Conversely, the amount of oxidative stress could have been measured but there would 
have been major limitations in the temporality of these measures with the use of prevalent 
cases. Additionally, in very early or mild cases of skin lesions (some forms of melanosis) 
may not be readily visible with clinical examination; therefore, oxidative stress 
biomarkers could also suffer from reverse causation if it was not ensured that the 
measures were taken at an appropriate period before disease onset. A major strength of 
this study is the assessment of arsenic exposure. Arsenic exposure was ascertained based 
on well water arsenic concentration, as well as urinary arsenic measures including total 




constructs of exposure including total exposure burden as well as exposure methylation 
ability.      
 While there are many strengths of this study, there are several limitations that are 
acknowledged. The antioxidant defense system is comprised of enzymatic and non-
enzymatic antioxidants. The focus of this study was to examine the influence of 
polymorphisms of selected enzymatic antioxidants. The role of non-enzymatic 
antioxidants and activity of enzymatic antioxidants are unmeasured; therefore, the total 
antioxidant potential of the cell remains unknown. Additionally, arsenic serves as a proxy 
measure to the actual measure of interest, which is arsenic-induced oxidative stress. 
There is evidence from prior studies to suggest that MMA may be the most relevant 
arsenic species to the oxidative stress pathway, as discussed previously; however, we can 
only infer from this work that individuals with a higher concentration of MMA 
experience higher levels of oxidative stress and have not measured it directly. 
Alternatively, biomarkers of oxidative stress could have been measured. The assessment 
of the effect of SNPs on prevalent skin lesions is also limited for the evaluation of 
mechanistic hypotheses and phenotype considerations since the association may be 
related to disease prevalence or progression and not disease incidence. Therefore, 
findings from these analyses should be replicated with incident cases. However, we deem 
the effect of disease prevalence to be minimal since arsenical skin lesions are typically 
not fatal. Additionally, in the subset analysis we conducted to evaluate the associations of 
SNPs with arsenical skin lesion severity, it did not appear that these SNPs were related to 




selected based on a candidate-gene approach, and only a single SNP in each gene of 
interest was examined. Future studies should take a more comprehensive genomewide 
approach for evaluating genetic variants in the antioxidant enzyme pathway in relation to 
skin lesion status. Findings from this type of “discovery” approach could then be 
evaluated in candidate-gene studies employing SNPs which comprehensively tag the 
genes of interest.  
The findings of this study have potentially important scientific and public health 
implications for arsenic in drinking water. Prior epidemiologic research has suggested 
oxidative stress as a potential mechanism of arsenic toxicity, which observations from 
this study suggest is a viable mechanism for arsenic toxicity and warrants further 
investigation. Additionally, individuals deficient in arsenic metabolism (as characterized 
by the primary methylation index) and carried multiple risk alleles in antioxidant 
enzymes had increased prevalence of skin lesions, which highlights potential pathways 
for intervention in individuals with manifest skin lesions.     
In conclusion, there was marginal evidence that skin lesion prevalence was 
increased among individuals who carried 4 or more risk alleles compared to individuals 
carrying 0-3 risk alleles in antioxidant enzyme SNPs (SOD2, rs4880; CAT, rs1001179; 
GPX1, rs1050450; and MPO, rs2333227). Additionally, we observed a significant 
departure from additivity for the risk allele score and primary methylation index on skin 
lesion prevalence, indicating that skin lesion prevalence was greater in individuals 
carrying 4 or more risk alleles and with poorer arsenic methylation ability than was 




investigation into cumulative effects of variants in antioxidant enzyme genes is 
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TABLE 1. Single Nucleotide Polymorphisms 




success rate (%) α 
SOD2 4880 6 Ex2+24C>T A16V 96.5 0.03 
CAT  1001179  11 -329T>C   96.3 0.01 
GPX1  1050450  3 Ex1-226C>T  P200L  96.4 -0.03 














(95% CI) N % N % N % 
Sex        
Male 5,042 42.9 507 82.6 440 40.8 1.0 
Female 6,704 57.1 106 17.4 639 59.2 0.1 (0.1, 0.1) 
Age, years        
18-30 3,653 31.1 161 26.4 386 35.8 1.0 
31-40 4,186 35.7 224 36.7 237 22.0 2.5 (1.8, 3.4)  
41-50 2,730 23.2 60 9.8 355 32.9 5.6 (4.0, 7.8) 
51-75 1,176 10.0 165 27.0 100 9.3 9.8 (6.7, 14.1) 
BMI4, kg/m2         
<18.50 4,555 39.7 305 50.4 402 37.5 1.0 
18-50-24.99 6,107 53.3 280 46.3 589 54.9 0.6 (0.5, 0.8) 
≥25.00 805 7.0 20 3.3 81 7.6 0.3 (0.2, 0.5) 
Cigarette smoking        
Never 7,568 64.5 177 29.0 698 64.7 1.0 
Ever 4,173 35.5 433 71.0 381 35.3 4.5 (3.6, 5.6) 
Fruit/vegetable intake, g/day        
74.0-415.5 3,868 33.4 232 39.9 344 33.3 1.0 
415.6-593.0 3,752 32.4 168 28.9 344 33.3 0.7 (0.6, 0.9) 
≥593.1 3,950 34.2 181 31.2 344 33.3 0.8 (0.6, 1.0) 
Well water arsenic, μg/L5        
0.1-10 2,743 23.4 72 11.8 265 24.6 1.0 
10.1-50 2,511 21.4 97 15.9 248 23.0 1.4 (1.0, 2.0) 
50.1-150 3,600 30.7 202 33.1 330 30.6 2.2 (1.6, 3.1) 
150.1-864  2,889 24.6 239 39.2 236 21.9 3.7 (2.7, 5.1) 
Urinary total arsenic, μg/g6        
16-103 2,725 24.2 64 10.5 269 24.9 1.0 
104-192 2,713 24.2 121 19.8 271 25.1 1.9 (1.3, 2.6) 
193-339 2,822 25.1 164 26.9 269 24.9 2.6 (1.8, 3.6) 
340-8556 2,964 26.4 261 42.8 270 25.1 4.1 (2.9, 5.6) 
 
                                                            
3 POR, Prevalence odds ratio; unadjusted.  
4 BMI cut-point defined by WHO BMI classification for underweight, normal, and overweight/obese.  
5 Water arsenic concentration cut-points roughly correspond to quartiles of the exposure distribution for the 
controls but have been slightly adjust to reflect policy relevant parameters.   














N % N % POR 95% CI 
% Total MMA       
<8.650 59 10.0 260 25.0 1.0  
8.650-11.765 130 22.0 261 25.0 2.2 1.5, 3.1 
11.766-14.903 146 24.7 269 25.0 2.5 1.7, 3.5 
14.904-33.415 257 43.4 260 25.0 4.4 3.1, 6.0 
% Total DMA       
<63.500 192 32.4 260 25.0 1.0  
63.500-69.215 152 25.7 260 25.0 0.8 0.6, 1.0 
69.216-74.480 124 21.0 262 25.1 0.6 0.5, 0.8 
74.481-90.828 124 21.0 260 24.9 0.6 0.5, 0.9 
% Inorganic arsenic9        
<10.81 152 25.7 260 25.0 1.0  
10.81-14.20 145 24.5 261 25.0 0.9 0.7, 1.3 
14.21-18.31 141 23.8 262 25.1 0.9 0.7, 1.2 
18.32-69.30 154 26.0 259 24.9 1.0 0.7, 1.3 
Primary methylation index10,11       
<0.580 70 11.8 260 25.0 1.0  
0.580-0.835 132 22.3 259 25.0 1.9 1.3, 2.6 
0.836-1.154 171 28.9 260 25.0 2.4 1.8, 3.4 
1.155-19.570 218 36.9 260 25.0 3.1 2.3, 4.3 
Secondary methylation index12,13       
<4.316 236 39.9 259 25.0 1.0  
4.316-5.855 153 25.9 259 25.0 0.6 0.5, 0.8 
5.856-8.211 128 21.7 259 25.0 0.5 0.4, 0.7 
8.212-32.300 74 12.5 259 25.0 0.3 0.2, 0.4 
 
                                                            
7 All arsenic metabolites data missing for 18 case subjects.  
8 All arsenic metabolite data missing for 37 control subjects.  
9 Inorganic arsenic is sum of arsenate and arsenite.   
10 The primary methylation index was calculated as % MMA / % Inorganic arsenic.  
11 Primary methylation index missing for 1 additional case and 3 additional controls subjects due to 0 
values.   
12 The secondary methylation index was calculated as % DMA / % MMA. 
13 Secondary methylation index missing for 1 additional case and 6 additional control subjects due to 0 





TABLE 4.  Prevalence Odds Ratios and 95% CIs for Skin Lesion Prevalence in Relation to Antioxidant 







Estimate P for 
trend 
Multivariate 
Estimate15 P for 
trend N % N % POR 95% CI 
POR 95% 
CI 
SOD2 T=0.45           
CC  173 30.6 302 31.5 1.0   1.0   
CT  268 47.3 456 47.5 1.0 0.8, 1.3  1.0 0.8, 1.3  
TT  125 22.1 202 21.0 1.1 0.8, 1.4  1.0 0.7, 1.4  
Per allele      1.0 0.9, 1.2 0.61 1.0 0.9, 1.2 0.91 
GPX1 T=0.19           
CC  372 65.4 623 65.2 1.0   1.0   
CT  174 30.6 297 31.1 1.0 0.8, 1.2  1.0 0.7, 1.3  
TT  23 4.0 36 3.8 1.1 0.6, 1.8  1.2 0.6, 2.3  
Per allele      1.0 0.8, 1.2 0.98 1.0 0.8, 1.3 0.87 
CAT T=0.23           
CC  358 63.5 571 59.5 1.0   1.0   
CT  185 32.8 343 35.8 0.9 0.7, 1.1  1.0 0.8, 1.3  
TT  21 3.7 45 4.7 0.7 0.4, 1.3  0.9 0.5, 1.7  
Per allele      0.9 0.7, 1.0 0.11 1.0 0.8, 1.2 0.80 
MPO A=0.14           
GG  423 74.3 709 73.6 1.0   1.0   
GA  134 23.6 237 24.6 0.9 0.7, 1.2  1.0 0.7, 1.3  
AA  12 2.1 17 1.8 1.2 0.6, 2.5  1.3 0.5, 3.1  
Per allele      0.9 0.8, 1.2 0.88 1.0 0.8, 1.3 0.94 
 
                                                            
14 Minor allele frequency in the controls.   





TABLE 5.  Prevalence Odds Ratios and 95% CIs for Skin Lesion Prevalence in Relation to Antioxidant 











Estimate16 P for 
trend N % N % POR 95% CI POR 95% CI 
0–3 309 59.8 559 64.4 1.0   1.0   
4–7 208 40.2 309 35.6 1.2 1.0, 1.6 0.08 1.1 0.9, 1.5 0.29 
 
                                                            






TABLE 6.  Prevalence Odds Ratios17 and 95% CIs for Skin Lesion Prevalence in Relation to Antioxidant 
Enzyme SNPs by Well Water Arsenic Concentration, Araihazar, Bangladesh, 2000-2002 
SNP Well Water Arsenic Concentration (μg/L) RERI 0.1-50 50.1-100 100.1-150 150.1-864 
SOD2     0.01 
(-0.20, 0. 20) CC 1.00 1.23 (0.62, 2.45) 1.67 (0.88, 3.16) 3.69 (1.99, 6.86) 
CT/TT 1.0018 1.33 (0.74, 2.40) 2.14 (1.24, 3.71) 3.23 (1.84, 5.65)  
GPX1     -0.13 
(-0.42, 0.10) CC 1.00 1.42 (0.87, 2.31) 1.94 (1.24, 3.04) 4.08 (2.61, 6.37) 
CT/TT 1.0019 1.37 (0.76, 2.45) 2.49 (1.53, 4.08) 2.66 (1.59, 4.45)  
CAT     0.14 
(-0.87, 0.66) TT 1.00 1.52 (0.27, 8.48) 1.76 (0.34, 9.16) 2.86 (0.48, 17.03) 
CT/CC 1.0020 1.51 (0.43, 5.33) 2.20 (0.63, 7.67) 3.72 (1.06, 12.99)  
MPO     -0.02 
(-0.22, 0.23) GG 1.00 1.71 (1.05, 2.78) 3.23 (2.07, 5.04) 4.09 (2.60, 6.43) 
GA/AA 1.0021 1.76 (0.92, 3.35) 1.64 (0.91, 2.96) 6.05 (3.42, 10.73)  
      
Risk allele     0.05  
(-0.20, 0.27) 0–3 1.00 1.72 (1.02, 2.91) 2.22 (1.36, 3.64) 3.79 (2.32, 6.18)  
4–7 1.0022 1.65 (0.89, 3.04) 2.79 (1.66, 4.69) 4.02 (2.35, 6.89)  
                                                            
17 Adjusted for sex and age.  
18 POR = 0.82 comparing CT/TT to CC in this lowest exposure quartile. 
19 POR = 1.11 comparing CT/TT to CC in this lowest exposure quartile. 
20 POR = 1.04 comparing CT/CC to TT in this lowest exposure quartile. 
21 POR = 1.51 comparing GA/AA to GG in this lowest exposure quartile. 





TABLE 7.  Prevalence Odds Ratios23 and 95% CIs for Skin Lesion Prevalence in Relation to Antioxidant 
Enzyme SNPs by Creatinine-adjusted Urinary Total Arsenic Concentration, Araihazar, Bangladesh, 2000-
2002 
SNP Creatinine-adjusted urinary total arsenic concentration (μg/g) RERI 16-103 104-192 193-339 340-8556 
SOD2     0.02 
(-0.23, 0.23) CC 1.00 1.58 (0.78, 3.19) 3.14 (1.56, 6.30) 4.71 (2.44, 9.08) 
CT/TT 1.0024 1.88 (1.01, 3.51) 2.44 (1.32, 4.49) 5.43 (2.97, 9.95)  
GPX1     -0.07 
(-0.32, 0.16) CC 1.00 1.86 (1.14, 3.01) 2.55 (1.58, 4.12) 5.28 (3.36, 8.31) 
CT/TT 1.0025 1.63 (0.93, 2.86) 2.78 (1.65, 4.70) 4.44 (2.64, 7.46)  
CAT     0.17 
(-0.62, 0.65) TT 1.00 3.33 (0.54, 20.56) 1.41 (0.29, 6.82) 3.73 (0.72, 19.35) 
CT/CC 1.0026 1.62 (0.52, 4.98) 2.41 (0.78, 7.40) 4.69 (1.53, 14.35)  
MPO     -0.03 
(-0.26, 0.23) GG 1.00 1.87 (1.16, 3.00) 2.73 (1.72, 4.32) 5.37 (3.42, 8.42) 
GA/AA 1.0027 1.88 (1.02, 3.47) 2.65 (1.43, 4.91) 5.04 (2.91, 8.74)  
      
Risk allele     0.05 
(-0.24, 0.30) 0–3 1.00 2.13 (1.24, 3.64) 2.75 (1.62, 4.68) 5.55 (3.32, 9.30) 
4–7 1.0028 2.00 (1.10, 3.66) 3.81 (2.13, 6.82) 5.48 (3.15, 9.51)  
 
                                                            
23 Adjusted for sex and age. 
24 POR = 1.03 comparing CT/TT to CC in this lowest exposure quartile. 
25 POR = 1.24 comparing CT/TT to CC in this lowest exposure quartile. 
26 POR = 0.98 comparing CT/CC to TT in this lowest exposure quartile. 
27 POR = 1.09 comparing GA/AA to GG in this lowest exposure quartile. 





TABLE 8.  Prevalence Odds Ratios29 and 95% CIs for Skin Lesion Prevalence in Relation to Antioxidant 
Enzyme SNPs by Primary Methylation Index, Araihazar, Bangladesh, 2000-2002 
 SNP 
Primary Methylation Index 
RERI <0.580 0.580-0.835 0.836-1.154 1.155-19.570 
SOD2     0.10 
(-0.14, 0.26) CC 1.00 1.56 (0.76, 3.20) 1.48 (0.74, 2.98) 1.22 (0.61, 2.44) 
CT/TT 1.0030 1.37 (0.72, 2.62) 1.37 (0.72, 2.59) 1.51 (0.80, 2.85)  
GPX1     -0.03 
(-0.26, 0.17) CC 1.00 1.44 (0.88, 2.37) 1.29 (0.79, 2.10) 1.59 (0.98, 2.58) 
CT/TT 1.0031 1.34 (0.73, 2.45) 1.72 (0.99, 2.97) 1.24 (0.72, 2.14)  
CAT     0.24 
(-0.50, 0.58) TT 1.00 0.65 (0.10, 4.22) 0.42 (0.07, 2.40) 0.60 (0.12, 3.04) 
CT/CC 1.0032 0.84 (0.23, 3.10) 0.82 (0.22, 3.01) 0.83 (0.23, 3.05)  
MPO     -0.03 
(-0.34, 0.15) GG 1.00 1.40 (0.88, 2.20) 1.52 (0.97, 2.37) 1.42 (0.92, 2.20) 
GA/AA 1.0033 1.38 (0.76, 2.47) 1.20 (0.68, 2.10) 1.33 (0.76, 2.35)  
      
Risk allele     0.22 
(0.03, 0.36) 0–3 1.00 1.16 (0.69, 1.95) 1.10 (0.67, 1.82) 1.07 (0.65, 1.77) 




29 Adjusted for sex and age. 
30 POR = 0.91 comparing CT/TT to CC in this lowest exposure quartile. 
31 POR = 0.94 comparing CT/TT to CC in this lowest exposure quartile. 
32 POR = 0.52 comparing CT/CC to TT in this lowest exposure quartile. 
33 POR = 0.98 comparing GA/AA to GG in this lowest exposure quartile. 





TABLE 9.  Prevalence Odds Ratios35 and 95% CIs for Skin Lesion Prevalence in Relation to Antioxidant 
Enzyme SNPs by Secondary Methylation Index, Araihazar, Bangladesh, 2000-2002 
 SNP 
Secondary Methylation Index 
RERI <4.316 4.316-5.855 5.856-8.211 8.212-32.300 
SOD2     0.004 
(-0.25, 0.17) CC 1.00 1.01 (0.58, 1.75) 1.00 (0.56, 1.76) 0.51 (0.25, 1.04) 
CT/TT 1.0036 0.87 (0.55, 1.37) 0.80 (0.50, 1.28) 0.70 (0.42, 1.17)  
GPX1     -0.03 
(-0.29, 0.16) CC 1.00 0.70 (0.48, 1.03) 0.69 (0.46, 1.03) 0.54 (0.34, 0.86) 
CT/TT 1.0037 0.80 (0.51, 1.27) 0.69 (0.42, 1.14) 0.49 (0.27, 0.89)  
CAT     0.03 
(-0.77, 0.45) TT 1.00 0.64 (0.14, 2.97) 0.37 (0.07, 2.02) 0.63 (0.11, 3.54) 
CT/CC 1.0038 0.83 (0.30, 2.35) 0.80 (0.28, 2.26) 0.57 (0.20, 1.65)  
MPO     0.09 
(-0.08, 0.24) GG 1.00 0.99 (0.69, 1.41) 0.81 (0.56, 1.18) 0.64 (0.41, 1.00) 
GA/AA 1.0039 0.63 (0.37, 1.08) 0.75 (0.44, 1.29) 0.46 (0.24, 0.88)  
      
Risk allele     -0.03 
(-0.38, 0.20) 0–3 1.00 0.75 (0.50, 1.13) 0.66 (0.43, 1.02) 0.48 (0.29, 0.80) 
4–7 1.0040 0.95 (0.59, 1.52) 0.85 (0.52, 1.41) 0.59 (0.33, 1.05)  
                                                            
35 Adjusted for sex and age. 
36 POR = 1.12 comparing CT/TT to CC in this lowest exposure quartile.  
37 POR = 0.85 comparing CT/TT to CC in this lowest exposure quartile. 
38 POR = 1.09 comparing CT/CC to TT in this lowest exposure quartile. 
39 POR = 1.31 comparing GA/AA to GG in this lowest exposure quartile. 





TABLE 10.  Prevalence Odds Ratios41 and 95% CIs for Skin Lesion Prevalence in Relation to Antioxidant 
Enzyme SNPs by Body Mass Index, Araihazar, Bangladesh, 2000-2002 
SNP 
Body Mass Index (kg/m2) 
RERI <18.5 18.5-24.9 >25.0 
SOD2    0.13 
(-0.27, 0.38) CC 1.00 0.98 (0.63, 1.53) 0.51 (0.18, 1.41) 
CT/TT 1.0042 0.86 (0.58, 1.27) 0.58 (0.27, 1.25)  
GPX1    -0.22 
(-0.97, 0.15) CC 1.00 0.69 (0.51, 0.94) 0.42 (0.20, 0.91) 
CT/TT 1.0043 0.81 (0.56, 1.15) 0.45 (0.18, 1.11)  
CAT    0.28 
(-1.03, 0.75) TT 1.00 0.98 (0.27, 3.62) 1.06 (0.12, 9.29) 
CT/CC 1.0044 0.99 (0.35, 2.82) 0.53 (0.16, 1.74)  
MPO    0.10 
(-0.41, 0.41) GG 1.00 0.83 (0.62, 1.10) 0.48 (0.24, 0.97) 
GA/AA 1.0045 0.82 (0.56, 1.21) 0.33 (0.10, 1.09)  
     
Risk allele    0.02 
(-0.63, 0.40) 0–3 1.00 0.73 (0.52, 1.02) 0.54 (0.24, 1.22) 
4–7 1.0046 0.93 (0.64, 1.35) 0.45 (0.17, 1.16)  
                                                            
41 Adjusted for sex, age, and well water arsenic concentration.  
42 POR = 1.16 comparing CT/TT to CC in this lowest exposure tertile.  
43 POR = 0.85 comparing CT/TT to CC in this lowest exposure tertile. 
44 POR = 1.30 comparing CT/CC to TT in this lowest exposure tertile. 
45 POR = 1.07 comparing GA/AA to GG in this lowest exposure tertile. 





TABLE 11.  Prevalence Odds Ratios 47 and 95% CIs for Skin Lesion Prevalence in Relation to Antioxidant 
Enzyme SNPs by Smoking Status, Araihazar, Bangladesh, 2000-2002 
 SNP 
Smoking Status 
RERI Never Ever 
SOD2   -0.41 
(-1.4, 0.20) CC 1.00 1.56 (0.97, 2.52) 
CT/TT 1.0048 1.37 (0.89, 2.11)  
GPX1   -0.28 
(-0.97, 0.30) CC 1.00 1.39 (0.96, 2.01) 
CT/TT 1.0049 1.26 (0.83, 1.90)  
CAT   0.19 
(-1.44, 1.14) TT 1.00 1.07 (0.31, 3.66) 
CT/CC 1.0050 1.25 (0.47, 3.32)  
MPO   0.24 
(-0.40, 0.78) GG 1.00 1.19 (0.84, 1.69) 
GA/AA 1.0051 1.26 (0.84, 1.91)  
    
Risk allele   -0.65 
(-1.65, 0.09) 0–3 1.00 1.64 (1.11, 2.42) 
4–7 1.0052 1.53 (1.01, 2.33)  
                                                            
47 Adjusted for sex, age, and well water arsenic concentration.  
48 POR = 1.21 comparing CT/TT to CC in this lowest exposure category. 
49 POR = 1.15 comparing CT/TT to CC in this lowest exposure category. 
50 POR = 0.99 comparing CT/CC to TT in this lowest exposure category. 
51 POR = 0.83 comparing GA/AA to GG in this lowest exposure category. 





TABLE 12.  Prevalence Odds Ratios 53 and 95% CIs for Skin Lesion Prevalence in Relation to Antioxidant 
Enzyme SNPs by Fruit and Vegetable Intake, Araihazar, Bangladesh, 2000-2002 
SNP 
Fruit and vegetable intake 
RERI 74.0-415.5 415.6-593.0 ≥593.1 
SOD2    0.18 
(-0.15, 0.45) CC 1.00 0.66 (0.38, 1.16) 0.64 (0.37, 1.11) 
CT/TT 1.0054 0.62 (0.39, 1.00) 0.52 (0.32, 0.84)  
GPX1    0.18 
(-0.17, 0.50) CC 1.00 0.67 (0.46, 0.99) 0.55 (0.37, 0.82) 
CT/TT 1.0055 0.56 (0.35, 0.90) 0.55 (0.34, 0.87)  
CAT    -0.19 
(-2.07, 0.69) TT 1.00 0.39 (0.08, 1.89) 0.40 (0.09, 1.79) 
CT/CC 1.0056 0.47 (0.15, 1.44) 0.42 (0.14, 1.30)  
MPO    -0.13 
(-0.54, 0.21) GG 1.00 0.56 (0.39, 0.81) 0.49 (0.33, 0.71) 
GA/AA 1.0057 0.54 (0.33, 0.88) 0.52 (0.31, 0.88)  
     
Risk allele    0.18 
(-0.01, 0.34) 0–3 1.00 0.64 (0.37, 1.12) 0.66 (0.38, 1.13)  
4–7 1.0058 0.70 (0.45, 1.17) 0.61 (0.38, 0.97)  
  
                                                            
53 Adjusted for sex, age, well water arsenic concentration, total energy intake, and BMI.  
54 POR = 1.21 comparing CT/TT to CC in this lowest exposure tertile.  
55 POR = 1.36 comparing CT/TT to CC in this lowest exposure tertile. 
56 POR = 0.85 comparing CT/CC to TT in this lowest exposure tertile. 
57 POR = 0.82 comparing GA/AA to GG in this lowest exposure tertile. 









Arsenic Exposure, DNA Repair Genes, and Skin Lesion Prevalence in an Adult 





One of the proposed pathways that may be related to arsenic toxicity is deficient DNA 
repair and therefore, may play a role in the association between arsenic and skin lesion 
risk. The objective of this analysis was to assess the relationship between SNPs in DNA 
repair genes (OGG1, rs1052133; XRCC1, rs25487 and rs1799782; XRCC3, rs861539; 
ERCC2, rs1052559; ERCC5, rs17655; and LIG4, rs1805388) and skin lesion prevalence 
among 610 population-based prevalent skin lesion cases and 1,079 controls enrolled in 
the HEALS cohort. In logistic regression models controlling for sex, age, and well water 
arsenic concentration, no associations were observed between measured SNPs and skin 
lesion prevalence. The results did not vary by arsenic exposure levels (as measured by 
well water arsenic concentration, urinary total arsenic concentration, primary methylation 
index, and secondary methylation index), body mass index, or smoking status. However, 
we did observe a significant inverse association of total fruit and vegetable consumption 
with skin lesion prevalence, and its additive interaction with the polymorphism in 





DNA repair is a proposed pathway that may modify the association between 
arsenic and skin lesion risk (1). In a cross-sectional study, arsenic concentrations in 
drinking water and toenail clippings were positively associated with ERCC1 mRNA 
expression levels suggesting arsenic exposure may induce a DNA repair response (2); 
although, an inverse association was found in another study (3). In vitro experiments 
have shown that arsenic induces DNA strand breaks in a concentration dependent manner 
(4). Arsenic has been shown to inhibit nucleotide excision repair (5, 6). DNA repair 
deficiency has been associated with increased micronuclei frequency (7). Reduced DNA 
repair capacity has been associated with increased arsenical skin lesion risk (8).   
DNA was genotyped for seven SNPs in the following DNA repair protein genes: 
8-oxoguanine DNA glycosylase (OGG1; rs1052133); X-ray repair complementing 
defective repair in Chinese hamster cells 1 (XRCC1; rs25487 and rs1799782); X-ray 
repair complementing defective repair in Chinese hamster cells 3 (XRCC3; rs861539); 
excision repair cross-complementing rodent repair deficiency, complementation group 2 
(ERCC2; rs1052559); excision repair cross-complementing rodent repair deficiency, 
complementation group 5 (ERCC5; rs17655); and ligase IV, DNA, ATP-dependent 
(LIG4; rs1805388). OGG1 is a DNA glycosylase involved in base excision repair (BER) 
of 8-OHdG, an adduct formed from oxidative stress (9). XRCC1 is a DNA repair enzyme 
that interacts with polynucleotide kinase (PNK), DNA polymerase-beta (POLB) and 
DNA ligase III (LIG3) as part of a complex to repair single-strand breaks and functions 




that forms a complex with RAD51 and RAD51C to repair double-strand DNA breaks 
through the homologous recombination pathway (11-14). ERCC2 is a DNA helicase 
involved in transcription and nucleotide excision repair (NER) (15). ERCC5 is a DNA 
repair protein involved in the NER pathway of UV-induced damage (16). LIG4 is a DNA 
double-strand break repair enzyme whose two main roles are the ligation step of the non-
homologous end-joining pathway and V(D)J recombination (17).  
 In this study, we evaluate whether SNPs in genes encoding DNA repair enzymes 
(OGG1, XRCC1, XRCC3, ERCC2, ERCC5, LIG4) were associated with prevalent 
arsenical skin lesion status in 610 cases and 1,079 controls from the Health Effects of 
Arsenic Longitudinal Study (HEALS) cohort. 
 
MATERIALS AND METHODS 
Study population 
HEALS is an ongoing, population-based cohort study examining both the short- 
and long-term health effects of arsenic exposure. The study was launched in Araihazar, 
Bangladesh, in 2000. The selection of cohort participants, study design and methods have 
been described in detail elsewhere (18).  
The HEALS cohort served as the source of prevalent cases and controls utilized in 
these analyses. Between October 2000 and May 2002, married individuals were 
sampled—an eligibility criteria to minimize loss to follow-up—who were aged 18–75 
years and residents of the study area for at least 5 years. From the 12,050 residents who 




11,746 (97.5% response rate) men and women (4,801 married couples and 2,144 married 
individuals whose spouses did not participate) were enrolled into the HEALS cohort. 
Among the 11,746 enrolled baseline cohort participants, 11,224 participants (95.6%) 
provided urine samples. At baseline, 610 cases of skin lesions were identified among the 
11,224 cohort members who provided urine samples and were included as prevalent 
cases in this study. Of the remaining participants with an available urine sample and 
known to be free of skin lesions at baseline (n=10,614), a ~10% random sample 
(n=1,079) was selected and included as controls in this study.  
Structured baseline questionnaires were administered to participants in Bengali by 
trained interviewers, who were blind to the water arsenic concentration of the 
participants’ wells. The questionnaires assessed sociodemographic characteristics, current 
and past tubewell use, typical water consumption patterns, food frequency of thirty-nine 
items common to the population (19), occupational exposures, and smoking habits. The 
study physicians also conducted a clinical examination, which included a skin evaluation 
for the detection of arsenical skin lesions based on a structured protocol (18, 20). Venous 
blood and spot urine samples were also collected from each participant on the day of the 
interview.                
The study protocol was approved by the Institutional Review Boards of Columbia 
University, The University of Chicago, and the Bangladesh Medical Research Council. 






Arsenic exposure assessment 
Three primary measures of arsenic exposure were estimated for each case-control 
participant: well water arsenic concentration, creatinine-adjusted urinary total arsenic 
concentration, and urinary arsenic metabolites.   
At the baseline survey, participants were asked to identify the well they primarily 
used as their source of drinking water, from which we were able to assign the appropriate 
well water arsenic concentration exposure. Well water arsenic concentrations of all 5,966 
tubewells in the study area were measured by graphite furnace atomic absorption 
spectrometry, with a detection limit of 5 μg/L. Samples below the limit of detection were 
subsequently reanalyzed by inductively coupled plasma-mass spectrometry (ICP-MS), 
with a detection limit of 0.1 μg/L (21).  
Urinary total arsenic concentration was measured in a spot urine sample collected 
at baseline by graphite furnace atomic absorption spectrometry, with a detection limit of 
2 μg/L (22). Urinary creatinine was measured by a colorimetric Sigma Diagnostics Kit 
(Sigma, St. Louis, MO), and urinary total arsenic was subsequently divided by creatinine 
to obtain a creatinine-adjusted urinary total arsenic concentration, expressed as μg/g 
creatinine (23). 
Urinary arsenic metabolites were measured based on the method by Reuter et al. 
(24) using high-performance liquid chromatography separation of arsenobetaine, 
arsenocholine, arsenate (AsV), arsenite (AsIII), total monomethyl arsenic (MMAIII + 




MS-dynamic reaction cell. Total inorganic arsenic (AsIII + AsV) is utilized in these 
analyses since AsIII can oxidize to AsV during sample transport, storage, and preparation.  
For purposes of analysis, well water arsenic was categorized into quartiles based 
on the distribution in the controls; however, since the first and second quartiles roughly 
corresponded to the World Health Organization’s guideline for arsenic in drinking water 
(10 μg/L) and the national standard for arsenic in drinking water in Bangladesh (50 
μg/L), respectively, we adjusted the cut points slightly to correspond to these regulatory 
levels. Urinary total arsenic concentration and arsenic metabolite metrics were quartiled 
based on the distribution in the controls. The percentages of MMA, DMA and inorganic 
arsenic were calculated after exclusion of arsenobetaine and arsenocholine from the total. 
In addition, two methylation indices were constructed: primary methylation index 
(PMI)—the ratio of MMA to inorganic arsenic—and secondary methylation index 
(SMI)—the ratio of DMA to MMA.  
Individuals who were missing data on a particular arsenic exposure measure were 
excluded from the analysis of that specific exposure. Well water arsenic and urinary total 
arsenic concentrations were available for all cases and controls. Arsenic metabolite data 
was missing for 18 case subjects and 37 control subjects.  
 
Single nucleotide polymorphism assessment 
High-throughput DNA extraction was completed in 96-well format using the 
QIAmp DNA 96 DNA Blood kit (Qiagen, Valencia, CA). Replica plates were made with 




PCR using appropriate primers. After PCR amplification, the primers and 
deoxynucleotide triphosphates in 10 µL PCR product were digested with the 10 µL 
shrimp alkaline phosphatase cocktail containing 1.0 µL (1 unit/µL) of shrimp alkaline 
phosphatase, 0.1 µL of Escherichia coli exonuclease I (10 units/µL; U.S. Biochemical, 
Cleveland, OH), 1.0 µL of 10x shrimp alkaline phosphatase buffer, and 7.9 µL of DNase 
and RNase-free water for 45 min at 37°C followed by heating at 95°C for 15 min for 
enzyme deactivation. Then, single nucleotide extension was carried out in the presence of 
the appropriate allele-specific dideoxynucleotide triphosphates fluorescence labeled with 
either R110 or TAMRA (PerkinElmer, Waltham, MA). For single nucleotide extension 
reactions, both the forward and reverse probes were initially tested to select the better 
probe based on clear signal clustering. Reaction mixture (13 µL/well) containing 0.025 
µL AcycloPrime enzyme, 0.5 µL terminator dye, 1 µL reaction buffer, 0.25 µL extension 
probe (10 pmol/µL), and 11.225 µL water was added to 7 µL of digested PCR product to 
make 20 µL reaction volume. Thermocycling was done at 95°C for 3 min followed by 
optimum number of cycles of 95°C for 15 s and 55°C for 30 s. Finally, the fluorescence 
was measured with Wallac 1420 Multilabel Counter Victor 3 (PerkinElmer, Waltham, 
MA). In addition to our assay-specific quality control samples, 10% of the samples were 
run in duplicate after relabeling to keep laboratory researchers blinded to its identity. 
Concordance based on the duplicates was >0.92. Call rates for the SNPs of interest 






Skin lesion assessment 
 Arsenical skin lesion assessment was conducted through skin examination at the 
baseline interview following a structured protocol by a trained study physician (18, 20). 
Arsenical skin lesions were categorized as the presence of melanosis on the body surface, 
leucomelanosis on the body surface, and keratosis on the hands or feet. For the purposes 
of this study, cases were selected as having the presence of any type of arsenical skin 
lesion. 
The distribution of skin lesion severity among the 610 cases was as follows: 359 
cases had melanosis only, 20 had leucomelanosis only, 10 had melanosis and 
leucomelanosis, 170 had melanosis and keratosis, 40 had leucomelanosis and keratosis, 
and 11 had melanosis, leucomelanosis, and keratosis.  
Individuals without keratotic arsenical lesions are generally thought to have a 
milder form of skin lesions, manifest as changes in the dermal pigmentation of the skin. 
This suggests that there is some heterogeneity of the skin lesion definition; therefore, 
subset analyses were conducted to evaluate the association of SNPs with skin lesion 
severity. Skin lesion severity was stratified into absence of keratotic skin lesions (n=389) 
and presence of keratotic skin lesions (n=221).        
 
Covariates 
 All covariate data was derived from the baseline interview. Demographic factors 
included sex and reported age at baseline. Self-reported smoking history was ascertained 




time of the baseline interview, height and weight of each participant was measured by the 
study physician; body mass index was constructed as weight in kilograms divided by 
height in meters squared and categorized by the World Health Organization cutoff points 
for underweight, normal weight, and overweight/obese.  
Fruit and vegetable consumption as well as total caloric intake was constructed 
based on the reported intake from the food frequency questionnaire (FFQ) (19). 
Participants were exclude from this analysis if they did not complete or reported an 
unlikely total caloric intake value on the FFQ (<500 or >4000 kcal/ day; n=47 missing 
and n=29 extreme values (total n=76 excluded)). A single variable for total fruit and 
vegetable intake was constructed by summing the average daily amount of fruit and 
vegetables consumed that was reported for 26 food items (Table B.1). The total fruit and 
vegetable intake was then tertiled based on the distribution in controls for the purposes of 
these analyses.  
 
Statistical analysis 
Hardy Weinberg Equilibrium (HWE) was calculated for the controls based on 
Pearson (χ2) tests and α. Violation of HWE is calculated based on statistical departure 
from expected HWE frequencies based on the exact test. α is used to denote the 
magnitude of departure from HWE. 
 




 The association between each SNP and arsenical skin lesion status was estimated 
by prevalence odds ratios (PORs) and their 95% confidence intervals (CIs) from logistic 
regression models employed by the LOGISTIC procedure in SAS. The PORs were 
adjusted for sex, age, and well water arsenic concentration, primarily because of the 
strong association of these covariates with the outcome. The genotype-specific PORs 
were estimated for each SNP using the homozygous major genotype as the reference 
category. Additionally, the per allele POR was estimated assuming a log-additive model. 
In these models, a single ordinal variable was included indicating the number of minor 
alleles (0, 1, 2) and the associated Wald statistic was interpreted as the P for trend.  
Haplotypes were constructed for the 2 SNPs in XRCC1 (rs25487 and rs1799782) 
using a maximum likelihood approach implemented in Hapstat, version 3.0 (26). 
Individuals who had genotype data for both SNPs were included (n=546 cases; n=926 
controls). Logistic regression was used to assess the association of skin lesion prevalence 
with the specific haplotypes. The haplotype with major alleles was used as the reference 
category. PORs and their 95% confidence intervals were adjusted for sex, age, and well 
water arsenic concentration. 
A summary risk allele count was created for the measured biallelic SNPs by 
summing the number of risk alleles carried by an individual, based on a priori knowledge 
of the SNP alleles on protein structure and function (OGG1=G allele, XRCC1 
(rs25487)=A allele, XRCC1 (rs1799782)=T allele,  XRCC3=T allele, ERCC2=C allele, 
ERCC5=C allele). For purposes of analysis, the risk allele count was dichotomized based 




of variability in the LIG4 SNP genotype in this population and the α statistic suggested a 
deviation from HWE in the control subjects, this SNP was excluded from the risk allele 
score and from evaluation of interaction.     
 We also evaluated possible additive interaction between arsenic exposure and 
each SNP and the risk allele count in separate analyses in relation to skin lesion 
prevalence. Multivariate adjusted estimates were used to estimate the relative excess risk 
for interaction (RERI), calculated as   
  RERI = exp(β1+β2+β3) – exp(β1) − exp(β2) +1.  
Here β1 is the coefficient of the ordinal arsenic exposure measure, β2 is the 
coefficient of the dichotomous SNP effect modifier measure, and β3 is the coefficient of 
the cross-product of the ordinal arsenic exposure and dichotomous SNP effect modifier 
(27, 28). Bias corrected and accelerated (BCa) 95% CIs of the RERI were estimated via 
1000 bootstrap samples. CIs of the RERI were also calculated using the delta method 
described by Hosmer and Lemeshow with similar results (not shown) (29). We also 
evaluated effect modification of the associations between lifestyle factors (BMI, smoking 
status, and fruit and vegetable intake) and skin lesions by each SNP and risk allele count 
in separate analyses on the additive scale, adjusting for well water arsenic exposure and 
other covariates. In these analyses, β1 is the coefficient of the ordinal lifestyle measure, 
β2 is the coefficient of the dichotomous SNP effect modifier measure, and β3 is the 
coefficient of the cross-product of the ordinal lifestyle measure and dichotomous SNP 
effect modifier—with the exception of smoking status, which was modeled as a 




In exploratory subset analyses, skin lesion severity was evaluated by stratifying 
arsenical skin lesion status into absence of keratotic skin lesions and presence of keratotic 
skin lesions. Prevalent skin lesion cases with melanosis and/or leucomelanosis but not 
keratosis (n=389) were classified as non-keratotic skin lesions and, individuals with 
keratosis (n=221) were classified as keratotic skin lesions. Ordered polytomous 
regression models were employed by the LOGISTIC procedure in SAS, comparing non-
keratotic skin lesions (coded=1) and keratotic skin lesions (coded=2) to the controls 




Information on the genotyped DNA repair SNPs is shown in Table 1. Based on 
the α statistic, there was evidence that the LIG4 SNP (rs1805388) deviated from Hardy-
Weinberg equilibrium indicating a potential source of genotyping error for this SNP; 
therefore, it was excluded from interaction analyses and the risk allele score. The 
distribution of selected characteristics in the total HEALS cohort and by the 610 
prevalent skin lesion cases and 1,079 controls are shown in Table 2. Since a random 
sample of the baseline cohort without skin lesions was selected as control participants for 
genotyping, the distribution of characteristics in the controls is not appreciably different 
from the total baseline cohort except for the distribution of age, where we see that control 
subjects were underrepresented in the 31–40 age range and overrepresented in the 41–50 




skin lesion prevalence (20), we observed based on the selected cases and controls for this 
analysis that males, older age, low BMI (<18.5 kg/m2), current or past cigarette smoking, 
and total fruit and vegetable intake were associated with increased skin lesion prevalence. 
Additionally, clear dose-response associations were observed with arsenic exposure as 
measured by well water arsenic and urinary total arsenic concentrations (Table 2), as 
well as with the distribution of urinary arsenic metabolites (Table 3).      
 
Evaluation of associations with single and cumulative SNP effects 
No significant associations were observed between each of the DNA repair SNPs 
and skin lesion prevalence, based on the genotype and per allele POR estimates (Table 
4). Haplotypes were constructed for the 2 SNPs in XRCC1 and no individuals were found 
to carry two copies of the minor alleles in both XRCC1 polymorphisms. There were no 
significant associations of haplotypes with skin lesion prevalence (Table 5). A risk allele 
score for the genotyped SNPs was constructed based on a priori evidence of the risk 
allele for each SNP and was not associated with skin lesion prevalence (Table 6). These 
results did not vary by skin lesion severity, classified as non-keratotic and keratotic skin 
lesions based on polytomous regression analysis (Table C.1). Additionally, in 
exploratory analyses we evaluated these associations in male participants only since their 
baseline skin lesion prevalence was appreciably higher than females and, we did not 
observe notable differences in the distribution of SNPs or the associations of the SNPs 
with skin lesion prevalence in males as compared to the total study sample, precluding 





Additive interaction evaluation 
We evaluated whether the associations between DNA repair SNPs and skin lesion 
prevalence were modified by various arsenic exposure measures and lifestyle factors on 
the additive scale. Departure from additivity was evaluated by well water arsenic 
concentration (Table 7), creatinine-adjusted urinary total arsenic concentration (Table 8), 
primary methylation index (Table 9), secondary methylation index (Table 10), BMI 
(Table 11), cigarette smoking status (Table 12), and total fruit and vegetable intake 
(Table 13). A significant departure from additivity was observed for the SNP in ERCC5 
and total fruit and vegetable intake on skin lesion prevalence (RERI=-0.78, 95% CI=1.43, 
-0.29; Table 13). On the additive scale, we observed that skin lesion prevalence was 
greater in individuals with the GC/CC genotype of the ERCC5 SNP with each 1 tertile 
increase in total fruit and vegetable intake than would be expected based on the additive 
independent effects of the ERCC5 variant and total fruit and vegetable intake alone. 
There were also significant main effects for tertiles of total fruit and vegetable intake, 
adjusted for sex, age, well water arsenic concentration, BMI, and total caloric intake 
(tertile 2 versus 1 POR=0.68, 95% CI=0.50, 0.91; tertile 3 versus 1 POR=0.57, 95% 
CI=0.42, 0.78). We did not observed any other evidence of interaction on the additive 
scale by measures of arsenic exposure, arsenic metabolism, or lifestyle factors as 







In this population-based case-control study of arsenical skin lesion prevalence in a 
Bangladeshi population, we systematically evaluated seven candidate SNPs in known 
DNA repair genes. There were no statistically significant associations between these 
SNPs (OGG1, rs1052133; XRCC1, rs25487 and rs1799782; XRCC3, rs861539; ERCC2, 
rs1052559; ERCC5, rs17655; and LIG4, rs1805388) and skin lesion prevalence. 
However, we observed a significant departure from additivity for the ERCC5 variant and 
total fruit and vegetable intake on skin lesion prevalence, adjusted for arsenic exposure 
and other covariates.  
The findings from this analysis further support previous research from this cohort. 
It was previously shown in a cross-sectional analysis of the prevalent skin lesions cases 
utilized in this analysis, that riboflavin, pyridozine, folic acid, vitamin A, vitamin C, and 
vitamin E intakes (as ascertained from the FFQ) were all inversely associated with skin 
lesion prevalence (30). In a recent analysis by Pierce et al (31) utilizing data from the 
HEALS cohort, it was shown that a diet comprised of vegetable intake was associated 
with a reduced risk of incident skin lesions. Additionally, it was also shown in a nested 
case-control study in the HEALS study population that folate deficiency was associated 
with skin lesion incidence (32).    
ERCC5 is known to be involved in nucleotide excision repair (NER), particularly 
of UV-induced DNA damage (16). One mechanism by which arsenic is hypothesized to 
cause carcinogenesis is through an indirect mechanism, as a co-carcinogen, by inhibiting 




carcinogens (33, 34). Numerous studies have shown that arsenic inhibits NER (5, 6, 35) 
and the repair of bulky DNA adducts in vitro and in laboratory animals (36-38). In recent 
epidemiologic studies by Andrew et al, arsenic exposure through drinking water was 
associated in a dose-dependent manner to decreased expression of NER genes and 
diminished repair of lesions in human lymphocytes (3, 39). Moreover, in a recent 
epidemiologic investigation of lung cancer in a Danish population, it was shown that 
polymorphisms in other NER-related genes interacted with intake of fruit on lung cancer 
risk (40). However, others have not show an effect of fruit and vegetable intake on DNA 
repair activity in leucocytes (41). To our knowledge, this is the first study to examine 
ERCC5 in relation to arsenic toxicity; therefore, replication of a potential involvement of 
ERCC5 in arsenic-related disease in future studies is needed.                        
In pilot work conducted by Ahsan et al (42) in the same cohort population as this 
analysis but using a non-overlapping set of prevalent skin lesion cases with keratosis and 
control subjects, evidence of an increased trend for the association between tertiles of 
creatinine-adjusted urinary total arsenic concentration and skin lesion prevalence were 
observed among individuals with the AA genotype of ERCC2 (rs1052559) compared to 
the AC/CC genotype trends; however, a formal statistical test of interaction was not 
presented. In this current study, we did not observe any evidence of interaction between 
the same genotyped polymorphism in ERCC2 and skin lesion prevalence. Based on the 
polytomous regression analysis conducted in this current study, stratifying cases by 
presence of keratosis did not reveal any significant difference in estimates between 




effect of creatinine-adjusted urinary total arsenic concentration and the ERCC2 SNP 
among the keratotic cases only compared to the control subjects and did not observe any 
evidence of a difference in prevalence trends (Table C.3). Since both the pilot work and 
the stratified analysis in this study were based on a small number of cases (n=29 and 
n=208, respectively), further investigation of this potential finding is warranted in a larger 
sample of well-defined keratotic skin lesion cases to draw more definitive conclusions.          
 The major strengths of this study were the use of a validated FFQ, measurement 
of genetic variants, large size of the study sample, the wide range of arsenic exposure, 
and the multiple constructs of arsenic exposure. First, we used a validated FFQ. Our 
study instrument contains the food items most commonly consumed by our study 
population based on comparison with food diaries in this population (19) and captures the 
major variability in diet. While the actual food intakes may not be accurately estimated 
by the FFQ within our study population, it is likely that it does rank participants 
reasonably well into tertiles of food intakes. Second, the advantage of measuring genetic 
variants is that they can be measured with little measurement error and bias. Additionally, 
SNPs are time-independent measures (43), which strengthens causal inference of the 
associations evaluated in this analysis between the measured SNPs and prevalent skin 
lesions. Conversely, the amount of DNA damage could have been measured but there 
would have been major limitations in the temporality of these measures with the use of 
prevalent cases. Additionally, in very early or mild cases of skin lesions (some forms of 
melanosis) may not be readily visible with clinical examination; therefore, biomarkers of 




measures were taken at an appropriate period before disease onset. Third, because we do 
not expect nutritional or genetics effects to be particularly large, the large sample size 
enhances our ability to detect associations. Finally, arsenic exposure was ascertained 
based on well water arsenic concentration, as well as urinary arsenic measures including 
total arsenic concentration and arsenic metabolites, which allowed us to evaluate various 
constructs of exposure including total exposure burden as well as exposure methylation 
ability.      
 While there are many strengths of this study, there are several limitations that are 
acknowledged. A limitation of this study is that the FFQ measures average diet; the food 
intake of the individual at the time of interview may have varied from the diet that the 
individual had at the time of skin lesion development for the prevalent cases or due to 
seasonal variability or fluctuations in household income for the cases and controls from 
the actual representative diet of the individual. Second, we conducted a series of analyses 
to evaluate main effects and interactions in this study that were pre-specified in our 
hypotheses. While there is evidence for the biologically plausibly of an interaction 
between intake of fruit and vegetable and the polymorphism in ERCC5 on skin lesion 
prevalence, we urge caution in the interpretation of this finding, without replication in 
other studies. It is possible that measurement error in the fruit and vegetable intake 
variable or SNP assessment could have produced the heterogeneity that appears between 
this SNP and fruit and vegetable intake since it is the only significant result we find 
among several comparisons. Third, the assessment of the effect of SNPs on prevalent 




considerations since the association may be related to disease prevalence or progression 
and not disease incidence. Therefore, findings from these analyses should be replicated 
with incident cases. However, we deem the effect of disease prevalence to be minimal 
since arsenical skin lesions are typically not fatal. Additionally, in the subset analysis we 
conducted to evaluate the associations of SNPs with arsenical skin lesion severity, it did 
not appear that these SNPs were related to disease progression. Finally, the SNPs and 
genes for which there is data available were selected based on a candidate-gene approach. 
Therefore, only a single SNP in the majority of genes of interest were examined. Future 
studies should take a more comprehensive genomewide approach for evaluating genetic 
variants in the DNA repair pathway in relation to skin lesion status. Findings from this 
type of “discovery” approach could then be evaluated in candidate-gene studies 
employing SNPs which comprehensively tag the genes of interest.  
The findings of this study have potentially important scientific and public health 
implications for arsenic in drinking water. Prior epidemiologic research has suggested 
DNA repair as a potential mechanism of arsenic toxicity, which observations from this 
study suggest is a viable mechanism for arsenic toxicity and warrants further 
investigation. Additionally, individuals deficient in fruit and vegetable intake and carried 
a risk allele in ERCC5 had increased prevalence of skin lesions, which highlights 
potential pathways for intervention in individuals with manifest skin lesions. 
In conclusion, our results suggest that the genetic polymorphisms in DNA repair 
genes measured in this study are not related to skin lesion prevalence in this Bangladeshi 




with skin lesion prevalence, and its additive interaction with a polymorphism in ERCC5 
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TABLE 1. Single Nucleotide Polymorphisms 












K751Q   97.9 0.01 
ERCC5 17655 13 Ex15-344G>C D1104H 96.8 -0.05 
LIG4 1805388 13 Ex3+54C>T T9I   96.6 -0.18 
XRCC1 1799782 19 Ex6-22C>T   R194W 95.2 0.07 
XRCC1 25487 19 Ex10-4A>G  Q399R 96.3 -0.01 















(95% CI) N % N % N % 
Sex        
Male 5,042 42.9 507 82.6 440 40.8 1.0 
Female 6,704 57.1 106 17.4 639 59.2 0.1 (0.1, 0.1) 
Age, years        
18-30 3,653 31.1 161 26.4 386 35.8 1.0 
31-40 4,186 35.7 224 36.7 237 22.0 2.5 (1.8, 3.4)  
41-50 2,730 23.2 60 9.8 355 32.9 5.6 (4.0, 7.8) 
51-75 1,176 10.0 165 27.0 100 9.3 9.8 (6.7, 14.1) 
BMI60, kg/m2         
<18.50 4,555 39.7 305 50.4 402 37.5 1.0 
18-50-24.99 6,107 53.3 280 46.3 589 54.9 0.6 (0.5, 0.8) 
≥25.00 805 7.0 20 3.3 81 7.6 0.3 (0.2, 0.5) 
Cigarette smoking        
Never 7,568 64.5 177 29.0 698 64.7 1.0 
Ever 4,173 35.5 433 71.0 381 35.3 4.5 (3.6, 5.6) 
Fruit/vegetable intake, g/day        
74.0-415.5 3,868 33.4 232 39.9 344 33.3 1.0 
415.6-593.0 3,752 32.4 168 28.9 344 33.3 0.7 (0.6, 0.9) 
≥593.1 3,950 34.2 181 31.2 344 33.3 0.8 (0.6, 1.0) 
Well water arsenic, μg/L61        
0.1-10 2,743 23.4 72 11.8 265 24.6 1.0 
10.1-50 2,511 21.4 97 15.9 248 23.0 1.4 (1.0, 2.0) 
50.1-150 3,600 30.7 202 33.1 330 30.6 2.2 (1.6, 3.1) 
150.1-864  2,889 24.6 239 39.2 236 21.9 3.7 (2.7, 5.1) 
Urinary total arsenic, μg/g62        
16-103 2,725 24.2 64 10.5 269 24.9 1.0 
104-192 2,713 24.2 121 19.8 271 25.1 1.9 (1.3, 2.6) 
193-339 2,822 25.1 164 26.9 269 24.9 2.6 (1.8, 3.6) 
340-8556 2,964 26.4 261 42.8 270 25.1 4.1 (2.9, 5.6) 
 
                                                            
59 POR, Prevalence odds ratio; unadjusted.  
60 BMI cut-point defined by WHO BMI classification for underweight, normal, and overweight/obese.  
61 Water arsenic concentration cut-points roughly correspond to quartiles of the exposure distribution for 
the controls but have been slightly adjust to reflect policy relevant parameters.   














N % N % POR 95% CI 
% Total MMA       
<8.650 59 10.0 260 25.0 1.0  
8.650-11.765 130 22.0 261 25.0 2.2 1.5, 3.1 
11.766-14.903 146 24.7 269 25.0 2.5 1.7, 3.5 
14.904-33.415 257 43.4 260 25.0 4.4 3.1, 6.0 
% Total DMA       
<63.500 192 32.4 260 25.0 1.0  
63.500-69.215 152 25.7 260 25.0 0.8 0.6, 1.0 
69.216-74.480 124 21.0 262 25.1 0.6 0.5, 0.8 
74.481-90.828 124 21.0 260 24.9 0.6 0.5, 0.9 
% Inorganic arsenic65        
<10.81 152 25.7 260 25.0 1.0  
10.81-14.20 145 24.5 261 25.0 0.9 0.7, 1.3 
14.21-18.31 141 23.8 262 25.1 0.9 0.7, 1.2 
18.32-69.30 154 26.0 259 24.9 1.0 0.7, 1.3 
Primary methylation index66,67       
<0.580 70 11.8 260 25.0 1.0  
0.580-0.835 132 22.3 259 25.0 1.9 1.3, 2.6 
0.836-1.154 171 28.9 260 25.0 2.4 1.8, 3.4 
1.155-19.570 218 36.9 260 25.0 3.1 2.3, 4.3 
Secondary methylation index68,69       
<4.316 236 39.9 259 25.0 1.0  
4.316-5.855 153 25.9 259 25.0 0.6 0.5, 0.8 
5.856-8.211 128 21.7 259 25.0 0.5 0.4, 0.7 
8.212-32.300 74 12.5 259 25.0 0.3 0.2, 0.4 
 
                                                            
63 All arsenic metabolites data missing for 18 case subjects.  
64 All arsenic metabolite data missing for 37 control subjects.  
65 Inorganic arsenic is sum of arsenate and arsenite.   
66 The primary methylation index was calculated as % MMA / % Inorganic arsenic.  
67 Primary methylation index missing for 1 additional case and 3 additional controls subjects due to 0 
values.   
68 The secondary methylation index was calculated as % DMA / % MMA. 
69 Secondary methylation index missing for 1 additional case and 6 additional control subjects due to 0 






TABLE 4.  Prevalence Odds Ratios and 95% CIs for Skin Lesion Prevalence in Relation to DNA Repair 










N % N % POR  (95% CI) 
POR 
(95% CI) 
OGG1 G=0.31         
CC  264 46.0 460 47.2 1.0  1.0  
CG  259 45.1 423 43.4 1.1 (0.9, 1.3)  0.9 (0.7, 1.2)  
GG  51 8.9 92 9.4 1.0 (0.7, 1.4)  0.8 (0.5, 1.3)  
Per allele      1.0 (0.9, 1.2) 0.85 0.9 (0.8, 1.1) 0.42 
ERCC2 C=0.33         
AA  242 43.4 421 44.5 1.0  1.0  
AC  262 46.9 419 44.3 1.1 (0.9, 1.4)  1.1 (0.8, 1.4)  
CC  54 9.7 105 11.1 0.9 (0.6, 1.3)  0.9 (0.6, 1.3)  
Per allele      1.0 (0.9, 1.2) 0.94 1.0 (0.8, 1.2) 0.91 
ERCC5 C=0.27         
GG  298 52.8 503 52.0 1.0  1.0  
GC  223 39.5 400 41.4 0.9 (0.8, 1.2)  0.9 (0.7, 1.2)  
CC  43 7.6 64 6.6 1.1 (0.8, 1.7)  1.1 (0.7, 1.7)  
Per allele      1.0 (0.8, 1.2) 0.95 1.0 (0.8, 1.2) 0.98 
LIG4 T=0.09         
CC  473 82.8 788 82.3 1.0  1.0  
CT  92 16.1 165 17.2 0.9 (0.7, 1.2)  1.0 (0.7, 1.3)  
TT  6 1.0 4 0.4 2.5 (0.7, 8.9)  2.6 (0.6, 11.4)  
Per allele      1.0 (0.8, 1.3) 0.95 1.1 (0.8, 1.4) 0.70 
XRCC1 (Ex6) T=0.10         
CC  445 79.5 763 80.6 1.0  1.0  
CT  104 18.6 170 18.0 1.0 (0.8, 1.4)  1.2 (0.8, 1.6)  
TT  11 2.0 13 1.4 1.4 (0.6, 3.3)  1.5 (0.5, 4.1)  
Per allele      1.1 (0.9, 1.4) 0.45 1.2 (0.9, 1.6) 0.23 
XRCC1 (Ex10) A=0.33         
GG  240 42.5 423 44.1 1.0  1.0  
GA  251 44.4 429 44.8 1.0 (0.8, 1.3)  1.0 (0.8, 1.3)  
AA  74 13.1 106 11.1 1.2 (0.9, 1.7)  1.3 (0.9, 1.9)  
Per allele      1.1 (0.9, 1.3) 0.30 1.1 (0.9, 1.3) 0.29 
XRCC3 T=0.20         
CC  352 63.4 619 65.3 1.0  1.0  
CT  180 32.4 287 30.3 1.1 (0.9, 1.4)  1.1 (0.8, 1.4)  
TT  23 4.1 42 4.4 1.0 (0.6, 1.6)  0.7 (0.4, 1.3)  
Per allele      1.0 (0.9, 1.3) 0.60 1.0 (0.8, 1.2) 0.95 
 
                                                            
70 Minor allele frequency in the controls.   
71 P for trend. 





TABLE 5.  Prevalence Odds Ratios and 95% CIs for Skin Lesion Prevalence in Relation to XRCC1 
Haplotypes, Araihazar, Bangladesh, 2000-2002 







CG 0.537 0.559 1.0 1.0 
CA 0.352 0.336 1.1 (0.9, 1.3) 1.1 (0.9, 1.3) 
TG 0.112 0.105 1.1 (0.9, 1.4) 1.1 (0.9, 1.4) 
                                                            





TABLE 6.  Prevalence Odds Ratios and 95% CIs for Skin Lesion Prevalence in Relation to DNA Repair 







 Crude Estimate  
Multivariate 
Estimate75 
N % N %  POR 95% CI POR 95% CI 
0–3 287 59.7 516 62.6  1.0   1.0  
4–8 194 40.3 308 37.4  1.1 0.9, 1.4  1.1 0.8, 1.4 
 
                                                            
74 LIG4 excluded from the risk allele count. 





TABLE 7.  Prevalence Odds Ratios76 and 95% CIs for Skin Lesion Prevalence in Relation to DNA Repair 
SNPs by Well Water Arsenic Concentration, Araihazar, Bangladesh, 2000-2002 
SNP Well Water Arsenic Concentration (µg/L) RERI 
0.1-50 50.1-100 100.1-150 150.1-864 
OGG1 -0.03 
(-0.25, 0.16) CC 1.00 1.90 (1.06, 3.39) 2.39 (1.41, 4.06) 4.40 (2.54, 7.63) 
CG/GG 1.0077 1.40 (0.78, 2.49) 2.50 (1.47, 4.22) 4.15 (2.46, 7.01) 
ERCC2 -0.01 
(-0.25, 0.25) AA 1.00 1.56 (0.83, 2.93) 3.31 (1.87, 5.86) 4.91 (2.74, 8.77) 
AC/CC 1.0078 2.03 (1.12, 3.71) 2.83 (1.62, 4.93) 5.36 (3.05, 9.41) 
ERCC5 -0.05 
(-0.25, 0.16) GG 1.00 1.79 (1.01, 3.16) 2.95 (1.78, 4.91) 4.28 (2.58, 7.10) 
GC/CC 1.0079 1.63 (0.93, 2.86) 2.16 (1.29, 3.61) 4.82 (2.84, 8.18) 
XRCC1 (Ex6) 0.03 
(-0.39, 0.36) CC 1.00 1.32 (0.84, 2.09) 2.26 (1.49, 3.40) 4.01 (2.64, 6.08) 
CT/TT 1.0080 1.97 (0.97, 4.01) 2.60 (1.47, 4.59) 4.15 (2.25, 7.64) 
XRCC1 (Ex10) 0.04 
(-0.15, 0.23) GG 1.00 1.13 (0.61, 2.10) 2.06 (1.19, 3.55) 3.19 (1.84, 5.54) 
GA/AA 1.0081 1.42 (0.80, 2.50) 1.91 (1.13, 3.22) 3.65 (2.15, 6.22) 
XRCC3 0.02 
(-0.22, 0.25) CC 1.00 1.24 (0.75, 2.06) 2.15 (1.36, 3.39) 3.88 (2.45, 6.16) 
CT/TT 1.0082 1.76 (0.99, 3.13) 2.47 (1.49, 4.09) 3.54 (2.10, 5.97) 
Risk allele 0.08 
(-0.16, 0.36) 0-3 1.00 1.35 (0.76, 2.39) 2.16 (1.31, 3.56) 4.47 (2.68, 7.46) 




76 Adjusted for sex and age. 
77 POR = 1.19 comparing CG/GG to CC in this lowest exposure quartile. 
78 POR = 1.55 comparing AC/CC to AA in this lowest exposure quartile. 
79 POR = 1.35 comparing GC/CC to GG in this lowest exposure quartile. 
80 POR = 1.40 comparing CT/TT to CC in this lowest exposure quartile. 
81 POR = 0.87 comparing GA/AA to GG in this lowest exposure quartile. 
82 POR = 0.85 comparing CT/TT to CC in this lowest exposure quartile. 





TABLE 8.  Prevalence Odds Ratios84 and 95% CIs for Skin Lesion Prevalence in Relation to DNA Repair 
SNPs by Creatinine-adjusted Urinary Total Arsenic Concentration, Araihazar, Bangladesh, 2000-2002 
SNP Creatinine-adjusted urinary total arsenic concentration (μg/g) RERI 
16-103 104-192 193-339 340-8556 
OGG1 -0.01 
(-0.21, 0.19) CC 1.00 2.98 (1.65, 5.36) 3.26 (1.86, 5.70) 6.09 (3.50, 10.60) 
CG/GG 1.0085 1.72 (0.98, 3.03) 3.12 (1.77, 5.49) 6.76 (3.96, 11.54) 
ERCC2 0.03 
(-0.22, 0.29) AA 1.00 2.34 (1.24, 4.39) 3.66 (1.98, 6.78) 6.79 (3.71, 12.43) 
AC/CC 1.0086 2.45 (1.33, 4.53) 3.48 (1.90, 6.37) 7.18 (4.00, 12.87) 
ERCC5 -0.03 
(-0.27, 0.17) GG 1.00 1.50 (0.86, 2.64) 2.59 (1.52, 4.42) 5.11 (3.07, 8.51) 
GC/CC 1.0087 1.73 (1.00, 3.00) 2.36 (1.37, 4.08) 4.85 (2.86, 8.23) 
XRCC1 (Ex6) 0.08 
(-0.22, 0.45) CC 1.00 1.82 (1.17, 2.84) 2.88 (1.86, 4.46) 5.15 (3.38, 7.85) 
CT/TT 1.0088 2.20 (1.13, 4.28) 2.26 (1.21, 4.23) 6.93 (3.83, 12.53) 
XRCC1 (Ex10) 0.06 
(-0.13, 0.23) GG 1.00 1.55 (0.85, 2.80) 2.49 (1.40, 4.41) 3.98 (2.30, 6.90) 
GA/AA 1.0089 1.56 (0.90, 2.71) 2.18 (1.27, 3.75) 5.05 (2.97, 8.60) 
XRCC3 0.11 
(-0.07, 0.33) CC 1.00 1.72 (1.05, 2.81) 2.08 (1.28, 3.39) 4.34 (2.73, 6.90) 
CT/TT 1.0090 1.33 (0.75, 2.36) 3.05 (1.77, 5.27) 5.23 (3.10, 8.82) 
Risk allele 0.16 
(-0.08, 0.45) 0-3 1.00 1.49 (0.85, 2.59) 2.65 (1.56, 4.53) 4.60 (2.75, 7.69) 




84 Adjusted for sex and age. 
85 POR = 1.54 comparing CG/GG to CC in this lowest exposure quartile. 
86 POR = 1.64 comparing AC/CC to AA in this lowest exposure quartile. 
87 POR = 0.95 comparing GC/CC to GG in this lowest exposure quartile. 
88 POR = 1.67 comparing CT/TT to CC in this lowest exposure quartile. 
89 POR = 0.87 comparing GA/AA to GG in this lowest exposure quartile. 
90 POR = 0.76 comparing CT/TT to CC in this lowest exposure quartile. 





TABLE 9.  Prevalence Odds Ratios92 and 95% CIs for Skin Lesion Prevalence in Relation to DNA Repair 
SNPs by Primary Methylation Index, Araihazar, Bangladesh, 2000-2002 
SNP Primary Methylation Index RERI 
<0.580 0.580-0.835 0.836-1.154 1.155-19.570 
OGG1 -0.11 
(-0.42, 0.10) CC 1.00 1.17 (0.66, 2.10) 1.49 (0.86, 2.59) 1.52 (0.88, 2.62) 
CG/GG 1.0093 1.74 (1.01, 3.01) 1.36 (0.79, 2.34) 1.35 (0.79, 2.31) 
ERCC2 0.11 
(-0.12, 0.26) AA 1.00 1.20 (0.66, 2.20) 1.33 (0.74, 2.41) 1.05 (0.59, 1.87) 
AC/CC 1.0094 1.38 (0.77, 2.47) 1.18 (0.67, 2.09) 1.34 (0.76, 2.36) 
ERCC5 0.13 
(-0.03, 0.27) GG 1.00 1.51 (0.89, 2.58) 1.67 (0.99, 2.82) 1.11 (0.65, 1.88) 
GC/CC 1.0095 1.25 (0.71, 2.19) 1.03 (0.60, 1.79) 1.64 (0.97, 2.77) 
XRCC1 (Ex6) 0.18 
(-0.12, 0.36) CC 1.00 1.42 (0.91, 2.22) 1.47 (0.95, 2.27) 1.30 (0.84, 2.00) 
CT/TT 1.0096 1.63 (0.85, 3.13) 1.51 (0.82, 2.79) 2.16 (1.17, 3.97) 
XRCC1 (Ex10) 0.06 
(-0.17, 0.23) GG 1.00 1.67 (0.91, 3.04) 1.55 (0.87, 2.78) 1.36 (0.77, 2.39) 
GA/AA 1.0097 1.49 (0.85, 2.60) 1.55 (0.89, 2.68) 1.66 (0.96, 2.88) 
XRCC3 -0.05 
(-0.38, 0.16) CC 1.00 1.46 (0.89, 2.41) 1.43 (0.88, 2.32) 1.55 (0.97, 2.50) 
CT/TT 1.0098 1.56 (0.88, 2.77) 1.62 (0.95, 2.79) 1.50 (0.87, 2.58) 
Risk allele 0.10 
(-0.18, 0.28) 0-3 1.00 1.38 (0.80, 2.39) 1.39 (0.82, 2.38) 1.23 (0.73, 2.07) 




92 Adjusted for sex and age. 
93 POR = 0.99 comparing CG/GG to CC in this lowest exposure quartile. 
94 POR = 0.80 comparing AC/CC to AA in this lowest exposure quartile. 
95 POR = 0.83 comparing GC/CC to GG in this lowest exposure quartile. 
96 POR = 0.87 comparing CT/TT to CC in this lowest exposure quartile. 
97 POR = 1.11 comparing GA/AA to GG in this lowest exposure quartile. 
98 POR = 1.20 comparing CT/TT to CC in this lowest exposure quartile. 





TABLE 10.  Prevalence Odds Ratios100 and 95% CIs for Skin Lesion Prevalence in Relation to DNA 
Repair SNPs by Secondary Methylation Index, Araihazar, Bangladesh, 2000-2002 
SNP Secondary Methylation Index RERI 
<4.316 4.316-5.855 5.856-8.211 8.212-32.300 
OGG1 0.01 
(-0.21, 0.18) CC 1.00 0.84 (0.54, 1.33) 0.59 (0.37, 0.94) 0.71 (0.42, 1.21) 
CG/GG 1.00101 0.76 (0.49, 1.17) 0.94 (0.59, 1.48) 0.47 (0.27, 0.80) 
ERCC2 -0.03 
(-0.29, 0.17) AA 1.00 0.82 (0.51, 1.29) 0.77 (0.47, 1.27) 0.54 (0.30, 0.97) 
AC/CC 1.00102 0.79 (0.50, 1.23) 0.82 (0.52, 1.30) 0.65 (0.39, 1.09) 
ERCC5 0.09 
(-0.10, 0.23) GG 1.00 0.93 (0.61, 1.42) 0.86 (0.55, 1.34) 0.72 (0.43, 1.18) 
GC/CC 1.00103 0.78 (0.50, 1.21) 0.77 (0.49, 1.21) 0.47 (0.27, 0.82) 
XRCC1 (Ex6) -0.06 
(-0.50, 0.20) CC 1.00 0.75 (0.53, 1.07) 0.71 (0.50, 1.03) 0.56 (0.37, 0.85) 
CT/TT 1.00104 1.13 (0.64, 2.02) 1.09 (0.60, 1.98) 0.57 (0.27, 1.21) 
XRCC1 (Ex10) -0.06 
(-0.31, 0.14) GG 1.00 0.81 (0.50, 1.30) 0.60 (0.36, 1.00) 0.55 (0.32, 0.94) 
GA/AA 1.00105 0.75 (0.49, 1.15) 0.83 (0.53, 1.29) 0.58 (0.34, 0.98) 
XRCC3 -0.22 
(-0.67, 0.05) CC 1.00 0.78 (0.53, 1.14) 0.70 (0.47, 1.06) 0.41 (0.26, 0.67) 
CT/TT 1.00106 0.83 (0.52, 1.31) 0.71 (0.44, 1.14) 0.81 (0.46, 1.41) 
Risk allele 0.10 
(-0.16, 0.27) 0-3 1.00 0.78 (0.50, 1.20) 0.85 (0.55, 1.32) 0.63 (0.38, 1.05) 
4-8 1.00107 1.00 (0.62, 1.61) 0.78 (0.46, 1.32) 0.57 (0.30, 1.07) 
 
                                                            
100 Adjusted for sex and age. 
101 POR = 0.99 comparing CG/GG to CC in this lowest exposure quartile. 
102 POR = 1.03 comparing AC/CC to AA in this lowest exposure quartile. 
103 POR = 1.14 comparing GC/CC to GG in this lowest exposure quartile. 
104 POR = 0.90 comparing CT/TT to CC in this lowest exposure quartile. 
105 POR = 0.98 comparing GA/AA to GG in this lowest exposure quartile. 
106 POR = 0.86 comparing CT/TT to CC in this lowest exposure quartile. 





TABLE 11.  Prevalence Odds Ratios108 and 95% CIs for Skin Lesion Prevalence in Relation to DNA 
Repair SNPs by Body Mass Index, Araihazar, Bangladesh, 2000-2002 
SNP Body Mass Index RERI 
<18.5 18.5-24.9 >25.0 
OGG1 -0.16 
(-0.71, 0.17) CC 1.00 0.75 (0.52, 1.08) 0.37 (0.15, 0.92) 
CG/GG 1.00109 0.72 (0.51, 1.03) 0.46 (0.21, 1.02) 
ERCC2 -0.05 
(-0.67, 0.30) AA 1.00 0.72 (0.50, 1.05) 0.40 (0.14, 1.12) 
AC/CC 1.00110 0.79 (0.56, 1.13) 0.52 (0.24, 1.09) 
ERCC5 -0.24 
(-0.94, 0.16) GG 1.00 0.75 (0.53, 1.05) 0.25 (0.10, 0.65) 
GC/CC 1.00111 0.73 (0.52, 1.02) 0.61 (0.27, 1.36) 
XRCC1 (Ex6) 0.24 
(-0.41, 0.53) CC 1.00 0.88 (0.66, 1.16) 0.47 (0.24, 0.92) 
CT/TT 1.00112 0.80 (0.51, 1.26) 1.06 (0.27, 4.12) 
XRCC1 (Ex10) -0.06 
(-0.65, 0.28) GG 1.00 0.79 (0.54, 1.16) 0.36 (0.14, 0.91) 
GA/AA 1.00113 0.83 (0.58, 1.18) 0.59 (0.26, 1.34) 
XRCC3 0.10 
(-0.39, 0.38) CC 1.00 0.89 (0.65, 1.22) 0.37 (0.17, 0.84) 
CT/TT 1.00114 0.80 (0.56, 1.15) 0.71 (0.29, 1.74) 
Risk allele 0.07 
(-0.64, 0.39) 0-3 1.00 0.72 (0.51, 1.02) 0.47 (0.20, 1.11) 
4-8 1.00115 0.81 (0.55, 1.18) 0.53 (0.20, 1.36) 
 
                                                            
108 Adjusted for sex, age, and well water arsenic concentration. 
109 POR = 0.85 comparing CG/GG to CC in this lowest exposure tertile. 
110 POR = 1.02 comparing AC/CC to AA in this lowest exposure tertile. 
111 POR = 0.89 comparing GC/CC to GG in this lowest exposure tertile. 
112 POR = 1.48 comparing CT/TT to CC in this lowest exposure tertile. 
113 POR = 1.05 comparing GA/AA to GG in this lowest exposure tertile. 
114 POR = 1.21 comparing CT/TT to CC in this lowest exposure tertile. 





TABLE 12.  Prevalence Odds Ratios116 and 95% CIs for Skin Lesion Prevalence in Relation to DNA 
Repair SNPs by Smoking Status, Araihazar, Bangladesh, 2000-2002 
SNP Smoking Status RERI 
Never Ever 
OGG1 -0.23 
(-0.86, 0.26) CC 1.00 1.33 (0.88, 2.00) 
CG/GG 1.00117 1.13 (0.76, 1.68) 
ERCC2 0.34 
(-0.22, 0.77) AA 1.00 1.01 (0.65, 1.55) 
AC/CC 1.00118 1.21 (0.80, 1.84) 
ERCC5 0.36 
(-0.14, 0.79) GG 1.00 1.06 (0.71, 1.57) 
GC/CC 1.00119 1.20 (0.80, 1.80) 
XRCC1 (Ex6) -0.55 
(-1.59, 0.31) CC 1.00 1.41 (1.00, 1.98) 
CT/TT 1.00120 1.39 (0.87, 2.22) 
XRCC1 (Ex10) -0.35 
(-1.24, 0.25) GG 1.00 1.40 (0.92, 2.16) 
GA/AA 1.00121 1.32 (0.87, 2.00) 
XRCC3 0.35 
(-0.28, 0.90) CC 1.00 1.16 (0.80, 1.69) 
CT/TT 1.00122 1.38 (0.92, 2.07) 
Risk allele -0.12 
(-0.96, 0.49) 0-3 1.00 1.35 (0.90, 2.05) 
4-8 1.00123 1.44 (0.92, 2.24) 
 
                                                            
116 Adjusted for sex, age, and well water arsenic concentration. 
117 POR = 1.04 comparing CG/GG to CC in this lowest exposure category. 
118 POR = 0.86 comparing AC/CC to AA in this lowest exposure category. 
119 POR = 0.78 comparing GC/CC to GG in this lowest exposure category. 
120 POR = 1.54 comparing CT/TT to CC in this lowest exposure category. 
121 POR = 1.27 comparing GA/AA to GG in this lowest exposure category. 
122 POR = 0.87 comparing CT/TT to CC in this lowest exposure category. 





TABLE 13.  Prevalence Odds Ratios124 and 95% CIs for Skin Lesion Prevalence in Relation to DNA 
Repair SNPs by Fruit and Vegetable Intake, Araihazar, Bangladesh, 2000-2002 
SNP 
Fruit and vegetable intake, g/day 
RERI 74.0-415.5 415.6-593.0 ≥593.1 
OGG1 -0.19 
(-0.63, 0.12) CC 1.00 0.65 (0.41, 1.01) 0.48 (0.30, 0.76) 
CG/GG 1.00125 0.56 (0.36, 0.87) 0.53 (0.34, 0.82)  
ERCC2 -0.16 
(-0.61, 0.17) AA 1.00 0.54 (0.33, 0.86) 0.46 (0.29, 0.74) 
AC/CC 1.00126 0.66 (0.43, 1.02) 0.49 (0.31, 0.77)  
ERCC5 -0.78 
(-1.43, -0.29) GG 1.00 0.48 (0.31, 0.73) 0.32 (0.20, 0.50) 
GC/CC 1.00127 0.48 (0.30, 0.75) 0.51 (0.33, 0.79)  
XRCC1 (Ex6) 0.04 
(-0.56, 0.49) CC 1.00 0.57 (0.40, 0.81) 0.54 (0.38, 0.78) 
CT/TT 1.00128 1.01 (0.58, 1.74) 0.52 (0.29, 0.94)  
XRCC1 (Ex10) -0.04 
(-0.47, 0.27) GG 1.00 0.67 (0.42, 1.05) 0.47 (0.29, 0.77) 
GA/AA 1.00129 0.66 (0.43, 1.02) 0.61 (0.40, 0.93)  
XRCC3 0.18 
(-0.18, 0.47) CC 1.00 0.69 (0.47, 1.03) 0.65 (0.44, 0.96) 
CT/TT 1.00130 0.80 (0.51, 1.28) 0.53 (0.33, 0.85)  
 
Risk allele -0.34 
(-0.99, 0.07) 0-3 1.00 0.51 (0.33, 0.79) 0.44 (0.28, 0.68) 
4-8 1.00131 0.73 (0.45, 1.19) 0.33 (0.32, 0.87)  
  
                                                            
124 Adjusted for sex, age, well water arsenic concentration, total caloric intake, and BMI.  
125 POR = 0.83 comparing CG/GG to CC in this lowest exposure tertile. 
126 POR = 0.85 comparing AC/CC to AA in this lowest exposure tertile. 
127 POR = 0.52 comparing GC/CC to GG in this lowest exposure tertile. 
128 POR = 0.99 comparing CT/TT to CC in this lowest exposure tertile. 
129 POR = 1.05 comparing GA/AA to GG in this lowest exposure tertile. 
130 POR = 1.33 comparing CT/TT to CC in this lowest exposure tertile. 








Gene-Gene, Gene-Environment, and Higher Order Interactions in Relation to 




 The oxidative stress and DNA repair pathways have been implicated in arsenic 
toxicity and have been hypothesized to underlie arsenic carcinogenesis. The object of this 
analysis was to explore gene-gene, gene-environment, and higher-order interactions 
among 10 single nucleotide polymorphisms (SNPs) related to the oxidative stress and 
DNA repair pathways by multifactor dimensionality reduction (MDR), classification and 
regression trees (CART) and logistic regression models. Data from 610 prevalent skin 
lesion cases and 1,079 controls from the Health Effects of Arsenic Longitudinal Study 
(HEALS) were utilized in these analyses. Based on single SNP evaluation in logistic 
regression models, none of the SNPs were associated with skin lesion prevalence, 
however, were evaluated for potential epistatic effects. Our analytic method utilized 
MDR and CART modeling approaches for the selection of potential gene-gene and gene-
environment interactions. Considerable overlap of the interactions detected by both these 
methods was observed, which were further evaluated by logistic regression. Results from 
logistic regression modeling indicated evidence for some of these statistical interactions; 
however, further investigation and replication of the statistical interactions detected in 





Globally, more than 100 million people, including approximately 28–57 million 
in Bangladesh, are chronically exposed to arsenic through naturally contaminated 
drinking water (1). The International Agency for Research on Cancer has categorized 
arsenic as a class I human carcinogen (2). Arsenic in drinking water has been associated 
with increased risk of a wide range of health outcomes including cancers of the skin, 
lung, bladder, liver, and kidney (3-7), neurological disease (8), cardiovascular disease (9), 
as well as other non-malignant diseases (10, 11). While most arsenic-related cancers have 
long average latency periods, skin lesions appear within a relatively shorter period of 
time following exposure to arsenic (12, 13). Additionally, skin lesions are considered 
precursors to a majority of the arsenic-induced basal and squamous cell skin cancers (14).  
Due to the absence of a suitable animal model for the evaluation of arsenic 
toxicity, a mode of action has yet to be determined for arsenic carcinogenesis (15, 16). 
Although, the oxidative stress and DNA repair pathways have been implicated in arsenic 
toxicity and have been hypothesized to underlie arsenic carcinogenesis (17). To date, few 
epidemiologic studies have evaluated genetic susceptibility to arsenical skin lesions based 
on single nucleotide polymorphisms (SNPs) in antioxidant enzyme or DNA repair genes. 
Only a single prior study by Ahsan et al. has evaluated SNPs in antioxidant enzyme genes 
(MPO and CAT) in relation to skin lesion prevalence and no significant main effects of 
the SNPs were observed (18). There have been 5 epidemiologic studies which have 
evaluated polymorphisms in DNA repair genes (ERCC2, APEX1, XRCC1, XRCC3, and 
OGG1) in relation to skin lesion prevalence and observations have been conflicting (19-
23). Banerjee et al. observed a significant increased risk of hyperkeratosis in relation to 
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the C allele of a polymorphism in ERCC2 (rs13181) (20), while others have not (19, 23). 
Breton et al. observed a significant increased risk of skin lesions in relation to the GG 
genotype compared to the TT genotype of a polymorphism in APEX1 (rs3136820) (21); 
however, this SNP has not been replicated in other studies with respect to skin lesion risk. 
Significant marginal effects of XRCC1, XRCC3, and OGG1 in relation to skin lesions 
have not been observed (21, 22).         
It has been previously described that genes may exhibit epistatic effects 
particularly for complex diseases, when no marginal effect of the gene is detected (24). 
There are several statistical approaches for evaluating gene-gene as well as gene-
environment interactions. Historically, epidemiologists have favored logistic regression 
for evaluating interaction within a case-control setting. With technological advances in 
genotyping, the number of SNPs that can be typed within a study has increasingly grown, 
which in turn has made the number of possible interactions to explore very large. For 
example, all possible pair-wise interactions between SNPs would equal N!/[2! (N−2)!], 
where N is the number of SNPs. For the 11 SNPs examined in this study, there would be 
55 SNP-pair interactions to evaluate. Therefore, for hypotheses where an a priori 
interaction is not specified, logistic regression is not an optimal tool for exploratory 
analyses of SNP-SNP interactions. Recently, dimensionality reduction approaches have 
been applied to these research questions, including multifactor dimensionality reduction 
(MDR) (25-29), classification and regression trees (CART) (30), and random forests (RF) 
(31). García-Magariños et al. (32) conducted a simulation study to evaluate the ability of 
these three methods as well as logistic regression to detect SNP-SNP interactions under 
different modeling scenarios (e.g., sample size, missing data, minor allele frequencies, 
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and penetrance); they concluded that CART performed well under all scenarios and was 
less computationally intensive than the other approaches. Additionally, Schwender et al. 
(33) conducted several classification methods in an analysis of 25 SNPs in a case-control 
study of breast cancer and also showed that the misclassification rate for the various 
methods applied was similar.  
In this study, we utilized data from 610 prevalent skin lesion cases and 1,079 
controls from the Health Effects of Arsenic Longitudinal Study (HEALS) cohort to 
evaluate gene-gene and gene-environment interactions in relation to skin lesion 
prevalence based on MDR, CART, and logistic regression analyses for SNPs in the 
oxidative stress (SOD2, rs4880; CAT, rs1001179; GPX1, rs1050450; and MPO, 
rs2333227) and DNA repair pathways (OGG1, rs1052133; XRCC1, rs25487 and 
rs1799782; XRCC3, rs861539; ERCC2, rs1052559; ERCC5, rs17655; and LIG4, 
rs1805388), as well as various measures of arsenic exposure in relation to skin lesion 
prevalence. 
 
MATERIALS AND METHODS 
Study Population 
HEALS is an ongoing, population-based cohort study examining both the short- 
and long-term health effects of arsenic exposure. The study was launched in Araihazar, 
Bangladesh, in 2000. The selection of cohort participants, study design and methods have 
been described in detail elsewhere (34).  
The prevalent cases and controls utilized in these analyses were selected from the 
baseline survey of the HEALS cohort. Between October 2000 and May 2002, married 
130 
 
individuals were sampled—an eligibility criteria to minimize loss to follow-up—who 
were aged between 18 and 75 years and were residents of the study area for at least 5 
years. From the 12,050 residents who met the eligibility criteria from an enumerated total 
65,876  persons in the study area, 11,746 (97.5% response rate) men and women (4,801 
married couples and 2,144 married individuals whose spouses did not participate) were 
enrolled into the HEALS cohort. Among the 11,746 enrolled baseline cohort participants, 
11,224 participants (95.6%) provided urine samples. At baseline, 610 cases of arsenical 
skin lesions were identified among the 11,224 cohort members who provided urine 
samples and were included as prevalent cases in this study. Of the remaining participants 
with an available urine sample and known to be free of skin lesions at baseline 
(n=10,614), a ~10% random sample (n=1,079) was selected and included as controls in 
this study.  
The distribution of skin lesion severity among the 610 cases was as follows: 359 
cases had melanosis only, 20 had leucomelanosis only, 10 had melanosis and 
leucomelanosis, 170 had melanosis and keratosis, 40 had leucomelanosis and keratosis, 
and 11 had melanosis, leucomelanosis, and keratosis.  
The study protocol was approved by the Institutional Review Boards of Columbia 
University, The University of Chicago, and the Bangladesh Medical Research Council. 
Informed consent was obtained from all participants prior to baseline interview.  
 
Single Nucleotide Polymorphism Assessment 
High-throughput DNA extraction was completed in 96-well format using the 
QIAmp DNA 96 DNA Blood kit (Qiagen, Valencia, CA). Replica plates were made with 
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12.5 ng DNA in 2.5 µL per well. In the first step, the genomic DNA was amplified by 
PCR using appropriate primers. After PCR amplification, the primers and 
deoxynucleotide triphosphates in 10 µL PCR product were digested with the 10 µL 
shrimp alkaline phosphatase cocktail containing 1.0 µL (1 unit/µL) of shrimp alkaline 
phosphatase, 0.1 µL of Escherichia coli exonuclease I (10 units/µL; U.S. Biochemical, 
Cleveland, OH), 1.0 µL of 10x shrimp alkaline phosphatase buffer, and 7.9 µL of DNase 
and RNase-free water for 45 min at 37°C followed by heating at 95°C for 15 min for 
enzyme deactivation. Then, single nucleotide extension was carried out in the presence of 
the appropriate allele-specific dideoxynucleotide triphosphates fluorescence labeled with 
either R110 or TAMRA (PerkinElmer, Waltham, MA). For single nucleotide extension 
reactions, both the forward and reverse probes were initially tested to select the better 
probe based on clear signal clustering. Reaction mixture (13 µL/well) containing 0.025 
µL AcycloPrime enzyme, 0.5 µL terminator dye, 1 µL reaction buffer, 0.25 µL extension 
probe (10 pmol/µL), and 11.225 µL water was added to 7 µL of digested PCR product to 
make 20 µL reaction volume. Thermocycling was done at 95°C for 3 min followed by 
optimum number of cycles of 95°C for 15 s and 55°C for 30 s. Finally, the fluorescence 
was measured with Wallac 1420 Multilabel Counter Victor 3 (PerkinElmer, Waltham, 
MA). In addition to our assay-specific quality control samples, 10% of the samples were 
run in duplicate after relabeling to keep laboratory researchers blinded to its identity. 
Concordance based on the duplicates was >0.92. Call rates for the SNPs of interest 





Skin Lesion Assessment 
 Arsenical skin lesion assessment was conducted through skin examination at the 
baseline interview following a structured protocol by a trained study physician (34, 35). 
Arsenical skin lesions were categorized as the presence of melanosis on the body surface, 
leucomelanosis on the body surface, and keratosis on the hands or feet. For the purposes 
of this study, cases were selected as having the presence of any type of arsenical skin 
lesion.      
 
Arsenic exposure assessment 
Three primary measures of arsenic exposure were estimated for each case-control 
participant: well water arsenic concentration, creatinine-adjusted urinary total arsenic 
concentration, and urinary arsenic metabolites.   
At the baseline survey, participants were asked to identify the well they primarily 
used as their source of drinking water, from which we were able to assign the appropriate 
well water arsenic concentration exposure. Well water arsenic concentrations of all 5,966 
tubewells in the study area were measured by graphite furnace atomic absorption 
spectrometry, with a detection limit of 5 μg/L. Samples below the limit of detection were 
subsequently reanalyzed by inductively coupled plasma-mass spectrometry (ICP-MS), 
with a detection limit of 0.1 μg/L (36).  
Urinary total arsenic concentration was measured in a spot urine sample collected 
at baseline by graphite furnace atomic absorption spectrometry, with a detection limit of 
2 μg/L (37). Urinary creatinine was measured by a colorimetric Sigma Diagnostics Kit 
(Sigma, St. Louis, MO), and urinary total arsenic was subsequently divided by creatinine 
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to obtain a creatinine-adjusted urinary total arsenic concentration, expressed as μg/g 
creatinine (38). 
Urinary arsenic metabolites were measured based on the method by Reuter et al. 
(39) using high-performance liquid chromatography separation of arsenobetaine, 
arsenocholine, arsenate (AsV), arsenite (AsIII), total monomethyl arsenic (MMAIII + 
MMAV), and total dimethyl arsenic (DMAIII + DMAV) followed by detection by ICP-
MS-dynamic reaction cell. Total inorganic arsenic (AsIII + AsV) is utilized in these 
analyses since AsIII can oxidize to AsV during sample transport, storage, and preparation.  
For purposes of analysis, well water arsenic was categorized into quartiles based 
on the distribution in the controls; however, since the first and second quartiles roughly 
corresponded to the World Health Organization’s guideline for arsenic in drinking water 
(10 μg/L) and the national standard for arsenic in drinking water in Bangladesh (50 
μg/L), respectively, we adjusted the cutoff points slightly to correspond to these 
regulatory levels. Urinary total arsenic concentration and arsenic metabolite metrics were 
quartiled based on the distribution in the controls. The percentages of MMA, DMA and 
inorganic arsenic were calculated after exclusion of arsenobetaine and arsenocholine 
from the total. In addition, two methylation indices were constructed: primary 
methylation index (PMI)—the ratio of MMA to inorganic arsenic—and secondary 
methylation index (SMI)—the ratio of DMA to MMA.  
 
Statistical Analysis 
Hardy Weinberg Equilibrium (HWE) was calculated for the controls based on 
Pearson (χ2) tests and α. Violation of HWE is calculated based on statistical departure 
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from expected HWE frequencies based on the exact test. α is used to denote the 
magnitude of departure from HWE. 
 
where Pgg, PGg, and PGG are the genotype proportions (40).  
 The association between each SNP and arsenical skin lesion status was estimated 
by prevalence odds ratios (PORs) and their 95% confidence intervals (CIs) from logistic 
regression models employed by the LOGISTIC procedure in SAS. The PORs were 
adjusted for sex, age, and well water arsenic concentration, primarily because of the 
strong association of these covariates with the outcome. The genotype-specific PORs 
were estimated for each SNP using the homozygous major genotype as the reference 
category.  
Two approaches were selected to evaluate SNP-SNP and higher order interactions 
(i.e., MDR and CART). Due to the fact that there was not a substantial amount of 
variability in the LIG4 SNP genotype in this population and the α statistic suggested a 
deviation from HWE in the control subjects, this SNP was excluded from evaluation of 
interaction.  
SNP-SNP interactions were first evaluated using MDR among the 10 genotyped 
SNPs, with no additional predictors specified. SNP-SNP interactions were then evaluated 
with the addition of various measures of arsenic exposure to the interaction models (i.e., 
well water arsenic concentration, creatinine-adjusted urinary total arsenic concentration, 
primary methylation index, and secondary methylation index). Each construct of arsenic 
exposure was modeled separately with the set of 10 SNPs. MDR is a nonparametric 
method that reduces data into a single dimensional variable (classifying individuals as 
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high and low risk groups), determined by the ratio of diseased to non-diseased individuals 
(28). Each model is constructed using ten-fold cross-validation, where 9/10 of the data 
are used to construct the models and 1/10 of the data are used to estimate the testing 
accuracy (i.e., the proportion of individuals the model correctly classifies). All SNPs 
were modeled as ordinal variables, coded as 0, 1, or 2, which represented the number of 
minor alleles carried. All measures of arsenic exposure were modeled as ordinal 
variables, coded as 0, 1, 2, or 3, which represented increasing quartile of exposure level. 
Individuals with data missing for any of the variables were excluded from the analysis. 
MDR analyses were conducted using MDR software (version 2.0 beta 8.3) (41).          
CART was utilized to assess SNP-SNP interactions based on the same strategy; 
first, interactions were evaluated among the 10 SNPs and then various constructs of 
arsenic exposure were integrated into the interaction models. CART analysis is a 
nonparametric recursive partitioning approach that constructs a decision tree using ten-
fold cross-validation (42). It is characterized by two central features in tree 
construction—1) recursive partitioning which splits the root node into offspring nodes 
and continues into further generation of nodes and 2) pruning which removes from the 
bottom up splits that are based on unreliably small sample sizes (42). All SNPs were 
modeled as ordinal variables, coded as 0, 1, or 2, which represented the number of minor 
alleles carried. All measures of arsenic exposure were modeled as ordinal variables, 
coded as 0, 1, 2, or 3, which represented increasing quartiles of exposure level. 
Participants with data missing for any of the variables were excluded from the analysis. 
Individuals were classified in the tree based on the Gini splitting rule and, the tree was 
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pruned to minimum cross-validated error in the terminal nodes (30). CART analyses 
were conducted using DTREG software (43).       
Logistic regression was finally employed to assess interactions that were 
predicted by both MDR and CART to evaluate how well the results converged. Logistic 
regression was conducted using the LOGISTIC procedure in SAS. The likelihood ratio 
test was used to evaluate interaction on the multiplicative scale by comparing the full 
model containing interactions terms to the reduced model without the interaction terms.  
 
RESULTS 
 Deviation from the expected genotype frequency distribution was observed for 
LIG4 so we elected to eliminate this SNP from evaluation of interaction analyses (Table 
1). Characteristics of the study populations are shown in Table 2. There was a higher 
prevalence of skin lesions among males and older individuals as well as evidence of a 
dose-response trend with increasing quartiles of well water arsenic concentration, 
creatinine-adjusted urinary total arsenic concentration, and the primary methylation 
index. An inverse trend was observed with increasing quartiles of the secondary 
methylation index. 
 Genotype frequencies of the SNPs as well as associations with skin lesion 
prevalence are shown in Table 3. There were no significant marginal effects observed; 
adjustment for sex, age, and well water arsenic concentration did not appreciably change 
the effect estimates (data not shown). The conditional effects of the SNPs (e.g., with the 
inclusion of all the SNPs in a single logistic regression model) were also evaluated and, 
we did not observe any significant associations with skin lesions (Table D.2). 
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Furthermore, utilizing Hierarchical Bayes modeling (44) to integrate information on the 
shared pathways (i.e., oxidative stress and DNA repair, Table D.1) of the SNPs did not 
yield considerably different results from the conditional model (Table D.2).      
 The results of the MDR interaction models are shown in Table 4, with the results 
for the best 1, 2, and 3 factor models indicated. Five different interaction modeling 
scenarios were evaluated, which included SNP-SNP and environment-SNP interactions. 
A different pattern of interactions was generally observed for each of the exposure 
modeling scenarios; however, in each case, the measure of arsenic exposure was the 
single most important predictor of skin lesions. Overall, the interaction model between 
well water arsenic concentration and the polymorphism in MPO provided the highest 
testing accuracy (0.6152) and maximum cross-validation consistency (10/10) for skin 
lesion prevalence. Based on these 2 factors, individuals who were classified as high risk 
were 2.6 (95% CI=2.0, 3.3) times more likely to have skin lesions than individuals who 
were classified as low risk (shown in Figure D.1).  
 The results of the CART analyses are shown in Figures D.4-D.8 for all prediction 
models. Again, a different pattern of interactions was generally observed for each of the 
exposure modeling scenarios; however, in each model that included arsenic exposure, 
arsenic was the single most important predictor of skin lesions indicated by the first split 
in each of the graphs by the arsenic variable. 
A comparison of the MDR and CART interaction models revealed consistency for 
the following interactions in the SNPs only model: 1) ERCC5*XRCC1 (Ex10) and 2) 
OGG1*ERCC5*XRCC1 (Ex10). In the model that included well water arsenic 
concentration, only the interaction between arsenic and MPO was observed in both 
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methods. The model that included primary methylation index showed consistency by 
both methods for: 1) PMI*OGG1 and 2) PMI*SOD2*OGG1. These interactions were 
subsequently evaluated by logistic regression.    
Both MDR and CART predicted an interaction between the polymorphisms in 
ERCC5 and XRCC1 (Ex10), which was confirmed by logistic regression (Table 5). 
Overall, the inclusion of interaction terms between ERCC5 and XRCC1 (Ex10) in the 
model were significant (adjusted model: χ2=13.8, 4 d.f., P for interaction=0.008). There 
was a significant antagonist interaction between the GC genotype of ERCC5 and the GA 
genotype of XRCC1 (Ex10). The data were too sparse to evaluate the three-way 
interaction between the polymorphisms in OGG1, ERCC5, and XRCC1 (Ex10), as shown 
in Figure D.2b. Evaluation of the interaction between well water arsenic concentration 
(dichotomized into lowest two quartiles versus highest two quartiles) and the 
polymorphism in MPO did not reveal any significant interaction overall by logistic 
regression modeling (Table 6); although, there appeared to be a slight reduction in risk 
among individuals with the GA genotype of MPO. When well water arsenic 
concentration was included in the model by 3 indicator variables to specify quartiles of 
exposure, the interaction term for the third quartile of exposure and the GA genotype of 
MPO showed statistical evidence of antagonism (βGxE=-1.1708, P value=0.0028). This 
antagonistic interaction was predicted by MDR, as shown in Figure D.1, with the 
individuals in the corresponding cell labeled low risk. Evaluation of the interaction 
between the primary methylation index (dichotomized into lowest two quartiles versus 
highest two quartiles) and the polymorphism in OGG1 did not reveal any significant 
interaction overall by logistic regression modeling (Table 7); nor was there any evidence 
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of interaction when the primary methylation index was modeled by 3 indicator variables 
(data not shown). Based on the MDR model (Figure D.3a), it appears there was positive 
interaction between low PMI and the CG genotype of OGG1, with those individuals 
classified as high risk, and an antagonistic interaction predicted between high PMI and 
the GG genotype of OGG1, with those individuals classified as low risk, that was not 
statistically observable in the logistic regression modeling. Finally, the three-way 
interaction between PMI, OGG1 and SOD2 was evaluated by logistic regression (Table 
8). There was evidence of a significant multiplicative SNP-SNP interaction between 
OGG1 and SOD2 (χ2=12.4, 4 d.f., P for interaction=0.01), with evidence for a significant 
antagonistic interaction between the CG genotype of OGG1 and the CT genotype of 
SOD2 as well as a significant antagonistic interaction between the GG genotype of 
OGG1 and the CT genotype of SOD2, also depicted in the MDR model (Figure D.3b). In 
an effort to evaluate the three-way interaction with PMI in the logistic regression models, 
the models were stratified by low and high PMI. While the multiplicative interaction was 
not statistically significant, the SNP-SNP interaction marginally appeared in the high 
PMI exposure group and was not apparent in the low PMI exposure group (P for 
interaction=0.06 and 0.29, respectively).       
 
DISCUSSION  
 In this study, we evaluated potential gene-gene interactions of 10 SNPs genotyped 
in candidate genes in the oxidative stress and DNA repair pathways. We additionally 
evaluated gene-environment interactions through the inclusion of various constructs of 
arsenic exposure (well water arsenic concentration, creatinine-adjusted urinary total 
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arsenic concentration, primary methylation index, and secondary methylation index) with 
the SNPs in the predictor variable sets for MDR and CART. The approach taken was to 
use the MDR and CART methods to select concordant interactions for evaluation by 
logistic regression. Several gene-gene and gene-environment interactions were consistent 
between MDR and CART including: ERCC5*XRCC1 (Ex10); OGG1*ERCC5*XRCC1 
(Ex10); well water arsenic*MPO; PMI*OGG1; and, PMI*SOD2*OGG1. These selected 
interactions were evaluated for statistical evidence of multiplicative interaction by 
logistic regression, which revealed significant antagonistic interactions for 
ERCC5*XRCC1 (Ex10) and PMI*SOD2*OGG1.        
The ERCC5 gene codes for a DNA repair protein involved in the NER pathway of 
UV-induced damage (45). This gene is located in chromosome region 13q33. A 
nonsynonymous SNP (G>C, Asp1104His, rs17655) in ERCC5 was examined in this 
study. While there is no current literature on the association of this gene with arsenic or 
skin lesions, there is evidence of a potential interaction between arsenic and UV (46, 47) 
in relation to skin lesions. XRCC1 is a DNA repair enzyme that interacts with 
polynucleotide kinase (PNK), DNA polymerase-beta (POLB) and DNA ligase III (LIG3) 
as part of a complex to repair single-strand breaks and functions in BER to repair damage 
caused by agents such as reactive oxygen species (48). This gene is located in 
chromosome region 19q.13.2. A nonsynonymous SNP (C>T, Arg194Trp, rs1799782) in 
this gene was genotyped in this study, of which the T allele has been associated with 
deficient DNA repair (49). In this study, there was statistically significant antagonistic 
interaction between the heterozygous genotypes of both ERCC5 and XRCC1 (Ex10). 
Both these genes have been previously examined in epidemiologic investigations related 
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to carcinogenesis (50-52); although, an interaction between these genes has not been 
previously reported.  
In this study we also observed significant antagonistic interaction between OGG1 
and SOD2, particularly among individuals with higher levels of the primary methylation 
index. OGG1 is a DNA glycosylase involved in base excision repair (BER) of 8-
hydroxydeoxyguanosine (8-OHdG), an adduct formed from oxidative stress (53). During 
BER, OGG1 removes damaged bases by cleaving N-glycosylic bonds (53). Prior in vitro 
(54) and animal (55, 56) studies have shown OGG1 to play a role in mitigating arsenic-
induced oxidative damage. This gene is located in chromosome region 3p26.2. A 
nonsynonymous SNP (C>G, Ser326Cys, rs1052133) in OGG1 was genotyped in this 
study. Proteins encoded with the G allele exhibit reduced 8-OHdG repair activity (57). 
Additionally, SOD2 protein plays a major role in maintaining oxidative balance by 
converting superoxide (O2-)—a precursor molecule for all other reactive oxygen 
species—into hydrogen peroxide and oxygen (58). Additionally, prior in vitro 
experiments have shown SOD2 to play a role in mitigating arsenic-induced DNA damage 
from oxidative stress (59, 60). This gene is located in chromosome region 6q25.3. A 
nonsynonymous SNP (C>T, Ala16Val, rs4880) in SOD2 was genotyped in this study. 
The C allele retains the alpha helical structure of the protein for normal activity of the 
enzyme (61). Finally, inefficient arsenic methylation (i.e., represented by elevated 
concentrations of MMA to inorganic arsenic in urine) has been consistently observed as a 
risk factor for skin lesion prevalence in previous epidemiologic studies (62-65). A recent 
cross-sectional study among arsenic-exposed individuals showed that lower primary 
methylation index was associated with lower plasma antioxidant capacity (66). Moreover, 
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in vitro studies have shown that MMA induces reactive oxygen species, particularly the 
trivalent form of this organic arsenic species (67, 68). In a study by Bailey et al. (68), in 
vitro experiments using normal human epidermal keratinocytes showed that MMAIII 
exhibited the greatest potential for skin carcinogenesis through the induction of oxidative 
stress, compared to the trivalent forms of inorganic arsenic and DMA. In a comparative 
functional genomics analysis in yeast, Jo et al. (69) showed that glutathione (related to 
cellular antioxidant status) was more important in MMAIII toxicity than trivalent 
inorganic arsenic toxicity. We observed a significant antagonistic interaction between the 
CG genotype of OGG1 and the CT genotype of SOD2 as well as a significant 
antagonistic interaction between the GG genotype of OGG1 and the CT genotype of 
SOD2. Both these genes have been associated with cancer outcomes (70-72), although an 
interaction between them has not been previously reported.  
There are several strengths of this study. First, the main strength of this study was 
our multi-analytic approach to the assessment of gene-gene, gene-environment, and 
higher-order interactions. We utilized two nonparametric approaches (i.e., MDR and 
CART) to select promising interactions for evaluation by logistic regression. MDR and 
CART proved to be powerful analytic methods for the detection of statistical gene-gene 
and gene-environment interactions, including higher-order interactions, with a limited 
sample size. MDR has been previously shown to undercover gene-gene and gene-
environment interactions in the absence of any significant marginal effects of the factors 
(73, 74). Even with the potential noise present in the predictor variable sets—with the 
inclusion of several SNPs unrelated to the outcome—both the MDR and CART methods 
consistently selected arsenic exposure as the most important predictor of skin lesions 
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when included in the predictor variable sets. Second, the measurement of various 
constructs of arsenic exposure was evaluated. Different components of arsenic have been 
assessed in this study population including well water arsenic concentration (a measure of 
external exposure), urinary total arsenic concentration (a measure of internal dose), as 
well as arsenic metabolites (a measure of biological response). It is possible that genes 
interact differently with each of the components of arsenic exposure, which we were able 
to systematically evaluate in this study.   
There are several limitations of this study that we also consider. First, significant 
interactions observed in these analyses may not be causal, but simply due to chance. We 
did not observe any significant marginal effects of the SNPs, and while it is possible that 
epistatic effects could still be present, we may have simply added noise to the predictor 
variable sets by including these SNPs. Second, the interactions observed were all 
antagonistic interactions between the heterozygous genotypes. The biological basis of 
this type of relationship is difficult to conceive. Third, the evaluation of three-way 
interactions using logistic regression in this study was hampered by the small sample size 
to asses these higher order interactions.     
In summary, our analytic method utilized MDR and CART modeling approaches 
for the selection of potential gene-gene and gene-environment interactions. We observed 
considerable overlap of the interactions detected by both these methods, which were 
further evaluated by logistic regression. Results from logistic regression modeling, 
confirmed some of these statistical interactions; however, further investigation and 
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TABLE 1. Single Nucleotide Polymorphisms 







Antioxidant enzymes genes 
SOD2 4880 6 Ex2+24C>T A16V 96.5 0.03 
CAT  1001179  11 -329T>C   96.3 0.01 
GPX1  1050450  3 Ex1-226C>T  P200L 96.4 -0.03 
MPO  2333227  17 -642G>A   96.8 -0.03 
DNA repair genes 
OGG1 1052133 3 Ex6-315C>G S326C 97.7 -0.01 
ERCC2 1052559 19 Ex23+61A>C  K751Q 97.9 0.01 
ERCC5 17655 13 Ex15-344G>C D1104H 96.8 -0.05 
LIG4 1805388 13 Ex3+54C>T T9I 96.6 -0.18 
XRCC1 1799782 19 Ex6-22C>T   R194W 95.2 0.07 
XRCC1 25487 19 Ex10-4A>G  Q399R 96.3 -0.01 











(95% CI) N % N % 
Sex      
Male 507 82.6 440 40.8 1.0 
Female 106 17.4 639 59.2 0.1 (0.1, 0.1) 
Age, years      
18-30 161 26.4 386 35.8 1.0 
31-40 224 36.7 237 22.0 2.5 (1.8, 3.4)  
41-50 60 9.8 355 32.9 5.6 (4.0, 7.8) 
51-75 165 27.0 100 9.3 9.8 (6.7, 14.1) 
Well water arsenic, μg/L133      
0.1-10 72 11.8 265 24.6 1.0 
10.1-50 97 15.9 248 23.0 1.4 (1.0, 2.0) 
50.1-150 202 33.1 330 30.6 2.2 (1.6, 3.1) 
150.1-864  239 39.2 236 21.9 3.7 (2.7, 5.1) 
Urinary total arsenic, μg/g134      
16-103 64 10.5 269 24.9 1.0 
104-192 121 19.8 271 25.1 1.9 (1.3, 2.6) 
193-339 164 26.9 269 24.9 2.6 (1.8, 3.6) 
340-8556 261 42.8 270 25.1 4.1 (2.9, 5.6) 
Primary methylation index135      
<0.580 70 11.8 260 25.0 1.0  
0.580-0.835 132 22.3 259 25.0 1.9 (1.3, 2.6) 
0.836-1.154 171 28.9 260 25.0 2.4 (1.8, 3.4) 
1.155-19.570 218 36.9 260 25.0 3.1 (2.3, 4.3) 
Secondary methylation index136      
<4.316 236 39.9 259 25.0 1.0 
4.316-5.855 153 25.9 259 25.0 0.6 (0.5, 0.8) 
5.856-8.211 128 21.7 259 25.0 0.5 (0.4, 0.7) 




132 POR, Prevalence odds ratio; unadjusted.  
133 Water arsenic concentration cut-points roughly correspond to quartiles of the exposure distribution for 
the controls but have been slightly adjust to reflect policy relevant parameters.   
134 Creatinine-adjusted urinary total arsenic concentration cut-points are quartiles of the exposure 
distribution in control subjects. 
135 The primary methylation index was calculated as % MMA / % Inorganic arsenic.  




TABLE 3.  Prevalence Odds Ratios and 95% CIs for Skin Lesion Prevalence in Relation to SNPs 
SNP MAF137 Cases Controls POR
138  
(95% CI) N % N % 
Antioxidant enzymes genes 
SOD2 T=0.45      
CC  173 30.6 302 31.5 1.0  
CT  268 47.3 456 47.5 1.0 (0.8, 1.3) 
TT  125 22.1 202 21.0 1.1 (0.8, 1.4) 
GPX1 T=0.19      
CC  372 65.4 623 65.2 1.0 
CT  174 30.6 297 31.1 1.0 (0.8, 1.2) 
TT  23 4.0 36 3.8 1.1 (0.6, 1.8) 
CAT T=0.23      
CC  358 63.5 571 59.5 1.0 
CT  185 32.8 343 35.8 0.9 (0.7, 1.1) 
TT  21 3.7 45 4.7 0.7 (0.4, 1.3) 
MPO A=0.14      
GG  423 74.3 709 73.6 1.0 
GA  134 23.6 237 24.6 0.9 (0.7, 1.2) 
AA  12 2.1 17 1.8 1.2 (0.6, 2.5) 
DNA repair genes 
OGG1 G=0.31      
CC  264 46.0 460 47.2 1.0 
CG  259 45.1 423 43.4 1.1 (0.9, 1.3) 
GG  51 8.9 92 9.4 1.0 (0.7, 1.4) 
ERCC2 C=0.33      
AA  242 43.4 421 44.5 1.0 
AC  262 46.9 419 44.3 1.1 (0.9, 1.4) 
CC  54 9.7 105 11.1 0.9 (0.6, 1.3) 
ERCC5 C=0.27      
GG  298 52.8 503 52.0 1.0 
GC  223 39.5 400 41.4 0.9 (0.8, 1.2) 
CC  43 7.6 64 6.6 1.1 (0.8, 1.7) 
LIG4 T=0.09      
CC  473 82.8 788 82.3 1.0 
CT  92 16.1 165 17.2 0.9 (0.7, 8.9) 
TT  6 1.0 4 0.4 2.5 (0.7, 8.9) 
XRCC1 (Ex6) T=0.10      
CC  445 79.5 763 80.6 1.0 
CT  104 18.6 170 18.0 1.0 (0.8, 1.4) 
TT  11 2.0 13 1.4 1.4 (0.6, 3.3) 
XRCC1 (Ex10) A=0.33      
GG  240 42.5 423 44.1 1.0 
GA  251 44.4 429 44.8 1.0 (0.8, 1.3) 
AA  74 13.1 106 11.1 1.2 (0.9, 1.7) 
XRCC3 T=0.20      
CC  352 63.4 619 65.3 1.0 
CT  180 32.4 287 30.3 1.1 (0.9, 1.4) 
TT  23 4.1 42 4.4 1.0 (0.6, 1.6) 
                                                            




TABLE 4.  MDR Interaction Models for Single Nucleotide Polymorphisms and Arsenic Exposure in 











1 CAT 0.4916 4/10 1.2 (0.9, 1.5) 
2 ERCC5, XRCC1 (Ex10) 0.5172 8/10 1.5 (1.2, 1.9) 
3 OGG1, ERCC5, XRCC1 (Ex10)  0.4921 6/10 1.8 (1.4, 2.3) 
     
Well water arsenic and SNPs 
1 Water arsenic 0.5957 10/10 2.3 (1.8, 2.9) 
2 Water arsenic, MPO 0.6152 10/10 2.6 (2.0, 3.3) 
3 Water arsenic, MPO, ERCC2 0.5704 3/10 2.8 (2.2, 3.5) 
     
Creatinine-adjusted urinary total arsenic and SNPs 
1 Urinary arsenic 0.6011 10/10 2.3 (1.8, 3.0) 
2 Urinary arsenic, XRCC1 (Ex6) 0.6077 10/10 2.5 (1.9, 3.2) 
3 Urinary arsenic, ERCC5, XRCC1 (Ex10) 0.5616 3/10 2.7 (2.1, 3.5) 
     
Primary methylation index and SNPs 
1 PMI 0.5650 10/10 1.8 (1.4, 2.3) 
2 PMI, OGG1 0.5606 6/10 2.3 (1.8, 3.0) 
3 PMI, SOD2, OGG1 0.5461 5/10 2.6 (2.0, 3.3) 
     
Secondary methylation index and SNPs 
1 SMI 0.5630 10/10 2.0 (1.5, 2.5) 
2 SMI, MPO 0.5758 5/10 2.3 (1.8, 2.9) 
3 SMI, CAT, ERCC2 0.5813 8/10 2.8 (2.2, 3.6) 
 
                                                            




TABLE 5. Logistic Regression Evaluation of ERCC5*XRCC1 (Ex10) Interaction Detected by Both MDR and CART for Skin Lesion Prevalence 
SNPs  Cases N (%) 
Controls 
N (%) 
Crude POR  
(95% CI) 
Adjusted POR140  
(95% CI) 
ERCC5 XRCC1 (Ex10)     
GG GG   139 (25.4)   197 (21.1) 1.0 1.0 
GG GA   115 (21.0)   231 (24.8) 0.7 (0.5, 0.9) 0.7 (0.5, 0.9) 
GG AA   38 (6.9)   54 (5.8) 1.0 (0.6, 1.6) 1.1 (0.6, 1.9) 
GC GG    77 (14.0)   186 (19.9) 0.6 (0.4, 0.8) 0.6 (0.4, 0.8) 
GC GA   110 (20.1)   157 (16.8) 1.0 (0.7, 1.4) 1.1 (0.7, 1.5) 
GC AA   28 (5.1)   46 (4.9) 0.9 (0.5, 1.5) 0.9 (0.5, 1.6) 
CC GG   16 (2.9)   28 (3.0) 0.8 (0.4, 1.5) 0.9 (0.4, 1.8) 
CC GA   21 (3.8)   31 (3.3) 1.0 (0.5, 1.7) 0.8 (0.4, 1.5) 
CC AA    4 (0.7)    3 (0.3) 1.9 (0.4, 8.6) 2.1 (0.4, 12.2) 
P for interaction   0.008141 0.008 
 
                                                            
140 Adjusted for well water arsenic concentration, sex and age. 




TABLE 6. Logistic Regression Evaluation of Well Water Arsenic*MPO Interaction Detected by Both MDR and CART for Skin Lesion Prevalence 
Factors  Cases N (%) 
Controls 
N (%) 
Crude POR  
(95% CI) 
Adjusted POR142  
(95% CI) 
Well water arsenic MPO     
0.1-50 GG 112 (19.7) 335 (34.8) 1.0 1.0 
0.1-50 GA 43 (7.6) 110 (11.4) 1.2 (0.8, 1.8) 1.1 (0.7, 1.8) 
0.1-50 AA 6 (1.1) 10 (1) 1.8 (0.6, 5.0) 1.9 (0.6, 6.3) 
50.1-864 GG 311 (54.7) 374 (38.8) 2.5 (1.9, 3.2) 2.7 (2.0, 3.6) 
50.1-864 GA 91 (16) 127 (13.2) 2.1 (1.5, 3.0) 2.3 (1.6, 3.4) 
50.1-864 AA 6 (1.1) 7 (0.7) 2.6 (0.8, 7.8) 3.0 (0.8, 10.6) 
P for interaction   0.19143 0.29 
 
                                                            
142 Adjusted for sex and age. 




TABLE 7. Logistic Regression Evaluation of Primary Methylation Index*OGG1 Interaction Detected by Both MDR and CART for Skin Lesion Prevalence 
Factors  Cases N (%) 
Controls 
N (%) 
Crude POR  
(95% CI) 
Adjusted POR144  
(95% CI) 
Primary methylation index OGG1     
<0.580-0.835 CC 78 (14) 216 (23.1) 1.0 1.0 
<0.580-0.835 CG 95 (17.1) 197 (21) 1.3 (0.9, 1.9) 1.3 (0.9, 2.0) 
<0.580-0.835 GG 19 (3.4) 46 (4.9) 1.1 (0.6, 2.1) 1.1 (0.6, 2.1) 
0.836-19.570 CC 176 (31.7) 228 (24.3) 2.1 (1.5, 3.0) 1.4 (0.9, 2.0) 
0.836-19.570 CG 157 (28.2) 210 (22.4) 2.1 (1.5, 2.9) 1.2 (0.9, 1.8) 
0.836-19.570 GG 31 (5.6) 40(4.3) 2.1 (1.3, 3.7) 1.1 (0.6, 2.0) 
P for interaction   0.38145 0.36 
                                                            
144 Adjusted for sex and age. 




TABLE 8. Logistic Regression Evaluation of Primary Methylation Index*OGG1*SOD2 Interaction Detected by Both MDR and CART 
  Cases N (%) 
Controls 
N (%) 
Overall POR  
(95% CI) Low PMI High PMI 
OGG1 SOD2      
CC CC 65 (11.7) 150 (16.0) 1.0 1.0 1.0 
CG CC 88 (15.9) 120 (12.8) 1.7 (1.1, 2.5) 2.1 (1.1, 4.1) 1.6 (0.9, 2.7) 
GG CC 18 (3.2) 27 (2.9) 1.5 (0.8, 3.0) 1.5 (0.5, 4.2) 2.2 (0.9, 5.8) 
CC CT 129 (23.2) 188 (20.0) 1.6 (1.1, 2.3) 1.5 (0.8, 2.8) 1.7 (1.1, 2.8) 
CG CT 115 (20.6) 206 (21.9) 1.3 (0.9, 1.9) 1.6 (0.9, 2.9) 1.2 (0.7, 1.9) 
GG CT 18 (3.2) 48 (5.1) 0.9 (0.5, 1.6) 0.8 (0.3, 2.4) 1.0 (0.4, 2.2) 
CC TT 61 (10.9) 103 (11.0) 1.4 (0.9, 2.1) 1.1 (0.5, 2.3) 1.6 (0.9, 2.9) 
CG TT 50 (9.0) 84 (8.9) 1.4 (0.9, 2.2) 1.4 (0.6, 3.0) 1.5 (0.8, 2.7) 
GG TT 13 (2.3) 14 (1.5) 2.1 (0.9, 4.8) 2.7 (0.7, 11.2) 2.1 (0.7, 6.2) 



















 The aims of this dissertation were to 1) evaluate the effect of single nucleotide 
polymorphisms (SNPs) in antioxidant enzymes genes in relation to skin lesion 
prevalence, 2) to evaluate the effect of SNPs in DNA repair genes in relation to skin 
lesion prevalence, 3) to evaluate SNP-environment interactions between SNPs on these 
pathways and environmental factors (i.e., arsenic exposure measures and lifestyle factors) 
using logistic regression to assess interaction on the additive scale, and 4) to evaluate 
gene-gene, gene-environment, and higher-order interactions of these genetic and 
environmental factors using a multi-analytic approach including nonparametric (i.e, 
MDR and CART) as well as parametric (i.e, logistic regression) methods.  
 
SUMMARY OF RESULTS 
In Chapter 2, we assessed the relationship between SNPs in antioxidant enzyme 
genes and skin lesion prevalence, as well as possible interactions of these associations on 
the additive scale by various environmental factors. There were no statistically significant 
associations between these SNPs (SOD2, rs4880; CAT, rs1001179; GPX1, rs1050450; 
and MPO, rs2333227) and skin lesion prevalence. The results did not vary by arsenic 
exposure levels (as measured by well water arsenic concentration, urinary total arsenic 
concentration, primary methylation index, and secondary methylation index), body mass 
index, smoking status, or fruit and vegetable intake. However, there was marginal 
evidence that skin lesion prevalence was increased among individuals who carried 4 or 




Additionally, we observed a significant departure from additivity for the risk allele score 
and primary methylation index on skin lesion prevalence. There was no evidence that 
these SNPs were associated with skin lesion severity, such as pigmentation changes and 
keratosis.  
In Chapter 3, we assessed the relationship between SNPs in DNA repair genes 
(OGG1, rs1052133; XRCC1, rs25487 and rs1799782; XRCC3, rs861539; ERCC2, 
rs1052559; ERCC5, rs17655; and LIG4, rs1805388) and skin lesion prevalence, as well 
as possible interactions of these associations on the additive scale by various 
environmental factors. In logistic regression models controlling for sex, age, and well 
water arsenic concentration, no associations were observed between measured SNPs and 
skin lesion prevalence. The results did not vary by arsenic exposure levels (as measured 
by well water arsenic concentration, urinary total arsenic concentration, primary 
methylation index, and secondary methylation index), body mass index, or smoking 
status. However, we did observe a significant inverse association of total fruit and 
vegetable consumption with skin lesion prevalence, and its additive interaction with the 
polymorphism in ERCC5.         
 In Chapter 4, we utilized a multi-analytic approach to explore gene-gene, gene-
environment, and higher-order interactions among 10 single nucleotide polymorphisms 
(SNPs) related to the oxidative stress and DNA repair pathways by MDR, CART, and 
logistic regression models. As shown in Chapters 2 and 3, none of these SNPs were 
associated with skin lesion prevalence, however, were evaluated for potential epistatic 




selection of potential gene-gene and gene-environment interactions. Considerable overlap 
of the interactions detected by both these methods was observed, which were further 
evaluated by logistic regression. Results from logistic regression modeling, confirmed 
some of these statistical interactions; however, their biological interpretation is limited. 
Therefore, further investigation and replication of the statistical interactions detected in 
this study is needed.      
 
STRENGTHS AND LIMITATIONS 
 To our knowledge, this is the first study to assess polymorphisms in a number of 
oxidative stress and DNA repair genes in relation to skin lesion prevalence, which have 
not been previously examined but have been implicated in arsenic toxicity and serve as 
good candidate genes for evaluation of genetic susceptibility.  There are several strengths 
and weakness of the study that we consider.   
 
Arsenic Exposure Constructs 
A strength of the analyses conducted in this dissertation was the availability of 
various constructs of arsenic exposure assessment. Arsenic exposure was ascertained 
based on well water arsenic concentration, as well as urinary arsenic measures including 
total arsenic concentration and arsenic metabolites. Different components of arsenic were 
captured by these various measurements including a measure of external exposure by 
well water arsenic concentration, a measure of internal dose by urinary total arsenic 




metabolites. While the arsenic exposure assessments were reasonably correlated within 
this study, there was still some variability across measures in this population and, it is 
possible that genes may interact differently with each of the components of arsenic 
exposure, which we were able to systematically evaluate this in this study.  
With respect to the measurement of arsenic metabolites, due to laboratory 
limitations, total MMA and DMA species (i.e., trivalent and pentavalent species) were 
assessed jointly. However, there is evidence in the literature to show that the trivalent 
organic arsenic species may be more toxic (1, 2) and the estimation of the distribution of 
the trivalent metabolites would be useful in future studies.  
Additionally, in the context of oxidative stress, arsenic exposure served as a proxy 
measure to the actual measure of interest, which is arsenic-induced oxidative stress. For 
the purposes of this dissertation, the assumption was made that individuals with a higher 
concentration of arsenic exposure experienced higher levels of oxidative stress. 
Alternatively, biomarkers of oxidative stress could have been measured.    
 
Skin Lesion Assessment 
 For the purposes of this study, prevalent skin lesion cases were selected as having 
the presence of any type of arsenical skin lesion (i.e., melanosis, leucomelanosis, or 
keratosis). In exploratory subset analyses, skin lesion severity was evaluated by 
stratifying arsenical skin lesion status into absence of keratotic skin lesions and presence 
of keratotic skin lesions. While we did not see any significantly different effects by skin 




single SNPs was actually rather quite small. Future studies should be conducted with 
precise case definitions and be well-powered to examine such differences.  
The assessment of the effect of SNPs on prevalent skin lesions is also a limitation 
for the evaluation of mechanistic hypotheses and phenotype considerations since the 
association may be related to disease prevalence or progression and not disease 
incidence. Therefore, findings from these analyses should be replicated with incident 
cases. However, we deem the effect of disease prevalence to be minimal since arsenical 
skin lesions are typically not fatal.   
 
Genetic Susceptibility Assessment 
 The advantage of using genetic variants is a strength of this type of research 
because they can be measured with little measurement error and bias. Additionally, SNPs 
are time-independent measures, which strengthen causal inference of the associations 
evaluated in this dissertation between the measured SNPs and skin lesion prevalence. 
However, a limitation in causal inference is that assumptions regarding the association of 
the gene with skin lesion prevalence cannot be derived from the null findings of the 
single SNPs in this study, since they may not be correlated with a causal variant in the 
gene and do not fully tag the variability in the gene. Therefore, our inferences are limited 
to the measured SNPs themselves.     
Conversely, the amount of oxidative stress or DNA breaks could have been 
measured but there would have been major limitations in the temporality of these 




lesions (some forms of melanosis) may not be readily visible with clinical examination; 
therefore, oxidative stress or DNA repair biomarkers could also suffer from reverse 
causation if it was not ensured that the measures were taken at an appropriate period 
before disease onset. The antioxidant defense system is comprised of both enzymatic and 
non-enzymatic antioxidants. The focus of this dissertation was to examine the influence 
of polymorphisms of selected enzymatic antioxidants. The role of non-enzymatic 
antioxidants and activity of enzymatic antioxidants were unmeasured, therefore the total 
antioxidant potential of the cell remains unknown.  
The effect of any single SNP on skin lesion prevalence is likely to be small; 
therefore, consideration of the cumulative effect of SNPs through the construction of the 
risk allele score was a strength in the analytic method of this dissertation.  
Finally, the SNPs and genes for which there is data available were selected based 
on a candidate-gene approach. Therefore, a limited number of SNPs and genes were 
examined in this dissertation research. Future studies could take a comprehensive 
genomewide approach for evaluating associations between tens of thousands of SNPs 
simultaneously (using a microarray platform) and skin lesion status. Findings from this 
type of “discovery” approach could then be evaluated in candidate-gene studies 
employing SNPs which comprehensively tag the genes of interest.    
 
Analytic Methods for Gene-Gene and Gene-Environment Interactions 
 The evaluation of SNP-SNP interactions in this study had several complications. 




DNA repair pathways. However, the genes themselves have yet to be implicated in skin 
lesion prevalence although the pathways have been hypothesized to have a role in arsenic 
toxicity with supporting evidence from in vitro and human studies. Therefore, it is not 
clear whether these SNPs could possibly have epistatic effects in relation to skin lesion 
prevalence or are noise SNPs. Based on the evidence from this study, we conclude that 
the genotyped SNPs had no independent marginal or epistatic effects with respect to skin 
lesion prevalence. As discussed previously, we cannot derive conclusions based on the 
SNPs as to whether gene-gene interactions are present between genes included in this 
study since the SNPs measured do not sufficiently represent the variability in the genes 
that may be related to susceptibility, either through linkage with a single causal SNP or 
tagging the gene in manner to represent the full variability of the coding variation.  
 A statistical issue with the evaluation of gene-gene and gene-environment 
interactions is that while the nonparametric methods  (i.e., MDR and CART) were quite 
powerful and efficient in evaluating two- and three-way interactions, the potential 
interactions these methods yielded were statistical interactions and their interpretation 
had limited biological relevance, based on the fact that significant interaction effects were 
primarily observed between heterozygous genotypes. Moore and Williams have 
discussed the challenge in interpreting statistical epistasis as biological epistasis (3), 
which has also been a theme in the epidemiologic literature with respect to interactions 
(4).  
However, a major strength of this work was the use of the multi-analytic approach 




evaluation of interactions in logistic regression, however, was on the multiplicative scale. 
The additive scale may also be of interest for the evaluation of gene-gene interactions; 
although, assessment of interactions on this scale currently has limited implementation 
due to lack of flexibility in the modeling of parameters for additive interaction estimation 
and is limited to evaluation of two-way interactions. Additionally, logistic regression is 
suited to evaluate only lower-order interactions. With higher-order interactions the 
models become too complex and the sample size becomes an issue for their evaluation (5, 
6).               
 
Statistical Conclusion Validity 
 Multiple comparisons were a possible threat to statistical validity in this study. In 
Chapters 2 and 3, we conducted several tests of SNP-environment interactions. Since we 
had specific pre-specified hypotheses regarding these interactions, we did not take 
measures to adjust the P values for multiple comparisons. However, we acknowledge that 
significant findings in this study could have arisen by chance and require replication by 
other studies.   
 
Study Sample 
 Individuals in this study were selected from the Health Effects of Arsenic 
Longitudinal Study (HEALS). This sampling scheme was efficient because it provided 
comprehensive exposure, covariate, and outcome data as well as biological samples for 




villages in Araihazar, a rural 25 km2 area in Bangladesh. The customary cultural practice 
among individuals in the region is subsequent to marriage for the wife to move to the 
spouse’s village; therefore, men remain in their home village and there is a patrilineal 
family structure within the villages. Therefore, it is possible that participants selected for 
this study may have had some degree of relatedness which would have introduced 
confounding into this study similar to population stratification (7, 8). Since the pedigree 
information for these families was not collected, the number and extent to which 
participants were related is unknown. However, evaluation of the number of individuals 
who shared a tubewell (a proxy for family unit) among the selected cases and controls 
shows that tubewells were utilized by a range of 1 to 6 individuals, with 1.3 users on 
average per tubewell. Thus, we do not deem relatedness to be a major issue in this study.  
 
PUBLIC HEALTH RELEVANCE 
While there is substantial evidence of dose-response associations between arsenic 
in drinking water and various health outcomes, studies have shown that remediation of 
arsenic exposure alone does not reduce arsenic-related health risks in the population (9-
11). In a recent publication using prospective data from the HEALS cohort, we showed 
utilizing repeated measures of urinary total arsenic exposure over time that once 
chronically exposed decreasing exposure for a short amount of time did not reduce one’s 
risk of mortality (9). Additionally, other studies have shown that mortality attributed to 
cancers and heart disease did not begin to decline until approximately 2 decades after 




prior studies and our data suggest that it may be important to consider other health 
prevention and promotion strategies in conjunction with remediation for arsenic-exposed 
populations. Evaluation of genetic determinants of skin lesion prevalence could 
contribute to a greater understanding of the genetic and molecular pathways that underlie 
arsenic toxicity and may inform future interventions of arsenic-exposed populations. In 
addition to elucidating biological mechanisms of action, investigating genetic 
susceptibility may help identify individuals with higher risk to arsenic-related toxicity, 
aiding in prevention and intervention of arsenic-exposed populations.  
 
In summary, there was marginal evidence that skin lesion prevalence was 
increased among individuals who carried 4 or more risk alleles in genotyped SNPs 
related to the oxidative stress pathway compared to individuals carrying 0-2 risk alleles in 
these SNPs and, we observed a significant departure from additivity for the risk allele 
score and primary methylation index on skin lesion prevalence. Additionally, we 
observed a significant inverse association of total fruit and vegetable consumption with 
skin lesion prevalence, and an additive interaction with the polymorphism in ERCC5 in 
the DNA repair pathway and fruit and vegetable intake in relation to skin lesion 
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TABLE B.1.  Prevalence Odds Ratios and 95% CIs for Skin Lesion Prevalence in Relation to Tertile of 
Food Item Intake, Araihazar, Bangladesh, 2000-2002 
Food Item 
Food Item Tertile of Intake 
P for trend Q1 Q2 Q3 
POR POR150 95% CI POR 95% CI 
Lentils 1.0 0.7 0.5, 0.9 0.3 0.3, 0.6 0.0001 
Watermelon 1.0 0.2 0.07, 0.9 0.4 0.3, 0.6 0.0001 
Mango 1.0 0.5 0.4, 0.7 0.8 0.6, 1.1 0.1572 
Banana 1.0 0.5 0.4, 0.7 0.6 0.5, 0.9 0.0030 
Jackfruit 1.0 0.8 0.6, 1.1 1.1 0.9, 1.5 0.3272 
Guava 1.0 0.3 0.2, 0.5 0.4 0.3, 0.6 0.0001 
Potato 1.0 0.6 0.4, 0.8 1.0 0.7, 1.3 0.8624 
Spinach 1.0 0.7 0.5, 0.9 0.6 0.5, 0.9 0.0025 
Bottle gourd 1.0 0.7 0.5, 0.9 0.8 0.6, 1.1 0.0868 
Pumpkin 1.0 0.5 0.4, 0.7 -- -- 0.0001 
Beans 1.0 0.6 0.4, 0.8 1.0 0.8, 1.4 0.7550 
Eggplant 1.0 1.0 0.7, 1.4 0.5 0.4, 0.6 0.0001 
Okra 1.0 0.7 0.5, 0.9 0.6 0.5, 0.8 0.0013 
Spinach stalks 1.0 0.6 0.5, 0.8 0.4 0.3, 0.5 0.0001 
Bitter gourd 1.0 1.1 0.8, 1.4 1.0 0.8, 1.3 0.9300 
Green papaya 1.0 0.4 0.3, 0.6 -- -- 0.0001 
Ridge gourd 1.0 1.2 0.8, 1.8 0.8 0.6, 1.1 0.1613 
Snake gourd 1.0 0.8 0.6, 1.0 0.6 0.5, 0.8 0.0008 
Yam 1.0 1.0 0.7, 1.3 0.6 0.4, 0.8 0.0005 
Cauliflower 1.0 0.6 0.4, 0.8 0.5 0.4, 0.7 0.0001 
Cabbage 1.0 0.4 0.3, 0.5 0.3 0.2, 0.4 0.0001 
Tomato 1.0 0.9 0.7, 1.3 1.3 1.0, 1.8 0.0505 
Parwar (squash) 1.0 0.7 0.5, 0.9 0.4 0.3, 0.6 0.0001 
Ghosala (squash) 1.0 0.6 0.4, 0.9 0.7 0.6, 0.9 0.0157 
Radish 1.0 0.8 0.6, 1.1 0.6 0.4, 0.8 0.0009 
Sweet potato 1.0 0.6 0.5, 0.8 0.7 0.6, 0.9 0.0202 
                                                            





TABLE B.2.  Prevalence Odds Ratios and 95% CIs for Skin Lesion Prevalence in Relation to Antioxidant 








N % N % POR151 95% CI N % POR
23 95% CI 
SOD2           
CC 302 31.5 111 31.0 1.0  62 29.8 1.0  
CT 456 47.5 162 45.3 0.9 0.7, 1.3 106 51.0 1.1 0.8, 1.6 
TT 202 21.0 85 23.7 1.1 0.8, 1.6 40 19.2 0.9 0.6, 1.5 
Per allele     1.0 0.9, 1.3   1.0 0.8, 1.2 
GPX1           
CC 623 65.2 239 66.6 1.0  133 63.3 1.0  
CT 297 31.1 106 29.5 0.9 0.7, 1.2 68 32.4 1.1 0.7, 1.5 
TT 36 3.7 14 3.9 1.1 0.5, 2.3 9 4.3 1.4 0.6, 3.2 
Per allele     1.0 0.8, 1.2   1.1 0.8, 1.5 
CAT           
CC 571 59.5 242 67.4 1.0  116 56.6 1.0  
CT 343 35.8 107 29.8 0.8 0.6, 1.1 78 38.0 1.3 0.9, 1.9 
TT 45 4.7 10 2.8 0.6 0.3, 1.3 11 5.4 1.6 0.7, 3.4 
Per allele     0.8 0.6, 1.1   1.3 1.0, 1.7 
MPO           
GG 709 73.6 280 77.1 1.0  143 69.4 1.0  
GA 237 24.6 76 20.9 0.8 0.6, 1.2 58 28.2 1.2 0.8, 1.8 
AA 17 1.8 7 2.0 1.1 0.4, 3.0 5 2.4 1.7 0.5, 5.1 
Per allele     0.9 0.7, 1.2   1.2 0.9, 1.7 
           
Risk allele count          
0–3 559 64.4 194 59.9 1.0  115 59.6 1.0  
4–7 309 35.6 130 40.1 1.1 0.9, 1.5 78 40.4 1.2 0.8, 1.6 
 
                                                            





TABLE B.3.  Prevalence Odds Ratios and 95% CIs for Skin Lesion Prevalence in Relation to Antioxidant 










Estimate152 P for 
trend N % N % POR 95% CI 
POR 95% 
CI 
SOD2           
CC 141 30.2 125 31.3 1.0   1.0   
CT 225 48.2 180 45.0 1.1 0.8, 1.5  1.1 0.8, 1.5  
TT 101 21.6 95 23.7 0.9 0.6, 1.4  1.0 0.7, 1.4  
Per allele     1.0 0.8, 1.2 0.83 1.0 0.8, 1.2 0.95 
GPX1           
CC 307 65.5 255 65.5 1.0   1.0   
CT 146 31.1 122 31.4 1.0 0.7, 1.3  1.0 0.7, 1.4  
TT 16 3.4 12 3.1 1.1 0.5, 2.4  1.0 0.4, 2.3  
Per allele     1.0 0.8, 1.3 0.91 1.0 0.8, 1.3 0.97 
CAT           
CC 298 63.7 240 61.2 1.0   1.0   
CT 154 32.9 133 33.9 0.9 0.7, 1.2  1.0 0.7, 1.4  
TT 16 3.4 19 4.9 0.7 0.3, 1.3  0.7 0.4, 1.6  
Per allele     0.9 0.7, 1.1 0.32 0.9 0.7, 1.2 0.70 
MPO           
GG 349 74.0 293 73.6 1.0   1.0   
GA+AA 123 26.0 105 26.4 1.0 0.7, 1.3 0.91 1.0 0.7, 1.4 0.94 
           
Risk allele count           
0–3 262 60.8 223 62.3 1.0   1.0   



















TABLE C.1.  Prevalence Odds Ratios and 95% CIs for Skin Lesion Prevalence in Relation to DNA Repair 








N % N % POR153 
95% 





OGG1           
CC 460 47.2 164 44.8 1.0  100 48.1 1.0  
CG 423 43.4 163 44.5 1.0 0.7, 1.3 96 46.1 0.9 0.6, 1.3 
GG 92 9.4 39 10.7 1.0 0.6, 1.6 12 5.8 0.5 0.2, 0.9 
Per allele     1.0 0.8, 1.2   0.8 0.6, 1.0 
ERCC2           
AA 421 44.5 156 44.6 1.0  86 41.4 1.0  
AC 419 44.3 160 45.7 1.1 0.8, 1.4 102 49.0 1.2 0.8, 1.7 
CC 105 11.1 34 9.7 0.8 0.5, 1.4 20 9.6 0.9 0.5, 1.6 
Per allele     1.0 0.8, 1.2   1.0 0.8, 1.3 
ERCC5           
GG 503 52.0 194 54.2 1.0  104 50.5 1.0  
GC 400 41.4 144 40.2 0.9 0.7, 1.2 79 38.3 1.0 0.7, 1.4 
CC 64 6.6 20 5.6 0.8 0.4, 1.4 23 11.2 1.7 0.9, 3.1 
Per allele     0.9 0.7, 1.1   1.2 0.9, 1.5 
LIG4           
CC 788 82.3 307 84.3 1.0  166 80.2 1.0  
CT/TT 169 17.7 57 15.7 0.3 0.1, 1.4 41 19.8 0.8 0.1, 8.8 
XRCC1 (Ex6)           
CC 763 80.6 278 78.3 1.0  167 81.5 1.0  
CT 170 18.0 69 19.4 1.2 0.9, 1.7 35 17.1 1.0 0.7, 1.6 
TT 13 1.4 8 2.3 1.7 0.6, 5.0 3 1.4 1.1 0.3, 4.5 
Per allele     1.3 0.9, 1.7   1.0 0.7, 1.5 
XRCC1 (Ex10)           
GG 423 44.1 154 43.0 1.0  86 41.6 1.0  
GA 429 44.8 152 42.5 0.9 0.7, 1.3 99 47.8 1.1 0.8, 1.6 
AA 106 11.1 52 14.5 1.4 0.9, 2.1 22 10.6 1.1 0.6, 1.9 
Per allele     1.1 0.9, 1.4   1.1 0.8, 1.4 
XRCC3           
CC 619 65.3 222 62.9 1.0  130 64.4 1.0  
CT 287 30.3 114 32.3 1.1 0.8, 1.5 66 32.7 1.1 0.8, 1.6 
TT 42 4.4 17 4.8 0.9 0.4, 1.6 6 2.9 0.5 0.2, 1.3 
Per allele     1.0 0.8, 1.3   0.9 0.7, 1.2 
           
Risk allele count          
0–3 516 62.6 180 60.2 1.0  107 58.8 1.0  









TABLE C.2.  Prevalence Odds Ratios and 95% CIs for Skin Lesion Prevalence in Relation to DNA Repair 






Crude Estimate P for 
trend 
Multivariate 
Estimate154 P for trend N % N % POR 95% CI POR 95% CI 
OGG1           
CC 215 45.4 181 44.8 1.0   1.0   
CG 215 45.4 180 45.6 1.0 0.8, 1.3  0.9 0.7, 1.2  
GG 44 9.2 43 10.6 0.9 0.5, 1.4  0.8 0.5, 1.3  
Per allele     1.0 0.8, 1.2 0.66 0.9 0.7, 1.1 0.30 
ERCC2           
AA 206 44.3 175 45.4 1.0   1.0   
AC 213 45.8 164 42.6 1.1 0.8, 1.5  1.1 0.8, 1.4  
CC 46 9.9 46 12.0 0.8 0.5, 1.3  0.9 0.5, 1.4  
Per allele     0.9 0.8, 1.2 0.84 1.0 0.8, 1.2 0.77 
ERCC5           
GG 237 51.3 217 54.4 1.0   1.0   
GC 188 40.7 153 38.3 1.1 0.8, 1.5  1.1 0.8, 1.5  
CC 37 8.0 29 7.3 1.2 0.7, 2.0  1.2 0.7, 2.0  
Per allele     1.1 0.9, 1.4 0.38 1.1 0.9, 1.4 0.70 
LIG4           
CC 384 81.7 343 86.4 1.0   1.0   
CT 81 17.2 51 12.8 1.4 1.0, 2.1  1.4 0.9, 2.1  
TT 5 1.1 3 0.8 1.5 0.3, 6.3  1.7 0.4, 7.7  
Per allele     1.4 1.0, 1.9 0.07 1.4 1.0, 2.0 0.07 
XRCC1 (Ex6)           
CC 374 80.6 312 81.5 1.0   1.0   
CT 80 17.2 68 17.7 1.0 0.7, 1.4  1.0 0.7, 1.4  
TT 10 2.2 3 0.8 2.8 0.8, 10.2  2.6 0.6, 10.9  
Per allele     1.1 0.8, 1.5 0.46 1.1 0.8, 1.5 0.58 
XRCC1 (Ex10)           
GG 197 42.2 165 42.0 1.0   1.0   
GA 212 45.4 183 46.6 1.0 0.7, 1.3  1.0 0.7, 1.3  
AA 58 12.4 45 11.4 1.1 0.7, 1.7  1.1 0.7, 1.8  
Per allele     1.0 0.8, 1.2 0.87 1.0 0.8, 1.3 0.70 
XRCC3           
CC 292 63.5 254 65.0 1.0   1.0   
CT 150 32.6 113 28.9 1.1 0.9, 1.5  1.1 0.8, 1.5  
TT 18 3.9 24 6.1 0.6 0.3, 1.2  0.6 0.3, 1.1  
Per allele     1.0 0.8, 1.2 0.85 0.9 0.7, 1.2 0.62 
           
Risk allele count           
0–3 241 60.2 207 61.1 1.0   1.0   
4–8 159 39.8 132 38.9 1.0 0.8, 1.4  1.0 0.7, 1.4  
 
                                                            





TABLE C.3.  Prevalence Odds Ratios155 and 95% CIs for Keratosis in Relation to ERCC2 by Creatinine-
adjusted Urinary Total Arsenic Concentration, Araihazar, Bangladesh, 2000-2002 
SNP Creatinine-adjusted urinary total arsenic concentration (μg/g) 
16-103 104-192 193-339 340-8556 
ERCC2 
AA 1.00 1.97 (0.78, 4.97) 3.57 (1.46, 8.73) 5.41 (2.26, 12.96) 
AC/CC 1.00 2.93 (1.22, 7.04) 2.58 (1.03, 6.33) 6.31 (2.73, 14.62) 
 
                                                            












 Hierarchial Bayes modeling. In supplementary analyses, we attempted to exploit 
the information of the pathway information of the SNPs utilizing Hierarchial Bayes 
modeling. The marginal effects of the SNPs are summarized in Table D.2 based on 
dichotomous SNP classifications, as indicated in the table with the heterozygous and 
homozygous genotypes containing the risk allele combined. A logistic regression model 
was run for each SNP individually to yield the marginal effects. For simplicity, 
unadjusted estimates are presented for all analyses, since adjustment did not appreciably 
change the PORs. We then summarized the conditional effect of the SNPs by running a 
single logistic regression model with all the SNPs simultaneously (Table D.2). Finally, 
we specified a two-stage model to conduct Hierarchical Bayes modeling (44). In the first-
stage we ran the conditional logistic regression model to generate the log odds estimates 
and the covariance matrix between the SNPs. Based on existing knowledge of the gene 
functions, we specified the design matrix (Table D.1) for the pathways for use in the 
second-stage regression model. A value of 1 was assigned to SNPs that were involved in 
a particularly pathway, otherwise 0 was assigned. In the second-stage model, we 
regressed the prior information of the pathways on the log odds of each SNP, specifying a 
residual variance (τ2) of 0.25. In general, we found Hierchical modeling yielded similar 
results to the conditional approach (Table D.2) and did not produce any significant 





TABLE D.1.  Second-stage Design Matrix 
for Multilevel Model 
SNP 
Pathway 
Antioxidant DNA Repair 
SOD2 1 0 
GPX1 1 0 
CAT 1 0 
MPO 1 0 
OGG1 1 1 
ERCC2 0 1 
ERCC5 0 1 
LIG4 0 1 
XRCC1 (Ex6) 0 1 
XRCC1 (Ex10) 0 1 






TABLE D.2.  Hierarchical Bayes Regression Estimates and 95% CIs for the Study Sample, Araihazar, 
Bangladesh, 2000-2002 
SNP Marginal Model Conditional Model Hierarchical Model 
POR 95% CI   POR 95% CI   POR 95% CI 
SOD2 - CT/TT 1.04 0.83, 1.30 1.06 0.82, 1.38 1.06 0.83, 1.37 
GPX1 - CT/TT 0.99 0.80, 1.23 1.07 0.83, 1.37 1.06 0.83, 1.36 
CAT - TC/CC 1.27 0.75, 2.16 1.44 0.77, 2.67 1.32 0.77, 2.27 
MPO - GA/AA 0.96 0.76, 1.22 0.91 0.69, 1.20 0.92 0.70, 1.20 
OGG1 - CG/GG 1.05 0.85, 1.29 1.06 0.83, 1.34 1.06 0.84, 1.34 
ERCC2 - AC/CC 1.05 0.85, 1.29 1.02 0.80, 1.30 1.02 0.81, 1.29 
ERCC5 - GC/CC 0.97 0.79, 1.19 0.91 0.72, 1.16 0.92 0.72, 1.16 
LIG4 - TC/CC 0.40 0.11, 1.41 1.26 0.23, 6.92 1.06 0.43, 2.61 
XRCC1 (Ex6) - CT/TT 1.08 0.83, 1.40 1.02 0.75, 1.38 1.02 0.76, 1.36 
XRCC1 (Ex10) - GA/AA 1.07 0.87, 1.32 1.07 0.84, 1.37 1.07 0.84, 1.36 







FIGURE D.1.  Graphical Presentation of MDR Interaction Model for Well Water Arsenic 
Concentration and MPO for Skin Lesion Prevalence 
 
Overall best model was the two factor model, which classified individuals based on well 
water arsenic concentration and MPO. The low risk group is indicated in light grey and 





FIGURE D.2a.  Graphical Presentation of MDR Interaction Model for SNPs  
 
a. Two factor model yielded XRCC1 (Ex10) (rs25487) and ERCC5 (rs17655) as the best 
model. The low risk group is indicated in light grey and the high risk group is indicated in 





FIGURE D.2b.  Graphical Presentation of MDR Interaction Model for SNPs  
 
b. Three factor model yielded OGG1 (rs1052133), XRCC1 (Ex10) (rs25487), and ERCC5 
(rs17655) as the best model. The low risk group is indicated in light grey, the high risk 




FIGURE D.3a.  Graphical Presentation of MDR Interaction Models for Primary 
Methylation Index and SNPs 
 
a. Two factor model yielded primary methylation index and OGG1 (rs1052133) as the 
best model. The low risk group is indicated in light grey and the high risk group is 
indicated in dark grey.  
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FIGURE D.3b.  Graphical Presentation of MDR Interaction Models for Primary Methylation Index and SNPs 
 
 
b. Three factor model yielded primary methylation index, OGG1 (rs1052133), and SOD2 (rs4880) as the best model. The low risk 
group is indicated in light grey and the high risk group is indicated in dark grey.  
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FIGURE D.8.  Graphical Presentation of CART Model for Secondary Methylation Index and Single Nucleotide Polymorphisms  
 
 
